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Zusammenfassung 
 
Zusammenfassung 
Die Standard-Konformation der Replikationsgabel ist eine dreiarmige DNS -Struktur. Die 
Transformation dieser dreiarmigen Struktur in eine vierarmige Struktur dient als physiologische 
Antwort von Zellen auf verschiedenste genotoxische Substanzen sowie auf die Aktivierung von 
Onkogenen und schwer replizierbare Regionen des Genoms. Dieser Prozess wird als "Umkehr 
der DNS Replikationsgabel" definiert.  Die Umkehr der DNS Replikationsgabeln - die 
Transformation einer dreiarmigen DNS-Struktur (Standard-Konformation der 
Replikationsgabeln) in die vier-armige - ist die generelle physiologische Antwort auf 
verschiedenste genotoxische Substanzen, Aktivierung von Onkogenen und auf schwer 
replizierbare Regionen innerhalb des Genoms. Es ist jedoch noch nicht genau bekannt, welche 
Proteine für diese molekulare Transformation in vivo verantwortlich sind. Viele verschiedene 
Proteingruppen wurden für diese Rolle vorgeschlagen, allerdings hauptsächlich auf 
biochemischen Daten basierend, die die Komplexität dieser Transformation in vivo kaum 
wiedergeben können. Wir haben unsere Forschung auf zwei Proteingruppen konzentriert, 
nämlich auf Annealing-Helikasen und Faktoren der post-replikativen Reparatur (PRR). Die 
erste Proteingruppe (SMARCAL1 und ZRANB3) hat die einzigartige Fähigkeit RPA-
gebundene einzelsträngige DNS zu doppelsträngiger DNS zusammenzufügen, was 
möglicherweise notwendig ist um Standard-Replikationsgabeln zu umgekehrten 
Replikationsgabeln umzuformen. Die zweite Proteingruppe (z. B. E2 Ubiquitin-konjugierendes 
Enzym UBC13 und poly-ubiquitiniertes PCNA) wurde ausgewählt, da frühere Studien gezeigt 
haben, dass der fehlerfreie Zweig der PRR durch "Template switching" Mechanismen abläuft 
und möglicherweise die Umkehr der DNS Replikationsgabel beinhaltet. Wir konnten in der Tat 
zeigen, das ZRANB3 für das effiziente Verlangsamen und Umkehren der Replikationsgabeln 
nach genotoxischem Stress benötigt wird. Im Moment sind wir dabei herauszufinden, welche 
Domänen des ZRANB3 Proteins für diese Funktion verantwortlich sind. Weiterhin haben wir 
den Beitrag von UBC13 und ubiquitiniertem PCNA zur aktiven Verlangsamung und zur 
Umkehr der Replikationsgabeln nach genotoxischem Stress definiert. 
Summary 
 
Summary 
Replication fork reversal - the transaction from a three-way junction (the usual conformation of 
replication forks) to a four-way junction - has been reported as a general response in face of a 
wide variety of genotoxic agents, oncogene activation and difficult-to-replicate regions of the 
genome. Proteins mediating this molecular transaction in vivo are still elusive. Many different 
groups of proteins have been proposed to execute this operation, yet most of the data come from 
biochemical experiments that may hardly recapitulate the complexity of this transaction in vivo. 
We focused our research on two groups of proteins, such as annealing helicases and post 
replicative repair (PRR) factors. The first group of proteins (SMARCAL1 and ZRANB3) have 
the unique ability to re-anneal RPA coated single stranded DNA (ssDNA), which may be 
necessary to convert standard replication forks to reversed forks. The second group of proteins 
(e.g. the E2 ubiquitin-conjugating enzyme UBC13 and polyubiquitinated PCNA) was selected 
as previous studies suggested the error-free branch of PRR to operate via template switching 
mechanisms, possibly entailing replication fork reversal. We could indeed determine that 
ZRANB3 is required for efficient fork slowing and reversal upon genotoxic stress and we are 
currently uncovering which domains are crucial for this function. We also uncovered the 
contribution of UBC13 and PCNA ubiquitination to active fork slowing and replication fork 
reversal upon genotoxic stress.  
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1. Introduction. 
1.1 DNA replication. 
1.1.1 General concepts of replication in eukaryotes. 
 
Genomes of the eukaryotes are large, ranging from 107 to >109 base pairs (bp) and are 
organized into chromosome(s). In a replicating eukaryotic cell, genome must be duplicated 
every cell cycle, more precisely in the S phase of the cell cycle. In order to maintain the fidelity 
of the genome, and therefore of the information stored in it, the process of replication has to be 
complete and precise. Errors in the process of replication can lead to variety of different 
malfunctions, both at cellular level (under- or over-replication, gene mutations, gene loss, 
expansions of repetitive sequences etc.), and at the organismal level (genetic diseases, cancer, 
birth defects etc.). To ensure the precise process of replication, the coordinated action of many 
different proteins, forming the “replisome”, is required. Different proteins are sequentially 
assembled and recruited to efficiently execute initiation, elongation and termination of 
replication. Each of these phases is strictly controlled to ensure exact, timely and complete 
replication.  
Eukaryotic cells have evolved checkpoint signaling as an additional mechanism of control, 
which regulates the cell cycle progression in case of DNA damage or perturbation of DNA 
synthesis (Thomas J. Kelly, 2000). 
 
1.1.2 Initiation of DNA replication. 
 
In eukaryotic cells, DNA replication is initiated from multiple sites on chromosomes, called 
"origins". In Saccharomyces cerevisiae the origins are short, well-defined sequences of about 
150 bp. These origins, termed autonomously replicating sequences (ARS) for their ability to 
confer autonomous replication to plasmids, fire asynchronously during S-phase in order to 
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ensure efficient replication of the chromosomes (Friedman KL, 1996). However, in higher 
eukaryotes  
 
origins are not well characterized, and in metazoans origins of replication seem to vary in size. 
It seems that in mammalian cells replication initiation requires AT rich sequences (Paixao S, 
2004; Wang L, 2004), dinucleotide repeats and asymmetrical purine-pyrimidine sequences 
(Wang L, 2004). Even though the origins of replication are difficult to define in metazoans, 
mechanisms driving the initiation of DNA replication are conserved in all eukaryotes.  
DNA replication is initiated by binding of the multi-subunit (heterohexameric) protein called 
origin recognition complex (ORC) – to the origins of replication (Bell S.P., 1992). In mammals, 
ORC binding does not show any sequence specificity (Vashee, 2003) and the access of 
initiation factors to the origins is regulated by chromatin structure (Cayrou C, 2010). Binding of 
ORC to the origin persists during the entire cell cycle, dissociating only briefly after replication. 
The next step in the process is loading the ring-shaped heterohexameric minichromosome 
maintenance protein (MCM) complex MCM2-7 to the replication origin (Remus D, 2009). This 
is brought about by at least two proteins, Cdc6 and Cdt1. This process is like a "clamp loading" 
procedure in which a clamp loader loads a ring shaped molecule onto the DNA by opening the 
ring. MCM 2-7 complex possesses an ATPase dependent DNA helicase activity and its 
recruitment to the origin is restricted to late mitosis and G1 phase, before initiation of DNA 
replication. Mcm10, a chromatin-binding protein, is required for the association of the MCM2–
7 complex with replication origins (Homesley L1, 2000). The recruitment of all these factors on 
chromatin occurs during late mitosis (M) and early G1 phase, generating the pre-replication 
complex (pre-RC) (Fig. 1.1). In order to initiate replication, DNA at the origin must unwind, 
generating single stranded DNA (ssDNA) to which the replicative polymerases can be loaded 
(Takeda DY, 2005).  
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Figure 1.1 Assembly of pre-replicative complex. Different steps of eukaryotic assembly of pre-replicative 
complex. DNA replication is initiated by recruitment of Pre-RC components to the origin. ORC recruits Cdc6 and 
Cdt1, required for the subsequent loading of the Mcm2−7 complex. Many Mcm2−7 complexes are loaded at each 
origin and Pre-RC formation occurs during late M and early G1 phases of the cell cycle, licensing DNA for 
replication during S phase (Takeda DY, 2005). 
 
The transition from G1 to S phase requires the conversion of pre-RCs into active replication 
forks. Initiation requires origin unwinding, stabilization of single stranded DNA, and loading of 
the replicative polymerases. This requires action of at least two kinases: S-phase cyclin 
dependent kinases (S-CDKs) and Dbf4-dependent Cdc7 kinase (DDK) (Thomas J. Kelly, 2000). 
These factors are temporally regulated throughout S phase, being associated with origins at the 
time of activation, suggesting that mechanisms influencing origin choice and timing probably 
regulate the targeting of these factors to origins (Takeda DY, 2005). CDKs are required to 
dissociate helicase-loading proteins Cdc6 and Cdt1, unwind the origin DNA and load DNA 
polymerases. In yeast Cdc6 is degraded, while in mammals Cdc6 is exported from the nucleus 
after CDK phosphorylation (Delmolino LM, 2001; Drury LS, 2000). Replication licensing shall 
occur only once per cell cycle, therefore initiation factors are regulated at different and 
redundant levels, comprising delocalization and degradation of some components upon entry in 
S-phase. These regulations are mostly mediated by CDK activity, which is required to activate 
the initiation complex and subsequently block re-initiation of DNA replication (Thomas J. 
Kelly, 2000). Protein kinases trigger DNA replication and at the same time prevent the 
assembly of new pre-replicative complex until the onset of new cell cycle. 
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1.1.3 Origin activation and chain elongation. 
 
Initiation of DNA replication requires transition from pre-RC into replication fork, and this 
depends on CDK and DDK activity. The activity of these kinases causes disassembly of pre-RC 
and binding of factors like Cdc45, GINS, Sld3, Sld2 and Dpb11 to replication origins, as well as 
Mcm10, the loading of which is required for the recruitment of Cdc45 (Gregan J 2003; Sawyer 
et al., 2004). Cdc45 loading on the origin is one of the crucial steps to form an initiation 
complex and to load many other replication proteins such as DNA polymerase α and DNA 
polymerase ε. Mcm10 facilitates DDK phosphorylation of Mcm2–7 by physically interacting 
with both complexes (Lee et al., 2003). Mcm10’s function in elongation may be related to its 
ability to retain Cdc45 on elongating forks. Mcm10 also interacts with the elongation factors 
DNA polymerase δ, DNA polymerase δ and DNA2 (Yasuo Kawasaki, 2001), and has been 
shown to activate the primase activity of DNA polymerase α in vitro (Fien, 2004). GINS 
complex is a stable, four-factor complex comprising Sld5, Psf1, Psf2 and Psf3, which is 
essential for DNA replication in both yeast and Xenopus egg extracts (Kubota and Takisawa, 
2003). GINS is prerequisite for the engagement of Cdc45 with the nascent replisome and is 
necessary to regulate association of Cdc45 with MCM subunits (Gambus et al., 2006; 
Takayama Y, 2003). It is also required for continued association between Cdc45 and MCM 
complex during S-phase progression (Kanemaki M, 2006; Labib, 2007). The GINS complex 
may be involved in coordinating the progression of the MCM helicase and priming events at the 
replication fork (Marinsek, 2006). The association of MCM, GINS and Cdc45 forms the CMG 
complex (Ilves et al., 2010). Replisome is believed to harbor factors that are not only essential 
for replication, but also involved in other chromosome transactions and chromatin regulation. 
These are referred to as "replisome progression complexes" (RPC), which are  
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composed of more than 20 replication related proteins (Gambus et al., 2006). In addition to 
Cdc45, MCM complex and GINS, the RPC contains MRC1, Tof1 and Csm3 (Claspin, Timeless 
and Tipin in mammalian cells), that are considered fork stabilization factors (Calzada et al., 
2005). In eukaryotes, the full CMG complex is the functional helicase machinery required for 
DNA unwinding (Hashimoto et al., 2012). Interaction of Ctf4, a polymerase accessory factor, 
with Mcm10 is required for the loading of DNA pol α on a chromatin (Zhu Z, 2008). Once 
CMG complex is formed, the helicase activity can facilitate DNA unwinding, generating 
ssDNA, subsequently stabilized by RPA (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Activation of pre-RC. Step wise demonstration of eukaryotic DNA replication. The formation of pre-
RC complex comprises binding of ORC to DNA and loading of Mcm2-7 helicase complex by Cdc6 and Cdt1. 
CDK/DDK-dependent phosphorylation of pre-RC components leads to Cdc45 loading, resulting in origin firing. 
MCMs and associated proteins unwind DNA to initiate replication (Noguchi, 2013).
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The leading strand is synthesized in a continuous way, while the lagging strand is copied in a 
discontinuous manner, generating short stretches of DNA: the Okazaki fragments 
(approximately 200 bp long). However, DNA polymerases are not able to initiate DNA 
synthesis de novo but they require a primer with a free 3’-OH. Therefore, both the leading 
strand and every Okazaki fragment on the lagging strand are primed by a short RNA that is 
synthesized de novo by a specialized RNA polymerase called primase, which in eukaryotes is 
part of the Pol α polymerase complex, known as Pol α–primase (Stillman, 2008). The primase 
initiates DNA synthesis, starting with a short RNA primer (approximately 10 nt), which is 
subsequently extended by DNA polymerase α forming a RNA-DNA primer of about 30 
nucleotides. This priming process takes place at the origin of replication of the leading strand 
and at the 5’end of each Okazaki fragment on the lagging strand. The leading strand is 
synthesized by polymerase ε in a continuous way, while the lagging strand is copied in a 
discontinuous manner by polymerase δ, generating short stretches of DNA: the Okazaki 
fragments, which are joined postreplicatively. After this initiation event, the clamp loader 
complex replication factor C (RFC) loads the sliding clamp proliferating cell nuclear antigen 
(PCNA) onto double-stranded DNA (Garg P, 2005). The sliding clamp encircles the double-
stranded DNA and tethers two polymerases - Pol δ and Pol ε to the template to increase enzyme 
processivity, although the mechanism by which this occurs is not clear. PCNA, a ring-shaped 
homotrimer, is able to slide along double-stranded DNA, acting as processivity factor for DNA 
polymerases (Prelich et al., 1987). The PCNA complex keeps polymerases on DNA, ensuring 
high-processivity of DNA replication. In addition to its function in replication, PCNA plays an 
essential role in regulating repair processes at the replication fork, acting as an interaction 
platform for repair factors (Moldovan et al., 2007). Pol ε has been shown to be the polymerase 
responsible for leading strand synthesis (Pursell et al., 2007) (Fig.1.3). It is a highly processive 
enzyme. Lagging strand synthesis on the other hand requires Pol δ (Fig.1.3). It is thought to 
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proceed in several discrete stages, i.e., initiation by DNA primase, limited elongation of the 
RNA primer by Pol α, a switch of the primer terminus from Pol α to Pol δ proposed to be 
brought about by RFC, elongation by Pol δ, and maturation of the completed Okazaki fragment 
in conjunction with Fen1 and DNA ligase1. Each transition is believed to be mediated by a 
specific protein or protein complex and has to occur with very high efficiency (Garg and 
Burgers, 2005). 
 
 
 
 
 
 
Figure 1.3 Model of an eukaryotic replication fork (McCulloch SD, 2008). 
 
The extensive unwinding of the DNA during replication generates topological stress which 
would slow down, and eventually stop, replication fork progression unless there were enzymes 
that are relieving it. DNA topoisomerases are enzymes that control and modify the topological 
state of DNA. Topoisomerases can be divided in two classes, type I and type II). Type I 
topoisomerases operate by transiently breaking a DNA strand and passing the other strand 
through the transient break. Type II topoisomerases operate by transiently breaking a pair of 
complementary strands and passing another double-stranded segment. 
 
1.1.4 Termination of DNA replication. 
 
Eukaryotic genomes have multiple origins of replication, which, when activated, enable start of 
replication bi-directionally, meaning that every origin produces two replication forks moving in 
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opposite direction. Termination of replication occurs when two replication forks, coming from 
adjacent active origins of replication, meet (Edenberg HJ, 1975). Termination of replication is 
often occurring at replication fork barriers (RFB) or replication termination sites. In these 
regions, termination is achieved by arresting the first fork that enters the termination region, 
forcing it to wait there for the inevitable convergence with the fork coming from the opposite 
direction. Specific termination sites (TERs) containing fork pausing elements such as RFBs 
have been characterized in eukaryotes (Fachinetti et al., 2010). Much is still unknown about the 
exact mechanism of fork fusion, but it seems possible that the presence of polar RFBs at TERs 
leads to the non-simultaneously converging of the two forks (Fig. 1.4). This process implies that 
at least one of the two forks would exit from the pause region with asymmetric leading and 
lagging strands before converging with the other fork. Topoisomerase II enzyme seems to be 
required to facilitate replication termination, resolving catenated junctions formed after fork 
fusion, and thus, preventing genome rearrangements. Rrm3 DNA helicase is also required for 
fork progression through TERs. 
 
 
Figure 1.4 Model for replication termination. One of the two converging 
forks stalls at a polar pausing site (red symbol) emerging with an asymmetric 
conformation. This process leads to non-simultaneously converging of the 
two forks. Top2 enzymes resolves catenated junctions formed after fork 
fusion, allowing chromosome resolution (Fachinetti et al., 2010). 
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1.2 DNA damage and repair mechanisms. 
1.2.1 DNA damage and consequences. 
 
Integrity of eukaryotic genome is constantly being under threat due to numerous endogenous 
and exogenous agents that are damaging the DNA, and this can lead to compromised cell 
survival and proliferation (Figure 1.5). Endogenous sources of DNA damage could be 
spontaneous reactions intrinsic to the chemical nature of DNA in an aqueous solution (mostly 
hydrolysis), that lead to creation of abasic sites and cause deamination (Lindahl, 1993). The 
other sources of endogenous DNA damage are reactive oxygen and nitrogen species, lipid 
peroxidation products, endogenous alkylating agents, estrogen and cholesterol metabolites, and 
reactive carbonyl species generated by cellular metabolism (De Bont R, 2004). Exogenous 
sources include physical and chemical agents like UV radiation, ionizing radiation and 
carcinogens present in different chemicals. Different sources of damage can cause very different 
types of damage. For instance, 8-oxoguanine, an oxidative lesion that on DNA replication pairs 
equally well with the cytosine (normal pairing) and adenine (abnormal pairing), causing 
GC→TA transversions (Akbari, 2008). Conversely, ionizing radiation or processing of 
interstrand cross-links causes double strand breaks (DSBs), which is one of the most serious 
lesions, as only one can be sufficient for cell death. Mutations arise from inaccurate processing 
of the lesions, and the genome is especially susceptible to such damage during the S-phase.  
Various types of repair mechanisms and checkpoints signaling pathways have evolved in order 
to ensure genome integrity in response to DNA damage. Deregulation of DNA damage repair 
and checkpoint signaling is associated with predisposition to many types of cancer. In some 
cases, replication may stall or arrest when encountering a base damage or strand break. Cells 
have also evolved mechanisms to bypass such damages before being repaired, ensuring the 
completion of the cell cycle. This strategy relies on specialized mechanisms, which are 
collectively named DNA damage tolerance mechanisms (DDT), and are sometimes referred as  
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post-replication repair (PRR).  PRR can be divided in two branches: an error-free pathway 
named “template switching” (TS) and error-prone pathways known as translesion synthesis 
(TLS). 
 
 
 Figure 1.5 Different sources of DNA damage and repair pathways (a) and possible outcomes (b) 
(Hoeijmakers, 2009). 
 
 1.2.2 DNA damage repair mechanisms.  
 
Base excision repair (BER) is the primary pathway responsible for repairing base damage 
generated by ROS, ionizing radiation or chemical agents like chemotherapeutic drugs. These 
damages arise through the processes of oxidation, alkylation, deamination and 
depurination/depyrimidination.  This pathway is subdivided into short patch BER (a single 
damaged nucleotide is replaced) or long patch BER (repair between 2 and 13 nucleotides). The 
main components facilitating this process are specific enzymes, including DNA glycosylases, 
AP endonucleases, DNA polymerases and ligases (Houtgraaf et al., 2006). 
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Nucleotide Excision repair (NER) pathway repairs helix-distorting DNA lesions such as 6-4 
photoproducts (6-4 PPs) and cyclobutane pyrimidine dimers (CPDs). These lesions are caused 
by UV radiation, ROS or chemical agents. NER also contributes to the repair of intrastrand and 
interstrand crosslinks (ICLs). Hereditary deficiency in NER pathway leads to UV sensitivity 
and skin cancer development (Andressoo et al., 2005). Human diseases Xeroderma 
Pigmentosum and Cockayne’s syndrome are known (Lehmann, 2003). Individuals diagnosed 
with Xeroderma Pigmentosum suffer from extreme sensitivity to UV light, increased cancer 
predisposition and in some cases problems with the nervous system (Brooks PJ, 2014). 
Cockayne syndrome patients suffer from impaired development of nervous system, short 
stature, extreme sensitivity to sunlight and microcephaly, but without apparent increased cancer 
development risk (Bender M, et al., 2003(Hoeijmakers, 2009). There are two modes of action 
for NER: the global genome NER (GG-NER), responsible for monitoring and repairing 
constantly the whole genome, and the transcription-coupled NER (TC-NER), activated in 
presence of transcription blocking lesions. 
Mismatch Repair (MMR) pathway corrects replication errors that can result in mismatched 
bases due to the wrong nucleotide incorporation (A-G or C-T). MMR can also recognize lesions 
resulting from cellular metabolisms and physical or chemical agents, such as 
chemotherapeutics. Defective MMR increases mutation rates and results in microsatellite 
instability (MSI), associated with cancer development (Umar, 2004). 
Homologous Recombination Repair (HR) repair pathway of double-strand breaks takes place 
during S and G2 phases of the cell cycle and is essential for the maintenance of genome 
stability. The extreme cytotoxic nature of DSBs requires fast and accurate repair, otherwise 
chromosomal rearrangements, translocations and deletions can easily occur. DSBs arise by 
ionizing radiations, ROS, chemotherapeutic drugs or can be formed by replication of a single-
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strand break. This pathway requires extensive sister chromatid homology and needs to be 
precise. HR is mediated  
by the Rad52 epistasis group, including Rad51 protein. Rad51 is a strand-exchange protein, 
which searches for an undamaged copy of the broken DNA on the sister chromatid to be used as 
DNA template. This way, the damage can be repaired without loss of genetic information (San 
Filippo J, 2006). 
Non Homologous End joining (NHEJ) another mechanism for repairing DSB, does not 
require homology, since the two ends of broken DNA are directly ligated together by DNA 
ligase/Xrcc4 complex.  NHEJ is less accurate than HR, but is active in all phases of the cell 
cycle, mainly during G0 and G1 and early S-phase (Shrivastav M, 2008) 
 
1.2.3 DNA damage tolerance (DTT) pathways. 
 
Cells possess multiple DNA repair mechanisms to counteract DNA damage and remove lesions 
on the DNA in timely and accurate manner. However, some DNA damage can remain 
unrepaired for prolonged time and/or not be recognized by the functionally adequate repair 
mechanism. If the damage persists, and cells need to go through S phase of the cell cycle, some 
of this damage has to be tolerated and repaired later on. In this way a mechanism is provided for 
cells to finish replication and move to the next cell phase, increasing the chances of survival and 
preventing genome instability. Interestingly, mechanisms in DTT are associated with increased 
mutagenesis, which can lead to various outcomes, from cell death to cancerogenesis (Ghosal G, 
2013). The DTT mechanism is also known as post replication repair (PRR). Studies in yeast and 
mammalian cells have marked two major pathways for PRR: translesion synthesis (TLS) and 
damage avoidance by template switching (TS) (Branzei D, 2010; Chang DJ, 2009; Lee KY, 
2008). A critical step for both pathways is monoubiquitination of PCNA – following DNA 
damage and/or replication stress PCNA gets mono- or polyubiquitinated on lysine 164 (K164) 
(Hoege C, 2002; Parker JL, 2009; Stelter P1, 2003). It was demonstrated in various systems that 
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monoubiquitination of PCNA promotes TLS (Bienko M, 2005; Kannouche, 2003; Kannouche, 
2004), while polyubiquitination of PCNA promotes damage avoidance through template 
switching (Daigaku Y, 2010; Parker JL, 2009). (Figure 1.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Post replicative repair pathways. Two major pathways of postreplicative repair (PRR) – the 
translesion synthesis (TLS) on the left, and template switching (TS) on the right (Ghosal G, 2013).  
 
In both yeast and human, monoubiquitination is mediated by Rad6/Rad18 complex (Broomfield 
S, 2001). Polyubiquitination in yeast is mediated by Mms2/Ubc13 and Rad5 (Broomfield S, 
2001; Kannouche, 2004; Karras GI, 2010) and in human by Mms2/Ubc13 and Rad 5 orthologs, 
supposedly HLTF and SHPRH (Motegi A, 2008; Unk I, 2010). 
 
 
Figure 3.
DNA damage tolerance pathway (DDT): lesions (yellow Square) in the DNA template
blocks progression of high-fidelity replicative polymerase resulting in stalled replication
forks. DNA damage tolerance mechanism mediates bypass of lesions by replicating over
damaged DNA by low-fidelity DNA polymerases (translesion synthesis) or using the
undamaged sister chromatid as a template (template switching). Template switching is
mediated by structural rearrangement of the replication fork either by recombination or fork
reversal. The key regulator of DDT pathway is the modification of PCNA. Under
undamaged conditions replicative polymerase binds to unmodified PCNA during DNA
replication. Upon genotoxic stress, PCNA is ubiquitinated at K164 to initiate DNA damage
tolerance pathways. Monoubiquitination of PCNA promotes translesion synthesis, while
polyubiquitination facilitates template switching. PCNA is monoubiquitinated by RAD18-
RAD6 E3-ligase and polyubiquitinated by Rad5 (human homologue, SHPRH or HLTF).
Following lesion bypass Usp1 deubiquitinates PCNA, thereby facilitating loading of the
replicative polymerase to resume DNA synthesis
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1.2.3.1 Translesion synthesis (TLS). 
 
It is generally not possible for the replicative polymerases to accommodate damaged base in 
their active site due to high stringency and fidelity. For this reason, replication past lesions 
requires the use of specialized DNA polymerases which have been adapted for this specific 
function. These polymerases have lower stringency than the replicative polymerase and their 
active sites are more open and can therefore accommodate damaged bases. There is a growing 
number of DNA polymerases recently found to mediate DNA synthesis across specific 
damages. In eukaryotic cells, five translesion polymerases have been identified: polη, polι, polκ 
and Rev1, belonging to the Y-family, and Polζ, belonging to B-family of DNA polymerases. 
Each of these polymerases shows specificity for different types of damages; some are able to 
bypass a specific DNA lesion, while others are only efficient in insertion or extension step of 
lesion bypass.  
Interferon-stimulated gene 15 (ISG15) modification, also named ISGylation, is involved in 
termination of error-prone TLS (Park et al., 2014). The deubiquitinating enzyme ubiquitin 
specific protease 1 (USP1) was found to deubiquitinate PCNA, inhibiting error-prone TLS 
(Huang TT, 2006). In response to cellular stress, such as UV irradiation, USP1 is auto-cleaved, 
allowing monoubiquitinated PCNA to accumulate and translesion synthesis to start. 
Even though PCNA is crucial for regulation of PRR, there are two new recently discovered 
factors – Spartan (C1orf124/DVC1) and PCNA – associated factor PAF15 (KIAA0101) 
(Centore R.C., 2012; Ghosal G., 2012; Mosbech A., 2012; Povlsen L.K., 2012). Spartan co 
localizes with PCNA and ub PCNA at damage sites and stabilizes Rad18 and ub PCNA at sites 
of damage. It preferentially binds to polη upon damage by UV, and to POLD3 in non-treated 
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conditions (Ghosal G., 2012). Upon depletion of Spartan POLD3 binds to error-prone TLS 
polymerase polζ and this leads to increased mutagenesis.  
 
In unperturbed S phase PAF15 is monoubiquitinated on two lysine residue (15 and 24) and is 
tightly bound to PCNA on chromatin. Upon DNA damage, it gets deubiquitinated and quickly 
removed from the chromatin. This allows for lesion bypass by means of polη recruitment 
(Povlsen LK, et al., 2012). 
It was proposed that for UV induced lesions like CPDs, translesion synthesis (TLS) with polη is 
most efficient, inserting the correct nucleotide opposite the damaged base (Chikahide Masutani, 
2000). In its absence, a less efficient and more error- prone pathway is brought into play leading 
to UV induced hypermutations in the DNA. A study has shown that polη localizes to the 
nucleus, and that during S phase it accumulates in nuclear foci at sites of DNA synthesis 
(Kannouche, 2001). In humans, the inactivation of polη causes cancer-prone syndrome, known 
as the variant form of xeroderma pigmentosum (XP-V) (Chikahide Masutani, 2000). The 
mechanism by which polη is thought to be recruited to the replication forks upon UV damage is 
by monoubiquitination of PCNA by Rad6 and Rad18 (Kannouche, 2004) which increases the 
affinity of PCNA for polη. This increased affinity for polη brings about the " polymerase 
switch" where polδ is replaced by polη at the damaged replication fork. polη then carries out 
replication past the CPD. After the lesion is bypassed, polη dissociates and chain extension is 
taken over by the more processive polδ. New evidence suggests that the PIP domain, rather than 
the direct binding of K164-linked ubiquitin moiety on PCNA, is required for polη accumulation 
at the site of damage (Narottam Acharyaa and Jerard Hurwitzc, 2008). Recent data indicated 
that Rad18 might be targeted to PCNA at the site of stalled replication fork by polη (Durando, 
2013) and this new role for polη in stimulation of PCNA monoubiquitination seems to be 
uncoupled from its DNA polymerase activity. 
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Polι, physically interacting with polη (Patricia Kannouche, 2003) is able to insert the correct 
base opposite many types of lesions, but cannot further synthesize from the inserted bases, so 
that another polymerase is required to complete the lesion bypass.  
Polκ can carry out TLS past benzo[a]pyrene-guanine both in vivo and in vitro (T. Ogi, 2002). 
UV sensitivity, showed by polκ-deficient cells, seems to imply a role for this polymerase in the 
repair synthesis step of NER (Lehmann, 2006). 
Rev1, even if is structurally a member of the Y-family, is a dCMP transferase rather than a 
DNA polymerase. Rev1 is able to insert dCMP opposite Gs or abasic sites. This polymerase 
plays a role in prevention of mutagenesis in yeast (Gibbs et al., 2000), but little is known about 
humans. Unlike the other Y-family polymerases, Rev1 is found at the site of DNA synthesis in 
only a small proportion of S-phase cells (Ogi et al., 2004), possibly because of the short time of 
residence in replication foci. The C-terminal of mammalian Rev1 can interact with the other 
three Y-family polymerases and with Rev7 subunit of polζ (Guo C, 2003), indicating that Rev1 
might act as a platform in switching between TLS and replicative polymerases.  
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Figure 1.7 Proposed model of translesion synthesis (TLS). Replication fork stalling uncouples the replicative 
helicase from normal high-fidelity DNA polymerases resulting in DNA unwinding and generation of tracts of 
ssDNA, which is coated by RPA. RPA-ssDNA also recruits RAD18 E3-ligase to activate DNA damage tolerance 
pathway. PCNA monoubiquitinated at K164 (ub-PCNA) by RAD18-RAD6 operates as a molecular switch from 
normal DNA replication to the TLS. Under normal conditions ubiquitinated PAF15 is bound to PCNA. Upon DNA 
damage PAF15 is degraded by the proteasome and this facilitates the binding of TLS polymerase to ub-PCNA. 
Additionally, Spartan is recruited to DNA damage sites by ub-PCNA and is required to stabilize RAD18 and ub-
PCNA on the chromatin. TLS polymerase Polη bound to ub-PCNA, inserts a nucleotide directly opposite the lesion 
and requires an additional TLS polymerase, such as Polζ (Pol zeta), to extend beyond the insertion. Following 
extension, the second polymerase switch is initiated where the TLS polymerase is replaced by high fidelity 
replicative DNA polymerase. USP1 deubiquitinates PCNA and DNA synthesis is resumed by high-fidelity 
replicative DNA polymerase. The precise mechanism of polymerase switching and regulation of TLS by Spartan, 
PAF15 and USP1 is still unclear (modified from (Ghosal G, 2013). 
 
Figure 4.
Proposed model for TLS pathway. Replication fork stalling uncouples the replicative
helicase from normal high-fidelity DNA polymerases resulting in DNA unwinding and
generation of tracts of ssDNA, which is coated by RPA. RPA-ssDNA serves to initiate the
ATR-Chk1 pathway to activate cell cycle checkpoint control. RPA-ssDNA also recruits
RAD18 E3-ligase to activate DNA damage tole ance pathway. PCNA monoubiquitinated at
K164 (ub-PCNA) by RAD18-RAD6 operates as a molecular switch from normal DNA
replication to the TLS. Under normal conditions ubiquitinated PAF15 is bound to PCNA.
Upon DNA damage PAF15 is degraded by the proteasome an  this facilitates the binding of
TLS p lymerase to ub-PCNA. Additi nally, Spartan is recruited to DNA damage site  by
ub-PCNA and is required to stabilize RAD18 and ub-PCNA on the chromatin. TLS
polymerase Polη (Pol eta) bound to ub-PCNA, inserts a nucleotide directly opposite the
lesion and requires an additional TLS polymerase, such as Polζ (Pol zeta), to extend beyond
the insertion. Following xtention, the second polymerase switch is initiated where the TLS
polymerase is replaced by high fidelity replicative DNA polymerase. USP1 deubiquitinates
PCNA and DNA synthesis is resumed by high-fidelity replicative DNA polymerase. The
precise mechanism of polymerase switching and regulation of TLS by Spartan, PAF15 and
USP1 is still unclear
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1.2.3.2 Template switching mechanisms. 
 
Template switching has evolved as a mechanism to promote DNA damage bypass by the 
replication fork and/or DNA damage tolerance followed by gap filling. In yeast, Rad5-Mms2-
Ubc13 genes, encoding ubiquitin ligases and ubiquitin conjugating enzymes, control this 
pathway and mediate PCNA polyubiquitination, acting as a signal for error-free bypass 
mechanisms. The pathway is still mechanistically unclear and subjected to intense studies in 
higher eukaryotes. This process was proposed to involve a switch of template and, in fact, the 
blocked nascent strand might use the undamaged newly synthesized strand of the sister 
chromatin as a template (Xiao W, 2000).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Model for template switching mechanisms. Representation of mechanisms promoting template 
switching events at the fork or behind the fork (Branzei D, 2004). 
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Two models describing template-switching mechanism, at and behind the fork, have been 
proposed (Branzei D, 2004) (Fig. 1.8). In the first model, the lesion is bypassed through the 
formation of a regressed fork intermediate and would not invoke the role of recombination 
proteins. In this fork reversal model, also known as “chicken foot” model, the newly 
synthesized strands are displaced and the parental and daughter strands annealed, regressing the 
replication fork and creating an alternative template for DNA synthesis. It was demonstrated 
that Rad5 ATPase and helicase activities promote fork reversal in vitro (Blastyak A., 2007), and 
human HLTF protein exhibits the same fork remodelling activity, being able to regress 
replication-fork like DNA structures in an ATP-dependent manner (Blaystak et al., 2009). 
Nevertheless, it still needs to be clarified whether reversed fork intermediates can promote 
error-free DNA damage tolerance in vivo. Findings from the recent study showed that HIRAN 
domain of the HLTF protein is necessary for replication fork slow down upon nucleotide 
depletion, presumably through promoting replication fork reversal (Kile AC, 2015). Additional 
observations, mostly collected in yeast, led to the postulation of a second model of template 
switching that involves recombination-like invasion mechanisms and might occur behind the 
fork. In this model, the blocked nascent strand invades the opposite homologous duplex, 
utilizing the undamaged sister chromatid as a template. Template switching behind the fork 
leads to the formation of X-shaped structures (Minca et al., 2010; Branzei et al., 2008) 
containing linked sister chromatids (Branzei et al., 2011). These template-switch intermediates 
may also contain Holliday Junctions (HJs) (Ashton et al., 2011) and need to be resolved to 
restore normal replication. Recent work in yeast has demonstrated that upon damage and 
activation of TLS the gap region on the parental strand that resulted from fork stalling at the 
lesion, actually becomes paired with the newly created duplex, creating three stranded DNA 
region. The pairing of parental strands leads to displacement of the newly synthetized strand 
which now can serve as a template for extension of the 3’ end of the strand that was stalled at 
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the lesion. This would result in Holliday Junction like structures that are resolved by highly 
regulated “resolvases” (Giannattasio M, 2014). Many resolvases have been identified in 
eukaryotes (Wyatt and West, 2014). Enzymes identified so far, which are required for the 
resolution of damage-induced template-switch intermediates, are RecQ helicase Sgs1 (BLM in 
human) or topoisomerase III. Therefore, cells in which these enzymes are not functional 
accumulate sister chromatid junctions (SCJs) near the replication fork (Hickson and Mankouri, 
2006). PCNA polyubiquitination and error-free PRR factors are required for both gap-filling 
damage tolerance and for template switching-mediated SCJ formation behind the fork. 
Recent findings indicated that Rad18-Rad5 play a role not only in gap-filling by template 
switching (Minca et al., 2010), but also in DBS repair by HR (Szuts et al., 2006). This complex 
may act with recombination factors to join sister chromatids and promote damage bypass by 
template switching (Branzei et al., 2008). While in the reversed fork model these events must 
occur at the fork, in recombination-like invasion mechanisms they can take place either at the 
fork or behind.  
Besides being ubiquitynated, PCNA can also be sumoylated at two lysine residues, K164 and 
K127 (Hoege et al., 2002). PCNA sumoylation favours damage bypass of the lesion utilizing 
factors acting in the error-free branch of PRR. In S.cerevisiae, during unperturbed DNA 
replication, PCNA is SUMOylated at Lys164 to recruit Srs2 helicase. This helicase negatively 
regulates recombination by disrupting Rad51 nucleoprotein filament (Esta et al., 2013). (Hoege 
et al., 2002) (Fig 1.10). Relatively recently it was shown that even in human cells PCNA can get 
SUMOylated, and that this modification may serve to prevent replication fork collapse upon 
DSBs, and therefore promote genome stability (Gali H, et al., 2012).
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1.3 Replication stress. 
1.3.1 Definition and detection of replication stress. 
 
Replication stress has been a well-known phenomenon for many years, however a consensus 
over the exact definition was difficult to reach. Reasons for this are that replication stress has 
many different sources, with many different outcomes in the cells. Nevertheless, one unifying 
definition has emerged stating that replication stress identifies a high number of different 
circumstances slowing or stalling of replication fork progression and/or DNA synthesis 
(Zeman MK, 2014).  
Different sources of replication stress usually lead to single-stranded DNA stretches (ssDNA) 
created as the replicative helicase continues to unwind the parental DNA after the polymerase 
has stalled (Pacek M et al., 2004). These ssDNA stretches are coated by RPA and this serves 
as a signal for activation of the replication stress kinase ATM-Rad3-related (ATR) (Zou L, et 
al., 2003, MacDougal C, et al., 2007, Nam E, et al., 2011). This leads to cell cycle arrest and 
inhibition of late origin firing by phosphorylation of many downstream targets.  
Phosphorylation of histone variant H2AX was proposed to be one of the markers of 
replication stress. However, later on was discovered that this modification can be induced by 
several kinases and that those can reflect different types of damage throughout the cell cycle. 
More reliable marks of replication stress would be ATR-dependent phosphorylation of RPA 
(Ser33) or Chk1 (Ser345), or detection of ssDNA, directly using native BrdU 
immunofluorescence or indirectly through formation of RPA foci (Nam E, et al., 2011, 
Marechal A, et al 2013). The most reliable readout of replication stress is probably direct 
measurement of DNA synthesis using DNA fiber or DNA combing assays, which rely on the 
incorporation of nucleotide analogues (Bianco J, et al., 2012). 
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1.3.2 Sources of replication stress. 
There are a number of recognized sources of replication stress, to name just a few (for 
schematic overview see Figure 1.9): 
1) Nicks, gaps, and ssDNA – can be both sources and symptoms of replication stress. 
DNA lesions – probably the most-studied source of replication stress. Lesions could 
be caused by UV light, chemical mutagens, byproducts of cellular metabolism, etc. 
(Ciccia A, et al., 2010). 
2) Misincorporation of ribonucleotides - polymerase ε and polymerase δ are very 
specific enzymes in terms of base pairing, however they are less specific when it 
comes to distinction between deoxyribonucleotides (dNTPs) and ribonucleotides 
(rNTPs). This is usually dealt with by RNase H2, FEN1 and EXO1 (Sparks J, et al., 
2012). 
3) Unusual DNA structures – trinucleotide repeats leading to formation of hairpins 
triplexes etc. (Mcurray C, et al., 2010, Kim J, et al., 2013), and as of recently G – 
quadruplexes that form in GC – rich regions (Paeschke K, et al., 2013, Bochman M, 
et al., 2012). 
4) Conflict between replication and transcription – since both replication and 
transcription are occurring on the DNA molecule, collisions are almost inevitable. 
Recent studies identified a class of fragile sites (“early replicating fragile sites”) that 
lie within highly replicated genes in early S phase (Barlow J, et al., 2013). Formation 
of R – loops was also widely implicated in replication stress (Aguilera A, et al., 
2012). 
5) Limiting levels of “building blocks” or essential replication factors – e.g. 
insufficiency of nucleotides, replication factors, histone and histone chaperones (Poli 
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J, et al., 2012, Bester A, et al., 2011, Anglana M, et al., 2003, Aguilera A, et al., 2013; 
Toledo LI, et al., 2013). 
6) Common fragile sites – genomic regions prone to replication stress-induced DSBs, 
which are usually prevented by ATR activity (Debatisse M, et al., 2012, Casper A, et 
a., 2002). The molecular determinants of fragility in these regions are less clear and 
more heterogenous – including collision of replication machinery with transcription 
of very long genes (Bochman M, et al., 2012) and lack of replication origins in these 
regions (Letessier A. et al., 2011). 
7) Oncogene induced replication stress – overexpression or constitutive expression of 
several different oncogenes (w.g. H-RAS, MYC and cyclin E) leads to replication 
stress probably because of depletion of nucleotide pools and/or increased collisions 
with transcription (Bester A, et al., 2011, Srinivasan S., et al., 2013, Jones R, et al., 
2012, Halazonetis T, et al., 2008). 
8) Chromatin inaccessibility – the chromatin status seems to play a role in replication 
stress. Compacted chromatin may pose an obstacle for the replication machinery. 
Studies show that chromatin relaxation can reduce common fragile sites breakage 
(Jiang Y, et al., 2009).  
 
 
 
 
 
 
 
 
Figure 1.9 Different sources of replication stress (Zeman MK, 2014). 
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Recent reports have identified replication fork reversal as a cellular response to different 
types of replication stress, namely replication through trinucleotide repeats, oncogene 
overexpression and different genotoxic agents (Follonier C, et al., 2013, Neelsen K.J, et al 
2013, Zellweger R, et al., 2015). The process and benefits of fork reversal are discussed in 
details in the next chapter.   
 
1.4 Replication fork reversal. 
1.4.1 Definition. 
 
Replication fork reversal identifies the process of transition of a normal replication fork 
(three-way junction) into a four-way junction, where the two nascent strands are unwound 
from their parental partners and annealed with each other, while the parental strands are also 
reannealed, leading to back-tracking of the replication fork (Neelsen and Lopes, 2015) (see 
figure 1.10 for clarification). Although a transaction of this kind was suggested 4 decades 
ago, it was not widely accepted due to technical concerns of the method used to obtain 
results. 
Replication fork reversal in prokaryotes is well characterized: key findings are published in 
high-profile papers (Manosas M, et al., 2012, De Septenville A.L, et al., 2012, Nelson 
S.W.&BenkovicD.J., 2010) and have been summarized in a recent review (Atkinson and 
McGlynn, NAR 2009). However, in eukaryotic cells remained elusive until recently. 
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Shortly after, this hypothesis was confirmed by electron 
microscopy analysis of these replication inter mediates10. 
Thus, 26 years after it was first proposed as a damage-
bypass mechanism, the direct visualization of fork 
reversal in eukaryotic cells led to its association with the 
inability to restart stalled replication forks. Since then, 
fork reversal has been consistently interpreted as a patho-
logical transaction at replication forks that have lost their 
replication capacity11.
Although 2D-gel electrophoresis cannot identif y 
reversed forks unambiguously (Supplementary 
informa tion S2 (figure)), molecular biology approaches 
were often used in both Saccharomyces cerevisiae and 
Schizosaccharomyces pombe to deduce the existence of 
fork reversal as a consequence of increased topological 
stress and/or replisome destabilization, induced at stalled 
forks by defects in the DNA replication checkpoint12,13. 
In S. pombe, complex chromosomal re arrangements 
were also suggested to be the consequence of nascent 
strand extrusion and template switching, which occur dur-
ing recombination-mediated restart of stalled forks14. 
Although replication perturbation by nucleotide pool 
depletion, or by DNA damage caused by ultraviolet light 
or methylating agents, fail to induce detectable levels of 
fork reversal in checkpoint-proficient yeast cells9,15,16, 
anticancer agents that increase topological stress dur-
ing replication — such as DNA topoisomeras e I (Top1) 
inhibitors — were recently shown to induce frequent 
fork reversal in wild-type S. cerevisiae cells17. Unlike 
other genotoxic treatments, Top1 inhibition in yeast 
is known to be checkpoint-blind18; this observation 
re inforced the hypothesis that fork reversal is a patho-
logical transaction in response to excessive topological 
constraints, and that the DNA damage checkpoints acti-
vated by other types of replication stress prevent fork 
reversal11,12. The role of checkpoints in preventing the 
formation and/or accumulation of reversed forks was 
further confirmed by recently obtained electron micros-
copy evidence from S. pombe, in which checkpoin-
t-mediated phosphorylation of the DNA replication 
ATP-dependent helicas e–nuclease 2 (Dna2) was pro-
posed to promote the processing of reversed replication 
forks19. Overall, these studies support a model in which 
replication fork reversal in yeast is primarily a patho-
logical process that is actively prevented by factors that 
maintain fork stability in response to replication pertur-
bation. An alternative interpretation of the available data 
is that reversed forks do form following replication stress 
in wild-type yeast cells, but they are usually too transient 
to be detected. In this view, genetic interference with rep-
lication fork restart (for example, in checkpoint-deficien t 
cells)10 and/ or experimentally increased torsional stress17 
— which was amply reported to promote replication fork 
reversal in prokaryotic systems20–23 — should reveal 
the existence of reversed replication forks in yeast. 
Furthermore, efficient re-priming downstream of DNA 
lesions may kinetically disfavour fork reversal in yeast 
and promote DNA damage bypass behind replication 
forks through recombination24, as mutations affecting 
primase efficiency lead to elevated levels of fork reversal 
in damaged S. cerevisiae cells25.
Figure 1 | Transactions at replication forks following genotoxic stress. a | The 
process of replication fork reversal. The main mechanistic steps leading to replication 
fork reversal are the unwinding of newly synthesized strands (top panel), annealing of the 
parental strands (middle panel), and annealing of the newly synthesized strands (bottom 
panel). As a result, the three-way junction at the replication fork is converted into a 
four-way junction and is backtracked along the replicating DNA molecule. Depending on 
the proteins involved in the reaction, fork reversal may occur through a stepwise strand 
exchange, as depicted here, or through simultaneous re-annealing of the parental 
strands with the annealing of the nascent strands. b | Nomenclature of replication stress. 
Fork collapse is defined as the loss of replication competence and may occur when a 
functional replication fork (an active fork) is challenged by an impediment to its 
progression (indicated by the ‘STOP’ sign on the figure). This is usually accompanied by 
loss of the replication apparatus (replisome, top panel; the replisome has been omitted 
KP|VJGNQYGTRCPGNUVQUKORNKH[VJGITCRJKECNTGRTGUGPVCVKQP(QTMDTGCMCIGQEEWTUYJGP
a fork has stopped progressing (stalled fork) or has undergone collapse, and the DNA at 
VJG|LWPEVKQPWPFGTIQGURJ[UKECNDTGCMCIG
DTQMGPHQTMGKVJGTRCUUKXGN[QTCEVKXGN[XKC 
cleavage by endonucleases (middle panel). The term ‘fork collapse’ is occasionally also 
used to describe the process of fork breakage. Fork reversal (or fork regression) occurs 
when a replication fork faces genotoxic stress. Uncoupling of leading and lagging strand 
synthesis results in the accumulation of single-stranded DNA (ssDNA) at the replication 
junction (uncoupled fork; bottom panel). Controlled unwinding and annealing reactions 
(see panel a) lead to its conversion into a four-way junction, called a reversed fork, 
regressed fork or chicken-foot structure. The fourth arm created by fork reversal is called 
the regressed arm. The conversion of a reversed fork back into a standard three-way 
replication fork is called replication fork restoration (or fork restart). Once the replication 
fork has been restored, polymerization may resume. Fork restart may evidently also occur 
at a temporarily blocked replication fork without undergoing reversal.
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Figure 1.10 Process of replication fork reversal– Fork reversal might occur through stepwise strand 
exchange, as shown in the scheme, or through simultaneous re-annealing of the parental strands with the 
annealing of the nascent strands. (Neelsen KJ, 2015). 
In eukaryotes replication fork was a matter of substantial debate among opposing groups of 
thinking. On one side, it was considered pathological. The proof of this was the notion that in 
yeast (Saccharomyces cerevisiae) these structures could only be observed in checkpoint 
defective upon treatment with various genotoxic agents (UV irradiation, methyl 
methanesulfonate – MMS and ribonucleotidereductase inhibitor hydroxyurea –HU), (Sogo 
J.M, et al., 2001, Lopes M, et al., 2006, Mojas N, et al., 2007). However, using 
topoisomerase inhibitors in checkpoint proficient S. cerevisiae cells, frequent fork reversal 
was observed (Ray Chaudhuri A, et al., 2012). Importantly, in yeast cells TopI inhibition is 
known to be checkpoint-blind (Radon C, et al., 2003), and the checkpoints are responsible for 
checkpoint-mediated phosphorylation of DNA replication ATP-dependent helicase-nuclease 
2 (Dna2), which is processing reversed replication forks (Hu J, et al., 2012). 
DNA topoisomerases solve the topological problems associated with DNA replication, 
transcription, recombination, and chromatin remodeling by introducing temporary single- or 
double-strand breaks in the DNA. In addition, these enzymes fine-tune the steady-state level 
of DNA supercoiling both to facilitate protein interactions with the DNA and to prevent 
deleterious excessive supercoiling (Champoux, 2001). 
Camptothecin (CPT), or its clinically relevant derivatives irinotecan and topotecan, inhibit 
TopI action by trapping it in a covalent complex with DNA after its cleavage (TopI cleavage 
complexes; TopIccs). Replication fork collision with the TopIccs was proposed as the 
primary cytotoxic mechanism for TopI inhibitors in dividing cells (Holm et al., 1989). This 
hypothesis is known as ‘’Replication run-off’’ theory. In this scenario collision of the 
replication forks with the TopIccs results in double strand breaks (DSBs). This hypothesis 
was supported by data implicating the role of DNA damage markers like H2AX 
phosphorylation and homologous recombination factors in CPT induced cytotoxicity 
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(Pommier, 2006). Indeed, CPT is commonly used in many basic research laboratories as 
agent of choice to induce DSBs. 
Some reports have recently challenged this theory, by showing that TopI inhibitors also 
prevent relaxation activity of TopI, leading to accumulation of positive supercoils, potentially 
contributing to TopI inhibitors-mediated cytotoxicity (Koster et al., 2010). 
Recent work investigated the cellular response to TopI poisoning by CPT or its derivatives in 
more detail. It was shown in several different eukaryotic systems (S. cerevisiae, Xenopus 
laevis egg extracts, cultured mouse embryonic fibroblasts and human cells) that, upon 
treatment with low doses of TopI inhibitors, replication forks undergo rapid slowdown and 
frequent reversal, uncoupled from DSB formation (Ray Chaudhuri et al., 2012). Replication 
fork reversal was proven to be a global, evolutionary conserved response to replication stress 
induced by TopI inhibitors. These observations were made upon treatment with low (25nM), 
but clinically relevant doses of CPT, uncovering potential drug resistance mechanisms in 
cancer chemotherapy.  
Another study identified replication fork reversal as a general response to replication stress 
induced by chemotherapeutic treatment. The genotoxic agents used in the research belong to 
four different groups: Topoisomerase inhibitors (etoposide - ETO, and doxorubicin - DOXO), 
base damaging agents (UV-C irradiation, MMS, and hydrogen peroxide H2O2), DNA 
crosslinking agents (mitomycin C - MMC and cis-diamminedichloroplatinum - CDDP) and 
antimetabolites that inhibit nucleotide biosynthesis (HU) or DNA polymerases (aphidicolin - 
APH) (Zellweger R, 2015). 
Thorough analysis of the replication intermediates isolated from non-treated (NT) or treated 
cells revealed accumulation of short (40nt) ssDNA at the junctions, presumably identifying 
lagging strand synthesis. All treatments led to extended (1.5-2 fold) ssDNA at the junctions, 
reflecting uncoupling of DNA synthesis at the fork. The extent of fork uncoupling upon 
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different treatments is strictly correlated with the frequency of reversed replication forks - i.e. 
the more uncoupling, the higher reversed replication fork frequency. Having in mind that 
RAD51 binds to long stretches of ssDNA to drive homology directed strand invasion during 
homologous recombination (Symington and Gautier, 2011), its potential role in the process of 
fork reversal was investigated. Strikingly, upon downregulation of RAD51, reversed 
replication fork frequency in CPT, MMC and HU treated dramatically dropped compared to 
mock transfected cells. Interestingly, upon all tested treatments, reduction in reversed fork 
frequency was accompanied by an increase in the length of the ssDNA at the junction, 
suggesting that uncoupled forks are precursors of RAD51-mediated fork reversal.  
Poly (ADP-ribose) polymerase (PARP) activity is required to observe CPT, MMC and HU-
induced replication fork slowing and reversal. Its activity was shown to limit the activity of 
the RECQ1 helicase - which in turn drives reversed fork restart upon CPT (Berti M, et al., 
2013) (see figure 1.11) as well as MMC and HU treatments (Zellweger R, et al., 2015) - thus 
allowing stabilization and accumulation of reversed forks. The dependency of efficient fork 
reversal on PARP activity may contribute to explain the promising synergistic effect of TopI 
and PARP inhibitors and opens new synthetic lethality treatment concepts, especially 
considering that MMC- and HU-induced fork slowing and reversal are also, at least partially, 
PARP dependent. 
Another recent study revealed that, besides RECQ1, DNA2 and WRN proteins have also a 
role in the restart of the reversed replication forks (Thangavel S, et al., 2015) (see figure 
1.11). Co-depletion of RECQ1 and DNA2 leads to a more marked accumulation of reversed 
replication forks compared to single RECQ1 or DNA2 depletion, suggesting two 
possibilities: either these proteins are involved in distinct mechanisms of replication fork 
restart, or that RECQ1 acts downstream of DNA2. The study also shows that nuclease 
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activity of DNA2 and the ATPase activity of WRN are crucial for processing of stalled forks, 
and that REQ1 regulates fork processing activity of DNA2.  
 
Figure 1.11 Processing of reversed replication forks – restart of the reversed replication forks goes through 
action of RecQ1, WRN and DNA2 proteins. (Neelsen and Lopes, 2015). 
 
Other recent publications documented the detection of reversed replication forks in vivo in 
yet different situations associated with replication stress – namely trinucleotide repeats and 
oncogene overexpression. It was shown, by using plasmid based system, that the reversed 
forks frequency was very high upon replication through trinucleotide repeats of different 
length (Follonier C, et al., 2013), possibly contributing to the inherent instability of these 
repeats (Mirkin, Nature 2007; Neelsen and Lopes, 2015). Upon overexpression of different 
oncogenes (CyclinE and CDC25A overexpression), reversed forks were identified among the 
most prominent structures observed under these conditions and, in the case of CDC25A 
overexpression, were shown to be processed into DSB by the deregulated action of structure-
specific nucleases (Neelsen K.J, et al., 2013). Thus overall, albeit contributing to a 
physiological and protective response to genotoxic stress, reversed forks may also contribute 
to genome rearrangements. Overall, we believe that fork reversal should be seen as a 
“double-edged sword”, with physiological and pathological outcomes that depending on the 
cellular context and on the specific condition of replication stress, as discussed in the next 
chapter. 
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cells60, this DNA2-dependent end-processing pathway 
in human cells is independent of the DSB resection 
activities of proteins such as CtBP-interacting protein 
(CtIP; also known as RBBP8), meiotic recombination 11 
homologue A (MRE11) and EXO1 (REF. 61). These 
observations in human cells are consistent with reports 
on S. pombe Dna2, which was found to resect regressed 
leading and lagging strands in vitro and in vivo under 
conditions of replication stress, thereby preventing the 
accumulation of reversed forks. Importantly, fork pro-
cessing by S. pombe Dna2 was strictly dependent on 
its phosphorylation by the central checkpoint kinase 
Cds1 (checking DNA synthesis kinase; also known as 
Chk2)19, suggesting that checkpoints could generally 
modulate reversed fork accumulation.
Given the spectrum of conditions in which fork 
reversal occurs, it is likely that these are not the only 
mechanisms controlling the restart of reversed forks. 
For instance, controlled resection of regressed arms 
may, in principle, stimulate further recruitment of 
recombination factors, similarly to DSB repair, and pro-
mote homology-directed fork restart, which was previ-
ously genetically linked to RAD51 (REFS 61,62) (FIG. 3). 
Investigating recombination-mediated fork restart is 
complicated by the role of RAD51 (REF. 30) and possi-
bly other recombination factors that are also involved in 
reversed fork formation (FIG. 3a). Specific genetic tools 
will thus be required to dissect the role of RAD51 and 
other homologous recombination factors and Fanconi 
anaemia factors in fork reversal and/or restart.
Figure 3 | Forming and processing reversed forks KP|XKXQ. a | The involvement of homologous recombination factors in 
replication fork remodelling. The top panel shows that following replication stress and fork uncoupling, RAD51 partially 
replaces replication protein A (RPA) on extended single-stranded DNA (ssDNA) regions. This is possibly assisted by the 
controlled resection of newly synthesized strands by as-yet-unknown factors that are likely to belong to the Fanconi anaemia 
(FA) and homologous recombination (HR) pathways. RAD51-mediated homology search and strand invasion may drive the 
re-annealing of parental strands, further limiting strand uncoupling and priming fork reversal30, which is assisted by 
(DQZEQPVCKPKPI&0#|JGNKECUG
($*OGFKCVGFFKURNCEGOGPVQHVJGITQYKPINCIIKPIUVTCPF43,48. Once reversed forks are 
formed, the presence of ssDNA regions on the regressed arm — which are possibly expanded by controlled nucleolytic 
degradation — may also recruit RAD51 (bottom panel), promote homology-driven invasion of the re-annealed template 
strands and thus result in recombination-mediated fork restart. Note that despite the striking mechanistic similarity with 
standard HR, these proposed transactions would occur in the absence of any DNA double-strand break (DSB) at the 
replication fork, and may only partially mirror genetic dependencies found for DSB repair. b | Currently known mechanisms 
for th  restart of reversed forks. The specialized ATP-dependent DNA helicase Q1 (RECQ1) binds reversed forks and primes 
their restart by branch migration. RECQ1 is transiently inhibited by poly(ADP-ribose) polymerase (PARP) and only reactivated 
(RECQ1*) when DNA repair and replication stress release allow local PARP inactivation29,30. RECQ1 binding inhibits a second 
pathway implied in reversed fork restart, composed of unwinding and nucleolytic degradation of the regressed arm by 
VJG|PWENGCUGCEVKXKVKGUQH9GTPGTU[PFTQOG#62FGRGPFGPVJGNKECUG
940CPF&0#TGRNKECVKQP#62FGRGPFGPVJGNKECUGs
nuclease (DNA2), respectively. The resected regressed arm may allow the recruitment of alternative, as-yet-unknown 
DTCPEJ|OKITCVKQPHCEVQTUQTRTQOQVGJQOQNQIQWUTGEQODKPCVKQPFGRGPFGPVTGUVCTVCUFGUETKDGFCDQXG61.
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1.4.2 Replication fork reversal -  a friend or a foe? 
 
The situations in which fork reversal could be beneficial for maintenance of genomic stability 
are lesions on the template strand, lack of nucleotides, discontinuities on the template strand  
and possibly interstrand crosslinks. Reversing the fork could prevent the excessive 
accumulation of single-stranded DNA (ssDNA), allow more time for repair of DNA lesions 
and enable excision repair by repositioning a lesion in double stranded DNA (Figure 1.12a) 
Conversely, the situations in which fork reversal would lead to increase in genomic 
instability are replication through trinucleotide repeats and oncogene overexpression. In 
replication through trinucleotide repeats there could be misalignment of the repeats on the 
regressed arm, so when the fork is restarted potential deletions or insertions of repeats could 
be provoked in the next round of replication. As mentioned above emergence of replication 
forks was observed even upon oncogene overexpression. These structures were cleaved by 
methanesulfonate UV-sensitive clone 81 (MUS81) and synthetic lethal of unknown function 
4 (SLX4) endonucleases, leading to double strand breaks in checkpoint deregulated systems 
(Figure 1.12b). 
Having in mind all this, it is difficult to make a definite statement what is direct role of 
replication fork reversal in human health, other than that is a mechanism primarily designed 
to prevent genetic instability. Healthy cells would probably benefit of fork reversal – genome 
stability is prerequisite for normal divisions and unperturbed transcription, in one-word 
viability. But, cancer cells can also exploit this role of fork reversal and thus use it as a 
mechanism to tolerate drugs, i.e. to develop resistance (example of TopI inhibitor). So the 
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role in maintaining genome stability can have positive and negative outcomes. Conversely, as 
discussed, promoting instability of trinucleotide repeats could have deleterious effects on 
individual’s health in some conditions.   
 
 
 
 
Numerous questions remain open on the process of fork reversal and its cellular role (Neelsen 
and Lopes, 2015). Most notably, it is still elusive what is(are) cellular factor(s) responsible 
for replication fork reversal upon replication stress induced by chemotherapeutics treatment. 
Extensive literature analysis has resulted in a few promising candidates. 
Figure 1.12. Different roles of fork reversal. a) Roles in maintaining genomic stability. b) Roles in 
destabilization of genomic integrity (Neelsen and Lopes, 2015). 
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1.4.3. Protein(s) potentially involved in replication fork reversal. 
 
Annealing DNA helicases–HARP (SMARCAL1) and ZRANB3 (AH2) - The term 
‘’annealing helicase’’ was created upon discovery of helicase domain-containing proteins 
that had annealing and no unwinding activity. The first to be discovered was HARP (HepA 
related protein), also referred to as SMARCAL1 (SWI/SNF-related, matrix associated, actin-
dependent regulator of chromatin, subfamily a-like 1), which is member of the SWI/SNF 
family. Mutations in HARP are associated with Schimke Immuno-Osseous Dysplasia 
(SIOD), a multisystem autosomal recessive disorder characterized by short stature, kidney 
disease and a weakened immune system (Boerkoel et al., 2000). HARP has ability to catalyze 
the ATP-dependent reannealing of ssDNA bubbles coated with RPA (Yusufzai, 2008). In 
vitro data also show that HARP can catalyze branch migration of Holliday junctions (HJs) 
and regression of replication forks (Wu, 2012). Upon DNA damage, HARP co-localizes with 
RPA and γH2AX foci, and the interaction with RPA is required for localization to the sites of 
DNA damage (Yusufzai, 2009). HARP is phosphorylated in response to replication stress and 
DNA damage. It can be phosphorylated by ATM, ATR and DNA-PK, yet significance of 
these phosphorylations is unclear, as some promote and some inhibit it's function (Bansbach 
et al., 2009; Carroll et al., 2013; Couch et al., 2013; Postow et al., 2009). 
Recently, it was shown that HARP can promote both fork reversal and reversed fork restart, 
depending on where the ssDNA gap is located (i.e. leading or lagging strand) and on the 
presence or absence of RPA (Betous et al., 2013). This study showed that in presence of 
RPA, HARP is preferentially reversing model replication forks if the gap is on the leading 
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strand (Figure 1.13), presumably to allow for the bypass of the damage. Conversely, if the 
gap is on the lagging strand and the RPA is present (Figure 1.14), HARP is preferentially 
restarting reversed forks. This may suggest that HARP is necessary for keeping replication 
process unperturbed, as having replication forks reversed upon gap formation on the lagging 
strand would not be beneficial, but rather unnecessarily energy and time consuming, as these 
gaps are physiologically formed during the replication process. Interestingly, the preference 
for replication fork reversal, or reversed fork restart changes completely in the absence of 
RPA, although the physiological significance of this observation is debatable.  
 
                                           
    
  
 
 
 
 
After HARP, another annealing helicase was discovered – ZRANB3 (zinc-finger, RAN-
binding domain containing 3) also known as AH2 (annealing helicase 2) (Yusufzai and 
Kadonaga, 2010) (Figure 1.15). 
 
 
SMARCAL1 and ZRANB3 do not act redundantly because
knockdown of either causes replication-associated DNA dam-
age. It is unclear how these enzymes convert the energy of
ATP hydrolysis into fork-remodeling activity. One model is that
they act like E. coli RecG to translocate on double-stranded
DNA (dsDNA) nd have a domain that inserts into the DNA
branch point to facilitate fork regression (Singleton et al., 2001).
Here, we investigated the mechanism by which SMARCAL1
repairs damaged replication forks. We find that SMARCAL1
can catalyze both fork regression and restoration. Its interaction
with RPA directs these activities to provide the specificity
needed to yield regression of damaged forks and restoration of
normal fork structures. Single-molecule studies reveal how
RPA enforces this substrate preference, and comparisons to
other enzymes indicate a functional relationship between
SMARCAL1 and E. coli RecG. Together, our results explain
how SMARCAL1 is directed to remodel and repair stalled repli-
cation forks.
RESULTS
RPA Directs SMARCAL1 to Selectively Remodel Stalled
Replication Forks with a Leading-Strand Gap
SMARCAL1 catalyzes fork regression of synthetic replication
forks at least when no ssDNA gap or RPA is present on the sub-
strate (Be´tous et al., 2012; Ciccia et al., 2012). Fork regression
provides a mechanism of repair but should not happen at
actively elongating forks. Yet, SMARCAL1 is present even at
elongating replication forks because its interaction with RPA is
not regulated (Be´tous et al., 2012). Therefore, there must be
mechanisms to direct its activity specifically to damaged forks
and restrain its activity at normal forks. A ssDNA gap is present
on the lagging strand at normal elongating forks. When a repli-
some stalls at a DNA lesion on the leading-strand template,
uncoupling between the replicative polymerase and helicase
creates a ssDNA gap on the leading-strand template. In both
cases, the ssDNA is bound by RPA. To test if ssDNA gaps and
RPA influence SMARCAL1 function, we designed leading- and
lagging-strand gap fork substrates containing a 32 nt ssDNA
gap that can accommodate one RPA molecule in its high-affinity
DNA-bound conformation (Figures 1A and 1C). In the absence of
RPA, SMARCAL1 has higher activity on a lagging-strand gap
replication fork than on a leading-strand gap replication fork (Fig-
ures 1B, 1D, S1A, and S1B).
However, RPA inhibits SMARCAL1-catalyzed fork regression
of a lagging-gap replication fork and stimulates fork regression
of a leading-gap substrate (Figures 1B, 1D, S1A, and S1B). In
these experiments, RPAwas prebound to the gapped substrates
such that all of the substrate molecules had one RPA molecule
bound to the gap (Figures S1C and S1D). This stimulation of
SMARCAL1 on the leading-gap substrate relies on a direct
SMARCAL1-RPA interaction because RPA failed to stimulate a
Figure 1. RPA Directs SMARCAL1 Specifically to a Damaged Replication Fork Substrate and Inhibits Its Action at a Normal Fork
(A and C) Diagram of the lagging (A)- or leading (C)-gap replication fork regression assay. 32P-labeled strands are indicated with asterisks. A 2 bp mismatch is
present on the parental (black) strands to prevent spontaneous branch migration. The physiological reaction mimicked by the experimental assay is shown in
parentheses.
(B and D) Lagging (B)- or leading (D)-gap replication fork substrates were incubated 15 min at room temperature in the presence or absence of RPA. Increasing
amounts of SMARCAL1-WT or -D34 were added to the reaction and further incubated 20min at 30!C. DNA products were analyzed by native gel electrophoresis,
and phosphorimager quantitation of three experiments is shown (mean ± SD).
See also Figure S1.
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Figure 1.13. HARP promotes replication fork reversal in the presence of RPA if the gap is on the leading strand. 
(Betous R, et al., 2013) 
Figure 1.14. In the presence of RPA HARP promotes reversed fork restart if the gap is on the lagging strand. 
(Betous R, et al., 2013) 
Figure 1.15. ZRANB3 domains. Red coloured domains are necessary for annealing activity, green (PIP and 
APIM) for interaction with PCNA, purple (NZF) for interaction with polyubiquitinated PCNA, and grey (HNH) 
for endonuclease activity (Ciccia A, et al., 2012). 
Figure 1. PCNA-Dependent Recruitment of ZRANB3 to DNA Damage Sites
(A) Schematic representation of the protein domains of SMARCAL1 and ZRANB3. The helicase domains are indicated in red.
(B) Sequence alignments of the PIP box (left) and APIM (right) motifs of ZRANB3 with known PIP box and APIM motifs of other PCNA-interacting proteins. The
amino acids of the PIP box and APIM motifs that have been mutated are indicated by arrows.
(C) Localization ofWT ormutant GFP-ZRANB3 toDNA damage sites generated byUV-lasermicroirradiation. U2OS cells expressingWTGFP-ZRANB3 are shown
with or without PCNA siRNA treatment prior to UV microirradiation.
(D) Graphical representation of the percentage of U2OS cells that display colocalization of GFP-ZRANB3 with gH2AX at laser-generated stripes. The data
represent the average and standard deviation of three independent experiments performed on cells expressing the GFP constructs shown in (C).
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our previous studi indicate that SMARCAL1 can catalyze this
reaction (Be´tous et al., 2012). Furthermore, using magnetic
tweezers and a substrate that mimics a stalled fork without a
gap, we have observed that SMARCAL1 regresses the fork form-
ing a Holliday junction, migrates the Holliday junction, and
frequently switches directions toward either fork regression or
restoration (Figure S5). However, in cells, the leading and lagging
nascent strands are likely to have different lengths. Therefore,
regressed forks may have an extra ssDNA protrusion, which
will b bound by PA. Thus, either a nuclease activity to remove
this ssDNA end or an activity to remove the RPA and anneal the
nascent ssDNA to the template strand would be needed to fully
restore the fork.
To investigate whether SMARCAL1 could catalyze this reac-
tion, we designed a replication fork-restoration assay using
DNA substrates mimicking partially regressed replication forks
with a protruding 32 nt ssDNA tail (Figures 5A and 5C). The sub-
strates contain mismatches to prevent spontaneous branch
migration, contain heterologous arms to allow measurement of
only fork restoration, bind onemolecule of RPA in its high-affinity
DNA-bound state, and contain either a 30 or 50 ‘‘nascent’’ ssDNA
tail. Branch migration of these substrates would restore replica-
tion forks with a ssDNA gap either on the lagging or the leading
template strand depending on whether the nascent leading or
lagging strand was longer, respectively.
SM RCAL1 catalyzed fork restoration of both substrates
but with very different efficiencies. In the absence of RPA,
SMARCAL1 has a strong preference for restoring a lagging-
strand gap because much higher SMARCAL1 concentrations
were required to restore a replication fork with a leading-strand
gap (Figures 5B and S6). This difference in substrate preference
was exacerbated when RPA was bound. RPA strongly stimu-
lated SMARCAL1 activity to restore a normal fork configuration
with lagging template-strand gap while inhibiting its ability to
restore the l ading-strand gap fork (Figures 5D and S6). The
RPA stimulation partially depends on th direct i teraction
between SMARCAL1 and RPA because the SMARCAL1-D34
protein activity is also stimulated although not as strongly (Fig-
ures 5B and S6).
E. coli RecG, but Not Human ZRANB3, Shares Similar
Substrate Preferences to SMARCAL1
To determine if the SMARCAL1 family member ZRANB3 shares
a similar substrate preference, we assayed its activity using sub-
strates with ssDNA gaps. In contrast to SMARCAL1, ZRANB3
has no intrinsic preference for regressing either lagging- or
leading-strand gap forks (Figure 6A). Furthermore, unlike
SMARCAL1, RPA inhibits ZRANB3 fork-regression activity on
leading-strand gap substrates. When tested in the fork-restora-
tion assay, ZRANB3 exhibits a preference to restoring a normal
Figure 5. SMARCAL1 Preferentially Catalyzes Fork Restoration that Yields a Normal Lagging-Strand Gap Replication Fork in the Presence
of RPA
(A and C) Schematic of the leading (A)- or lagging (C)-gap replication fork restoration assay. 32P-labeled strands are indicated with asterisks. Mismatches in the
DNA strands were inserted between the longest nascent strand and the corresponding parental strand to prevent spontaneous fork restoration. In parentheses is
the physiological reaction mimicked by the experimental assay.
(B and D) Leading (B)- or lagging (D)-gap replication fork restoration substrates were incubated 15 min at room temperature in the presence or absence of RPA
sufficient to bind 100% of the DNA substrate. Increasing amounts of SMARCAL1-WT or -D34 were added to the reaction and further incubated 20 min. DNA
products were analyzed by native g l electrophoresis. Mean ± D from three independent experiments is depicted.
See also Figur S6 and Extended Results
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Similar to HARP, ZRANB3 displays DNA-dependent ATP-ase activity and ATP-dependent 
rewinding activity. In vivo data suggest that, unlike HARP, ZRANB3 does not interact with 
RPA, but it is recruited to the sites of DNA damage via interaction with PCNA. ZRANB3 
possesses three domains for interaction with PCNA, two of which (PIP box and APIM) are 
required for direct  
interaction with PCNA, and the third, called NZF (NPL4 zinc finger) recognize K63-linked 
ubiquitin chains. This motif is required for specific interaction with the K63-linked 
polyubiquitinated form of PCNA in vitro and for retention of ZRANB3 at damage sites in 
vivo (Ciccia et al., 2012). As mentioned above, the polyubiquitinated form of PCNA is 
involved in error-free PRR in the template switching process, so - taking all these data 
together - it was tempting to suggest that fork regression is executed by ZRANB3, which is 
recruited via polyubiqinated PCNA (this working hypothesis essentially represents the 
rationale of this PhD thesis). Apart from being able to reanneal ssDNA bubbles, it was 
reported from biochemical experiments that ZRANB3 can exhibit its activity on some 
additional substrates – it can regress stalled forks and can disrupt D-structures (Ciccia et al., 
2012). Additionally, a novel biochemical activity was reported for ZRANB3, as structure 
specific, ATP-dependent endonuclease (Weston et al., 2012). Latest reports suggest 
additional members of the ‘’annealing helicases’’ family – such as Rad54L and SMARCA1 
(Yuan et al., 2012). 
 
Factors involved in error free post-replicative repair (PRR) –  As described before, upon 
DNA damage the Rad6-Rad18 complex monoubiquitinates PCNA, and this action can be 
followed by either error-prone TLS, error-free TLS, or error-free PRR controlled by Rad5 
and Mms2-Ubc13 proteins. Mms2-Ubc13 compose an ubiquitin conjugating complex, 
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whereas Rad5 has ubiquitin ligase and DNA dependent ATP-ase activity. In the error-free 
PRR Rad5 and Mms2-Ubc13 promote K63 linked polyubiquitination of the PCNA. In this 
pathway the damage is bypassed by template switching using the newly synthesized DNA 
strand of the sister duplex as the template. For this process to occur, a new primer-template 
junction needs to be formed, for which two mechanisms are proposed – one is post-
replicative strand invasion, the other is replication fork regression (Figure 1.16). Both X-
shaped sister chromatid junctions  
and regressed replication forks can be detected at damaged replication forks by electron 
microscopy, supporting the existence of the proposed intermediate DNA structures, although 
their relative abundance is quite different in lower and higher eukaryotes (Giannattasio et al., 
2014; Zellweger et al., 2015). Furthermore, double- 
stranded DNA containing only newly synthesized strands can also be detected by 
sedimentation analysis (Unk et al., 2010). 
 
 
 
Figure 1.16. Control of Rad6-Rad18 dependent damage tolerance by PCNA ubiquitination (y and h 
prefixes marking yeast and human proteins, respectively) (Unk et al., DNA Repair 9 (2010) 257-267). 
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Humans possess two RAD6 homologs – HHR6A and HHR6B and corresponding proteins 
show 70% identity with yeast Rad6. Human Rad18 has 62% similarity with yeast Rad18, and 
can interact with both HHR6 proteins in vivo. Also, human Mms2 and Ubc13 have been 
identified. Concerning Rad5, there are two human orthologues – HLTF and SHPRH. In vitro 
data suggests that both Rad5 and HLTF possess fork regression activity, while this remains to 
be determined for SHPRH (Unk et al., 2010). It was shown that HLTF and SHPRH act in a 
damage-specific manner – HLTF prevents mutations induced by UV, and SHPRH prevents 
mutations induced by MMS (Lin J.R, et al., 2011). As mentioned above, recent study 
revealed that HIRAN domain of the HLTF protein is prerequisite for replication fork slow 
down upon nucleotide depletion. Additionally, in vitro data from the same study revealed that 
HIRAN domain of the HLTF is necessary for replication fork reversal through recognition of 
the 3’ DNA ends (Kile AC, et al., 2015). A novel E3 ligase, TRAIP (RNF206), was 
implicated as an important factor associated with replication fork with a role in facilitating 
response to replication stress. It was shown that it interacts with unperturbed and stalled 
replication forks, and promotes ssDNA formation and checkpoint signaling at the stalled 
forks. Findings from this study also suggest that TRAIP’s PIP box, necessary for interaction 
with PCNA, and its E3 ligase activity are necessary for this protein’s function (Hoffmann S, 
et al., 2015). 
 
1.5 Proliferative Cell Nuclear Antigen (PCNA) and the role in DNA damage response. 
 
PCNA is a DNA polymerase processivity factor. It functions as a loading scaffold for the 
replication machinery through association with various replication-related factors (Moldovan 
G.L, et al., 2007). During DNA replication, the chaperonin-like replication factor C (RFC) 
binds to the RNA primer-DNA template junction and loads PCNA onto DNA (Bowman G.D, 
et al., 2004; Majka J, et al., 2004). Upon PCNA loading, Polα is released and Polε is loaded 
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to mediate leading-strand elongation (Kunkel T.A, et al., 2000). For the discontinuous 
lagging strand, firstly the short Okazaki fragments have to be produced by Polα and Polδ 
(Nick McElhinny S.A, et al., 2008). PCNA is characterized by its trimeric ring-shaped 
structure. Three PCNA monomers are associated to form a closed ring consisting of two 
sides. The topologically identical N and C termini of PCNA monomer are connected on one 
side while the other side contains several β sheets linked by loops (Krishna T.S, et al., 1994). 
The ring-shaped structure of PCNA is evolutionarily conserved and belongs to the family of 
β-clamps and (Schurtenberger P, et al., 1998). Rich in lysine and arginine residues, the inner 
ring of PCNA is positively charged, which allows for the effective encircling around the 
negatively charged duplex DNA. Recent studies reveal that PCNA is not only essential for 
replication in eukaryotes, but also plays critical roles in several DNA damage-responsive 
pathways (Moldovan G.L, eta al., 2007). Living organisms are constantly challenged by 
various sources of DNA damage. Environmental agents including radiation and chemical 
mutagens, and endogenous cellular metabolites can cause DNA damage (Friedberg E.C, et 
al., 2006). Under normal conditions, most DNA lesions can be removed by DNA repair 
pathways such as nucleotide excision repair and base excision repair. However, failure in 
lesion correction by these pathways prior to S phase in the cell cycle could pose severe 
consequences leading to genome instability or even cell death. Cells have evolved 
sophisticated lesion-bypass mechanisms to deal with this threat and ensure survival by 
allowing DNA synthesis in the presence of replication-blocking lesions. These lesion-bypass 
pathways in the budding yeast Saccharomyces cerevisiae are driven by factors belong to the 
RAD6 epistasis group (Prakash S, et al., 1993; Friedberg E.C, et al., 1988 and Broomfield S, 
et al., 2001) and have been classified as error-prone translesion synthesis (TLS), error-free 
TLS and error-free postreplication repair (Xiao W, et al 2000) or DNA damage tolerance 
(DDT). Interestingly, as briefly discussed above, all three bypass pathways require PCNA, 
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and different covalent modifications of PCNA by ubiquitin (Ub) or a small Ub-like modifier 
(SUMO) determine which tolerance pathway will be utilized in the face of unrepaired 
lesions (Andersen P.L, et al., 2008). Ubiquitination is a chemical process by which Ub is 
covalently attached to the Lys residue of a target protein by three enzymes: Ub-activating 
enzyme (Uba or E1), Ub-conjugating enzyme (Ubc or E2) and Ub ligase (E3) (Hershko and 
Ciechanover, 1998). Substrate proteins can be modified by a Ub monomer either at one Lys 
residue (monoubiquitination) or multiple Lys residues (multi-monoubiquitination). Proteins 
can also be modified by a Ub chain where Ub moieties sequentially link to a previous Ub 
(polyubiquitination) (Hochstrasser M, 1996). Although all 7 Lys residues (K6, K11, K27, 
K29, K33, K48 and K63) in Ub have been shown capable of forming poly-Ub chains (Peng J, 
et al., 2003; Xu and Peng, 2003), the physiological significance of some poly-Ub chains in 
living cells is not fully understood. The most characterized function of Ub modification is the 
K48-linked poly-Ub chain that targets proteins for degradation by the 26S 
proteasome (Hochstrasser M, 1996). On the other hand, K63-linked poly-Ub chain plays a 
role in regulating various signaling pathways largely in a proteolysis-independent 
manner (Pickart and Fushman, 2004). A paradigm of DNA-damage response through 
covalent modifications of PCNA was discovered by Stefan Jentsch and his colleagues (Hoege 
C, et al, 2002), in which PCNA can be either monoubiquitinated by the E2-E3 complex 
Rad6–Rad18 at the K164 residue or further modified with K63-linked Ub chain by another 
E2-E3 complex, Mms2-Ubc13-Rad5. Recently, the stepwise PCNA monoubiquitination and 
polyubiquitination by the two complexes was reconstituted in vitro (Parker and Ulrich, 2009), 
further confirming the above genetic model. In addition, the same K164 residue of PCNA can 
also be SUMOylated by yet another E2-E3 complex, Ubc9-Siz1 (Hoege C, et al., 2002; 
Stelter and Ulrich, 2003).  
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In mammalian cells, PCNA can also get mono- or poly-ubiquitinated. Mammalian 
homologues of Rad6/Rad18 complex, responsible for monoubiquitination of PCNA at K164 
residue have been identified. Also, mammalian homologues of Mms2/Ubc13 have been 
identified, while for the Rad5 homologues there are few candidates. Some reports suggest 
that damage induced PCNA polyubiquitination in mammalian cells is not entirely dependent 
on Mms2, suggesting some redundant mechnisms for execution of this action (Brun J, et al., 
2008). As mentioned, for the Rad5 homologues, there are few candidates, namely HLTF and 
SHPRH, which seem to work in a damage dependent manner (Lin JR, et al., 2012). TRAIP, a 
third E3 ligase associated with PCNA polyubiquitination, was recently discovered and 
implicated in maintainance of replication fork stability upon genotoxic stress (Hoffmann S, et 
al., 2015; Soo Lee N, et al., 2016). It is obvious that this pathway in mammalian cells is far 
more complex than in yeast and further research is needed to elucidate it completely.  
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2. Results. 
2.1 Downregulation of ZRANB3 rescues replication fork speed. 
 
Replication fork progression in vivo in cultured cells can be assessed by DNA fiber 
spreading, a technique based on pulse-labeling with halogenated nucleotides, cell lysis and 
DNA spreading over microscopy slides. When replication fork progression is analyzed this 
way in mock transfected cells treated with low doses of CPT (50nM), significant fork 
slowdown is rapidly observed upon treatment. In cells depleted of particular candidate factor 
with a potential role in fork reversal, we expected to observe impaired or no fork slowing 
upon CPT treatment. As a proof-of-principle, this result was obtained in cells treated with 
CPT and PARP inhibitor at the same time (Ray Chaudhury A, et al., 2012). In this case, as 
now clarified mechanistically (Berti et al., 2013), PARP inhibition ‘’unleashes’’ the activity 
of RecQ1 helicase, leading to untimely fork restart and impairing accumulation of forks 
arrested in the reversed conformation. We thus expected depletion of cellular factors driving 
fork reversal in response to mild CPT treatment to give very similar results to those observed 
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upon PARP inhibition. Indeed, after siRNA mediated knock down of ZRANB3 we could 
observe completely defective slowing of the replication fork progression (Figure 2.1). 
 
 
                                                                  
        
     
            
      
      
      
            
            
            
            
             
            
            
      
 
 
We decided to test the another genotoxic agent, mitomycin C (MMC), in low doses of 
200nM, in the same experimental setting. We could still observe at least partial rescue of 
replication fork speed in MMC-treated ZRANB3 downregulated cells (Figure 2.2).  
B tubulin (55kDa) 
ZRANB3 (123kDa) 
NT CPT NT CPT 
siZRANB3 siLuc 
 NT         CPT 
siLuc siZRANB3 
Figure 2.1 ZRANB3 downregulation leads to unrestrained replication fork progression upon low dose 
CPT treatment. U20S cells were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min 
later, cells were washed and supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or 
without low dose of camptothecine (50nM) for 30 min. The length of the tracks synthesized during the second 
label (green tracks) was measured to assess the ability of cells to continue replication in the presence or 
absence of the genotoxic agents. At least one hundred tracts were scored per sample. Whiskers: 10-90th 
percentile (***, P < 0.001; ns, non-significant, Mann – Whitney test. On the right is Western Blot showing 
efficiency of ZRANB3 downregulation. The experiment was repeated at least three times.  
 NT         CPT 
siZRANB3  siLuc 
 NT       MMC  NT          M C 
Figure 2.2 ZRANB3 downregulation leads to unrestrained replication fork progression upon 
MMC treatment. The experimental setting was the same as in Figure 2.1, except that 200nM 
mytomicin C (MMC) was used instead of CPT. At least one hundred tracts were scored per sample. 
Whiskers: 10-90th percentile (***, P < 0.0001; **, P < 0.01; *, P < 0.05 ns, non-significant, Mann – 
Whitney test. The experiment was repeated at least two times. 
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Having established that downregulation of ZRANB3 leads to complete (CPT treatment), or 
partial (MMC treatment) rescue of replication fork speed, we tested whether this could be an 
off-target effect of the siRNA. For this reason, we compared results obtained by two different 
oligonucleotides upon low dose CPT treatment, i.e. the condition that gave us clear cut results 
in this assay.  Even though with the second oligo we didn’t observe complete rescue of fork 
speed upon CPT treatment, we could see that forks were indeed moving faster in 
downregulated cells compared to mock transfected, treated cells. Of note, the downregulation 
of the protein achieved by the second oligo was much less efficient, thus reinforcing the link 
between effective ZRANB3 depletion and unrestrained fork progression (Figure 2.3). 
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ZRANB3 
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Figure 2.3 Testing additional siRNA for ZRANB3 downregulation. DNA fibers technique was again used to 
assess replication fork progression in the presence of genotoxic agent. Now, two different oligos for 
downregulation of ZRANB3 were used. U20S cells were provided with first nucleotide analogue, 
chlorodeoxyuridine (CldU). 30 min later, cells were washed and supplemented with second nucleotide analogue, 
iododeoxyuridine (IdU) with or without low dose of camptothecine (50nM) for 30 min. The length of the tracks 
synthesized during the second label (green tracks) was measured to assess the ability of cells to continue 
replication in the presence or absence of the genotoxic agents. At least one hundred tracts were scored per 
sample. Whiskers: 10-90th percentile (****, P < 0.0001; ns, non-significant, Mann – Whitney test. On the right 
is Western Blot showing efficiency of ZRANB3 downregulation. The experiment with Oligo_2 was done once. 
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2.2 Downregulation of ZRANB3 leads to impaired replication fork formation.  
 
In light of the promising DNA fiber results we were encouraged proceed with direct 
visualization of replication intermediates, namely by electron microscopy (EM).  
Firstly, we downregulated ZRANB3 protein by means of siRNA, and assessed reversed fork 
frequency upon genotoxic treatment. We could observe slightly elevated levels of reversed 
replication forks in ZRANB3-downregulated untreated cells (ca. 10% vs 3-5% of reversed 
replication forks usually observed in mock-transfected U2OS cells), possibly reflecting 
specific problems of the replication machinery to deal with some intrinsically difficult-to-
replicate regions even, where fork reversal may provide additional time for replication 
machinery to solve replication interference. Interestingly, upon genotoxic treatments, the 
level of fork reversal in ZRANB3-depleted cells did not further increase (in the case of CPT 
where the frequency was around 11%), or increased only marginally (Figure 2.4), nicely 
reflecting our DNA fiber results (Fig. 2.1-2.2) and implicating ZRANB3 in the process of 
drug-induced replication fork reversal. As already mentioned, ZRANB3 was reported as 
capable of regressing stalled forks in vitro (Ciccia A, et al., 2012). To our knowledge, this is 
the first evidence in vivo that this protein plays a crucial role on the formation of reversed 
replication forks upon genotoxic treatment. 
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2.3 ZRANB3 knock out cells.  
 
To further exclude off-target effects and possibly strengthen our point that ZRANB3 is 
indeed involved in fork slowing and remodeling in vivo upon genotoxic stress, we decided to 
use ZRANB3 knock out (ZRANB3 KO) cells in our assays. The ZRANB3 KO cells were 
generated by the Crispr-Cas9 system and were a generous gift from David Cortez 
(Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 
37232, USA). Firstly, we decided to perform fiber assays, as it is fast assay usually predictive 
of a possible role in replication fork reversal.   
2.3.1 ZRANB3 KO cells show no fork slowdown upon genotoxic treatment. 
 
The results of the fiber experiments nicely matched our previous results obtained by means of 
siRNA downregulation. 
 
 
Figure 2.4 Cells with ZRANB3 downregulation show elevated levels of endogenous fork reversal, but no, 
or marginal reversed fork induction upon genotoxic treatments. Cells were depleted of ZRANB3 protein by 
means of siRNA interference, as done in fibers experiments (Fig. 2.1-2.3). Then the cells were treated with 
either CPT (50nM) or MMC (200nM) for one hour. Afterwards, cells were crosslinked in order to preserve 
replication intermediates, the DNA was extracted, spread on carbon-coated copper grids, and analyzed by 
transmission electron microscope (TEM) (more on the technique details in Neelsen K.J, et al., 2014). On the 
right part of the figure is Western Blot showing downregulation efficiency. Experiment was repeated twice. 
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We used the same genotoxic treatments – CPT and MMC in low concentrations, treat the 
cells for 30 min, and assessed the lengths of the second label (green tracks). In WT cells the 
green labels upon treatments were significantly shorter than in non-treated cells, while in KO 
cells the green labels were approximately the same length in treated and non-treated cells, 
indicating the strict requirement of ZRANB3 for active fork slowing upon genotoxic stress 
(Figure 2.5). 
 
2.3.2 ZRANB3 KO cells show impaired reversed fork formation. 
 
WT                                      KO 
ZRANB3  
(123kDa) 
B tubulin  
(55kDa) 
WT                    KO 
Figure 2.5 ZRANB3 Wild Type (WT) and Knock Out (KO) cells. DNA fibers technique was used to 
assess replication fork progression in presence of genotoxic agents. WT or ZRANB3 KO U2OS cells 
cells were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min later, cells were 
washed and supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or without 
low dose of camptothecine (50nM) or mitomycin C (MMC) for 30 min. The length of the tracks 
synthesized during the second label (green tracks) was measured to assess the ability of cells to 
continue replication in the presence or absence of the genotoxic agents. At least one hundred tracts 
were scored per sample. Whiskers: 10-90th percentile (****, P < 0.0001; *, P < 0.05; ns, non-
significant, Mann – Whitney test. On the right is Western Blot as an evidence that ZRANB3 is not 
present in KO cells. The experiment was repeated twice.  
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In light of these promising DNA fiber data, we decided to use same knock out cells for EM 
experiments, using the same conditions as in knock down cells, i.e. low CPT and MMC 
treatment for 1h. In this experiment the results for reversed fork frequencies mirrored the data 
obtained by downregulation of the protein: there was initially a slightly elevated level of 
reversed forks in non-treated knock out cells (around 7%). However, there was only a 
marginal further induction of fork reversal after both treatments (13%) (Figure 2.6). These 
EM results prompted us to proceed with the experiments described below, aimed to dissect 
the role of different protein domains in fork slowing and remodeling.  
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2.4 Generation of stable cell lines. 
ZRANB3 protein has several domains, as described previously (Ciccia A, et al., 2012).  
We thus aimed to assess the contribution of individual domains of the ZRANB3 protein in 
the process of fork slowing and reversal. To this aim, we decided to generate stable cell lines 
expressing different mutants of the protein. In order to achieve this, we decided to use 
ZRANB3 knock out cells, where we introduced retrovirus-based constructs harboring a 
selectable resistance to puromycin and genes encoding the FLAG-tagged wild type ZRANB3 
protein or different mutants. The mutants that were produced had mutations in following 
domains: mutants in annealing helicase domain (HD, aspartic acid at position 157 and 
glutamic acid at position 158 changed to alanine), in endonuclease domain (ND, histidine at 
position 1045 changed to leucine in the domain responsible for interaction with 
polyubiquitinated PCNA (NZF, threonine at position 631 changed to leucine, and tyrosine at 
position 632 changed to valine), and domains responsible for interaction with PCNA (PIP, 
where glutamine at position 519 was changed to alanine, and isoleucine at position 522 was 
changed to alanine; APIM, where phenylalanines at position 525 and 526 were changed to 
alanines, and a stop codon was introduced instead of threonine at position 1073). I succeeded 
in generating all expressing stable cell lines, by the following procedure. I transfected 
Phoenix retrovirus producer cells with plasmids that were carrying the corresponding 
retroviruses. Afterwards, the media in which the cells were grown was collected and used for 
Knock Out Wild Type 
Figure 2.6 ZRANB3 KO cells show marginal reversed fork induction upon genotoxic 
treatment. WT or ZRANB3 KO U2OS cells treated with either CPT (50nM) or MMC (200nM) 
for one hour. Afterwards, cells were crosslinked in order to preserve replication intermediates, the 
DNA was extracted, spread on carbon-coated copper grids, and analyzed by transmission electron 
microscope (TEM) (more on the technique details in Neelsen K.J, et al., 2014). On the right part of 
the figure is Western Blot showing downregulation efficiency. Experiment was repeated twice. 
Western Blot confirming knock out cells have no traces of ZRANB3 is above the graph. 
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the infection of the target cells, in this case ZRANB3 knock out cells. Cells were kept in 
selection media containing this antibiotic for few days until cells from control group (that 
were not infected, and are sensitive to puromycin), died out. If the integration took place in 
the infected cells, they were supposed to survive, while the cells with no integration should 
die, as control uninfected cells. At this point we decided to pursue two different strategies for 
collecting surviving cells expressing the protein. The first strategy was to collect all the 
surviving cells from particular mutant and check for the expression level. The second strategy 
was to have different dilutions of particular mutant cell lines and to try to obtain individual 
colonies, which were then further propagated. The ratio behind choosing the two different 
approaches was as follows: with the collection of all surviving (puromycin-resistant) cells we 
obtained mixed population of cells with virus being integrated at various places in genome, 
yielding an heterogeneous population in terms of transgene expression, but minimizing the 
risk of biological effects. Conversely, selection of individual clones enables to select cells 
expressing the trasngene at the same level, but bear the risk of positional effects of construct 
integration. Therefore, we decided to use both strategies in parallel, and identify cell 
populations and/or clones with similar levels of transgene expression and no obvious 
integration effect. Following these two strategies, we managed to create mutants in all 
relevant ZRANB3 domains, and also to re-introduce the wild type protein in the ZRANB3-
KO cells. We used collection of the mixed population (the first strategy) for WT, NZF and 
PIP&APIM mutant. By means of Western Blot we showed that the expression level was 
similar to re-introduced wild type protein, and also to the endogenous wild type protein, 
detectable in the isogenic cell-line U2OS (Figure 2.7). 
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The second approach - selection of individual clones, was used for the HD and ND mutant. 
We had multiple clones for each mutant, and we selected for future experiments just the ones 
that were expressing the protein at similar levels as clones where the wild type protein was 
reintroduced. Also we compared all the expression levels with the level of the protein in wild 
type cells, and it was comfortingly comparable. There, too, we saw that expression levels of 
reintroduced wild type protein and mutants was similar to the parental U2OS cells (Figure 
2.8). 
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Figure 2.7 Generation of mutant cell lines – NZF and PIP APIM mutants. As described, these mutants were 
created by collecting the mixed population of cells from particular mutant. Nevertheless, for the two above 
mentioned mutants this approach could mimic the expression level of the protein in wild type cells, which was 
confirmed by Western Blot. The protein runs at slightly higher molecular weight than the protein extracted from 
wild type cells as it is FLAG-tagged.  
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2.4.1 NZF, PIP&APIM and HD mutant show no fork slowdown upon genotoxic 
treatment. 
Having obtained stable cell lines, we decided to explore the relative importance of individual 
domains in replication fork slowing and reversed fork formation, upon treatment with CPT 
(in light of the high number of cell lines, we limited this set of experiments to a single 
genotoxic agent). First we performed DNA fibers technique to assess the impact of the 
different mutations on replication speed. These results are preliminary, as these experiments 
were only performed once, but many of them are quite promising and in line with some other 
results within this thesis. The repetition is ongoing and will be completed after completion of 
this thesis, and prior to submission of the manuscript.  
We could observe that reintroducing WT ZRANB3 in ZRANB3-KO cells restored CPT-
induced replication fork slowing (compare Fig. 2.5 And Fig. 2.9). However, no significant 
fork slow down upon CPT treatment was observed reintroducing NZF, PIP&APIM and HD 
mutants, showing that all these domains are essential for active fork slow down upon 
genotoxic stress. Conversely, replication fork slowdown was restored in ZRANB3-KO cells 
even by reintroducing the ND mutant, suggesting that ZRANB3-nuclease activity is 
dispensable for active fork slowing. It should be noted that experiment with NZF and 
PIP&APIM mutant were done separately from that with HD and ND mutants, as the cell lines 
obtained came from different strategies of stable cell line production (pool of resistant cells 
B tubulin (55kDa) 
Figure 2.8 Generation of mutant cell lines – HD and ND mutants. As described, these mutants were created 
by selecting multiple clones. For the two above mentioned mutants this approach could mimic the expression 
level of the protein in wild type cells, which was confirmed by Western Blot. The protein runs at slightly higher 
molecular weight than the protein extracted from wild type cells as it is FLAG-tagged.  
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vs single clones, as described above (Figure 2.9). Accordingly, each set of mutants was 
compared to its own WT counterpart, obtained by the same strategy 
 
 
 
 
 
 
 
 
 
 
 
These data suggest that efficient interaction with PCNA and more specifically with its 
polyubiquitinated form are required for the replication fork slowdown. Similarly, in keeping 
with the published biochemical evidence on ZRANB3 fork regression activity, the helicase 
domain of ZRANB3 is required for fork slowdown upon damage. The only domain of 
ZRANB3 that seems dispensable for fork slowdown is the nuclease domain.  
 
2.4.2 NZF, PIP&APIM and HD mutant show no fork slowdown upon genotoxic 
treatment 
 
We next assessed the efficiency of replication fork reversal in vivo in all these cell lines. EM 
experiment showed that reintroducing the WT protein in ZRANB3-KO cells restored 
standard frequencies of fork reversal observed in the paternal cell line (ca. 3% in untreated, 
25-30% in CPT-treated cells). Similar results were obtained reintroducing the NZF-mutant 
Figure 2.9 Mutations in NZF, PIP&APIM and HD domains of ZRANB3 lead to replication rescue of 
replication fork slowdown. Fibers experiments were performed as previously, with or without 30min 50nM 
CPT treatment using U2OS cells stably expressing WT ZRANB3, or ZRANB3 with mutations in NZF or 
PIP&APIM domains, helicase dead mutant (HD) or nuclease dead mutants. Cells were provided with first 
nucleotide analogue, chlorodeoxyuridine (CldU). 30 min later, cells were washed and supplemented with second 
nucleotide analogue, iododeoxyuridine (IdU) with or without CPT. The length of the tracks synthesized during 
the second label (green tracks) was measured to assess the ability of cells to continue replication in the presence 
or absence of the genotoxic agent. At least one hundred tracts were scored per sample. Whiskers: 10-90th 
percentile (****, P < 0.0001; ns, non-significant, Mann – Whitney test). Experiments were performed once. 
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protein, suggesting that, at least in these experimental conditions, the residual binding to 
PCNA and polyubiquitinated PCNA reported in this mutant (Ciccia et al., Mol Cell 2012) 
may be sufficient to induce fork reversal upon CPT treatment. Conversely, reintroduction of 
the PIP&APIM mutant, which displays fully defective PCNA-interaction (Ciccia et al., Mol 
Cell 2012), did not restore the original phenotype observed in ZRANB3-KO cells 
reintroduced with WT protein in terms of reversed fork frequency, both in both non-treated 
(higher basal level, around 9%) and CPT-treated cells (marginal induction, to about 13%) 
(Figure 2.10). 
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Figure 2.10 Mutations in PIP&APIM mutant lead to impaired reversed fork formation upon 
CPT treatment. U2OS cells expressing either WT or mutated versions of ZRANB3 protein were 
treated with CPT (50nM) for one hour. Afterwards, cells were crosslinked in order to preserve 
replication intermediates, the DNA was extracted, spread on carbon-coated copper grids, and analyzed 
by transmission electron microscope (TEM). Experiment was done once. 
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Interestingly, comparable results were obtained in the KO ZRANB3 cells with reintroduced 
helicase dead (HD) mutant of ZRANB3, both in untreated and treated conditions (6% of 
reversed replication forks in non-treated, and 7% in CPT treated cells). From these 
preliminary results we can conclude that the interaction with PCNA and annealing helicase 
activities of ZRANB3 are crucial for it to be able to efficiently reverse the forks. However, in 
our experimental conditions, full binding to polyubiquitinated PCNA (via a fully functional 
NZF domain - which is required for efficient fork slowing) and its nuclease domain, do not 
seem to be essential for fork reversal upon genotoxic stress.  
 
2.5 PCNA and ubiquitin mutants 
 
Upon damage PCNA gets monoubiquitinated at the lysine K164 (by Rad6-Rad18 complex) 
in the process of PRR, driving its error-prone branch by TLS. The error-free branch of this 
pathway requires polyubiqitination of the same PCNA residue, via formation of K63 linked 
ubiquitin chains by the E2 Mms2-Ubc13 and the E3 Rad5 in yeast (Rad5 has multiple 
putative orthologues in human cells, i.e. SHPRH, HLTF and TRAIP). This promotes template 
switching potentially and possibly entails the frequent fork reversal observed in human cells. 
To test this possibility, we used two systems – the first one involved mouse embryonic 
fibroblasts (MEFs) that had PCNA mutated at lysine K164 to arginine, which cannot be 
ubiquitinated. The other system we used was tetracycline inducible replacement of 
endogenous ubiquitin with a specific mutant, that is defective in forming K63 polyubiquitin 
chains.  
 
2.5.1 PCNA 164K mutant mouse embryonic fibroblasts 
 
2. Results. 
 
 
Mouse embryonic fibroblasts with a K164R mutation on PCNA were generously provided by 
Heinz Jacobs (Netherlands Cancer Institute, Amsterdam, The Netherlands), along with their 
WT counterpart. We wanted to determine whether inability to ubiquitinate PCNA at this 
particular site would prevent replication fork slowing and impair efficient fork reversal upon 
mild genotoxic treatments.   
 
 
 
 
 
 
 
 
 
2.5.2 Mutating K164 in PCNA abolishes replication fork slowing upon DNA damage. 
 
The DNA fiber assay was performed as in previous cases – cells were either non-treated or 
treated with low CPT and MMC doses for 30min during the second label. The length of this 
second 
label was 
measured 
and 
plotted.  
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Importantly, upon 
both CPT and MMC 
treatment, this single point mutation in PCNA abolished statistically significant replication 
fork slowing, while wild type MEFs displayed as expected significant reduction of fork 
speed. We therefore decided to investigate fork architecture in these cells by EM experiments 
(Figure 2.11). 
 
2.5.3 PCNA K164 mutant shows defective replication fork reversal upon genotoxic 
treatments. 
Previous EM experiments published in our lab revealed that MEFs display a high basal level 
of reversed forks, probably resulting from replication stress associated with their 
immortalization procedure (Ahuja et al., 2016). However, fork reversal was further increased 
by both tested genotoxic treatments (Figure 2.12). MEFs bearing a K164 mutation in PCNA 
displayed a 2-fold reduction in the basal frequency of reversed forks, and only a marginal 
induction of fork reversal upon treatment (Figure 2.12). 
 
 
 
 
 
Figure 211. PCNA Wild Type (WT) and K164 mutant cells. Wild type or K164 mutant cells mouse 
embryonic fibroblasts (MEFs) were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min 
later, cells were washed and supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or 
without low dose of camptothecine (50nM) or mitomycin C (MMC) for 30 min. The length of the tracks 
synthesized during the second label (green tracks) was measured to assess the ability of cells to continue 
replication in the presence or absence of the genotoxic agents. At least one hundred tracts were scored per 
sample. Whiskers: 10-90th percentile (****, P < 0.0001; ***, P < 0.001; ns, non-significant, Mann – Whitney 
test. The experiment was repeated twice.  
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2.5.4 Inducible replacement of endogenous ubiquitin with a K63 mutant. 
 
Ubiquitin can form various types of chains (K6, K11, K27, K29, K33, K48, K63 and M1) 
linked at one of the seven different lysine residues on its N-terminus (Komander D, Rape M, 
2012). We were interested in the ubiquitin mutant that cannot form K63-linked chains, as 
were shown to be formed on PCNA and involved in template switching events in the error-
free PRR (refs?). We used a previously described U2OS-based cellular system (Xu et al., 
2009), that enables tetracycline dependent downregulation of the endogenous ubiquitin (by 
Figure 2.12 PCNA K164 mutant cells lines show no major induction of reversed replication forks upon 
genotoxic treatments. Mouse embryonic fibroblasts (MEFs) cells expressing either WT or K164R mutant 
PCNA protein were treated with either CPT (50nM) or MMC (200nM) for one hour. Afterwards, cells were 
crosslinked in order to preserve replication intermediates, the DNA was extracted, spread on carbon-coated 
copper grids, and analyzed by transmission electron microscope (TEM). Experiment was done twice. 
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shRNA) and at the same time induces expression of exogenous (shRNA-resistant) ubiquitin, 
either WT or mutated at K63 (K63R).  
The reason for choosing this system was that other available systems that enable, by transient 
transfection, downregulation of endogenous ubiquitin (by siRNA) and simultaneous 
overexpression of a specific mutant proved technically challenging. The main problem lays in 
the fact that cells need to be transfected twice, which in many cases is suboptimal in terms of 
cell survival. Also, from yeast to human, eukaryotic cells have 4 ubiquitin genes (UBC, 
UBA52, UBB and RPS27A), two of them encode linear polyubiquitin in which ubiquitin is 
linked to each other from ‘’head-tail’’, and the other two encode ubiquitin fused to ribosomal 
subunits (Finley et al., 1987). siRNA mediated depletion of the ubiquitin often leads to quite 
substantial left over of the endogenous protein, as it usually doesn’t lead to inactivation of 
expression from all ubiquitin genes.  
In this system, the constructs have two expression cassettes, one was driven by tetracycline 
itself, and the other by IRES sequence (internal ribosome entry site – sequence that allows 
translation initiation in the middle of messenger RNA). Apart from ubiquitin genes, the 
constructs coded for HA tag and two ribosomal subunits (L40 and 27A), as their expression 
was also shut down together with endogenous ubiquitin (Figure 2.13) 
 
 
 
 
 
 
Figure 1. Tetracycline-induced replacement of endogenous ubiquitin with Ub(K63R)
(A) A diagram of human ubiquitin genes and their chromosomal locations. Also shown is the
strategy to express wide type (WT) or K63R ubiquitin genes fused to ribosomal subunits (L40
and S27a) in the U2OS-shUb cells. Ubr indicates that silent mutations have been introduced
to ubiquitin genes to render them resistant to RNAi. Both ubiquitin expression cassettes are
under the control of a tetracycline promoter. An HA epitope is fused to the second ubiquitin
gene, whose translation is controlled by an internal ribosomal entry site (IRES). (B) U2OS-
shUb-Ub(WT) (lanes 1–4) or U2OS-shUb-Ub(K63R)(lanes 5–8) cells were treated with
tetracycline (1ȝg/ml) for 4 days, then total RNA was isolated for RT-PCR analyses of
endogenous Ub genes or exogenous Ub transgene (Ubr) expression. GAPDH RNA expression
was used as a control. RT: reverse transcriptase. (C) Quantification of wide type or K63R
ubiquitin by mass spectrometry. U2OS-shUb-Ub(K63R) cells were treated with tetracycline
(1 ȝg/ml) for 0, 3, 5 and 7 days, then ubiquitin was isolated for trypsin digestion and mass
spectrometry. The ratio of peptides containing K63, K63R or K48 to a reference ubiquitin
peptide (E64-R72) as a function of tetracycline induction time is presented. (D) U2OS-shUb-
Ub(WT) and U2OS-shUb-Ub(K63R) cells were treated with tetracycline (1ȝg/ml) for 4 days
before cell lysates were prepared for immunoprecipitation with an HA antibody. The
precipitated proteins were analyzed by immunoblotting with an antibody specific for the K63
linkage of ubiquitin chains or with the HA antibody to detect total ubiquitin.
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Figure 2.13 Scheme describing the two constructs used in ubiquitin replacement system. In yellow are 
depicted ubiquitin genes, in green HA, and red and blue are two different ribosomal subunits. Modified from Xu 
et al, 2009 
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The EM experiments performed using this system were performed upon doxycycline 
addition, comparing ubiquitin replacement with WT ubiquitin or with a K63R mutant. They 
showed that inability to form K63-linked chains leads to phenotypes similar to those 
observed in the PCNA-ubiquitination mutants and in ZRANB3-defective cells, i.e. there was 
only marginal reversed fork induction (13-14%) over background level (around 10%) 
following both CPT and MMC treatments (Figure 2.14). 
 
 
 
 
 
 
 
 
 
2.6 Ubc13 downregulation. 
 
At least three different E3 ligases for PCNA polyubiquitination in human cells (SHPRH, 
HLTF, TRAIP; refs), making it difficult to effectively impair this PCNA modification by 
inactivation of the E3. However, Ubc13 was previously involved as the E2 in the process of 
polyubiqitination of PCNA at the K164 lysine and, more generally, in the formation of K63-
linked ubiquitin chains (ref).Thus, to further test whether PCNA polyubiqutination is required 
Figure 2.14 Cell lines expressing K63 mutant version of ubiquitin show no major induction of 
reversed replication forks upon genotoxic treatments. U2OS cells expressing either WT K63R mutant 
ubiquitin protein were treated with either CPT (50nM) or MMC (200nM) for one hour. Afterwards, cells 
were crosslinked in order to preserve replication intermediates, the DNA was extracted, spread on carbon-
coated copper grids, and analyzed by transmission electron microscope (TEM). Experiment was done 
twice. 
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for fork reversal, we assessed whether inactivation of this E2 could lead to similar 
phenotypes as those described above for ZRANB3 defects, K164-PCNA mutant and 
ubiquitin K63 mutant. Again, replication fork speed and frequency of reversed replication 
forks were assessed upon CPT and MMC treatments. 
 
2.6.1 Upon UBC13 downregulation there is partial rescue of the replication fork speed. 
 
We used siRNA to deplete Ubc13 and then tested its effect in classical DNA fibers assay. 
Both mock transfected and downregulated cells were either treated or not with mild dose of 
MMC, then the fibers lengths were compared. As shown Figure 2.15, reduced UBC13 protein 
levels were associated with a partial defect in replication fork slowing upon MMC treatment 
(Figure 2.15).  
 
        
        
       
            
        
In light of these promising results, we decided to proceed with EM experiments on the same 
cellular system and to also assess complete ablation of UBC13.  
 
2.6.2 Ubc13 depletion leads to ineffective fork reversal induced by genotoxic agents. 
 
GAPDH (35kDa) 
Ubc 13 (17kDa) 
Figure 2.15 Ubc13 downregulation leads to rescue of replication fork speed upon genotoxic treatment. 
Ubc13 downregulated cells were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min 
later, cells were washed and supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or 
without low dose mitomycin C (MMC) for 30 min. The length of the tracks synthesized during the second label 
(green tracks) was measured to assess the ability of cells to continue replication in the presence or absence of the 
genotoxic agent. At least one hundred tracts were scored per sample. Whiskers: 10-90th percentile (****, P < 
0.0001; **, P < 0.01; ns, non-significant, Mann – Whitney test. The experiment was repeated at least twice.  
  NT     MMC 
   siUbc13 siLuc 
  NT      MMC  NT      MMC 
   siUbc13 siLuc 
  NT     MMC 
G
re
en
 tr
ac
t l
en
gt
h 
(µ
m
) 
2. Results. 
 
 
Using optional siRNA-mediated downregulation of UBC13, we assessed the frequency of 
reversed forks in unperturbed cells or upon treatment with low doses of MMC and CPT for 
1h.  
The experiment revealed that downregulation of the Ubc13 protein lead to slightly increased 
basal levels of reversed forks, possibly indicative of accumulating replication stress, leading 
to UBC13-independent fork reversal. However, UBC13 downregulation drastically impaired 
genotoxin-dependent induction of reversed forks (Figure 2.16). 
 
 
 
 
 
 
 
 
 
         
 
 
            
        
2.7 Ubc13 knock out cells. 
 
To avoid potential off target effects of the siRNAs that we used and to assess whether partial 
effects reflected the residual levels of UBC13 protein, we decided to perform similar 
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Figure 2.16 Cells with Ubc13 downregulation show no, or marginal reversed fork formation upon 
genotoxic treatment. U2OS cells were depleted of Ubc13 protein by means of siRNA interference, as in 
fibers experiments. Then the cells were treated with either CPT (50nM) or MMC (200nM) for one hour. 
Afterwards, cells were crosslinked in order to preserve replication intermediates, the DNA was extracted, 
spread on carbon-coated copper grids, and analyzed by transmission electron microscope (TEM). 
Experiment was done twice. 
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experiments on a HCT116 UBC13 knock out cell line, obtained as a generous gift from Niels 
Meiland from University of Copenhagen (Copenhagen, Denmark).   
 
2.7.1 Ubc13 KO cells have unrestrained replication fork progression upon low doses 
genotoxic treatment.  
 
Since the KO cells were obtained relatively recently, these experiments were only performed 
once and the results should thus be considered as preliminary. The results we obtained to a 
great extent match the results from the knock-down cells. In the fibers assay, we decided to 
test both drugs we usually use, CPT and MMC. We treated the cells based on the usual 
labelling scheme and then assessed the replication fork progression during the second label 
(upon optional treatment with CPT or MMC). UBC13 KO cells are completely defective in 
active fork slowing upon both treatments (Fig. 2.17). This result confirms our initial 
observations obtained by siRNA in U2OS cells and strongly suggest that the partial effects 
observed upon downregulation result from residual UBC13 protein levels in those conditions.  
 
             
 
 
 
 
 
 
 
 
2. Results. 
 
 
 
 
 
 
 
 
 
 
 
 
2.7.2 Ubc13 KO cells fail to increase the frequency of reversed replication forks upon 
genotoxic treatments. 
 
We next treated the both WT and KO cells with CPT and MMC for one hour, isolated DNA 
and assessed reversed fork frequency by our classical EM protocol. The results showed us 
that control HCT116 cells react to treatments as observed in numerous other cell lines, i.e. by 
a substantial accumulation of reversed forks upon both CPT and MMC treatments (27% and 
21%. respectively). However, as already observed upon ubiquitin replacement with the K63R 
mutant, UBC13 KO cells, displayed elevated basal levels of reversed forks, but no further 
significant induction of fork reversal after either CPT or MMC (11% and 12% respectively) 
(Figure 2.18). Overall, the data in Figs. 2.11-2.18 strongly suggest that PCNA 
polyubiquitination is required for replication fork reversal in vivo. As every other lab 
attempting this to date, we have been so far unsuccessful in directly revealing endogenous 
levels of PCNA polyubiquitination upon conditions of mild replication stress. A few 
                        WT                             Ubc13 KO 
     NT             CPT          MMC       NT           CPT          MMC 
Figure 2.17 Ubc13 KO cells show complete rescue of replication fork speed upon genotoxic treatment. 
Ubc13 KO HCT116 cells were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min 
later, cells were washed and supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or 
without low dose camptothecin (CPT, 50nM) or mitomycin C (MMC, 200nM) for 30 min. The length of the 
tracks synthesized during the second label (green tracks) was measured to assess the ability of cells to continue 
replication in the presence or absence of the genotoxic agent. At least one hundred tracts were scored per 
sample. Whiskers: 10-90th percentile (****, P < 0.0001; ns, non-significant, Mann – Whitney test. The 
experiment was done once. 
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unsuccessful attempts are described below (see 2.9), but a new set of experiments is currently 
ongoing, using different strategies for the enrichment of this rare modification. 
 
 
 
 
 
 
 
 
 
 
 
 
2.8 Additional experiments. 
2.8.1 Werner syndrome protein. 
 
Previous studies used oligonucleotide based substrates and could show that Werner syndrome 
protein (WRN) has an ability to both form and restore reversed replication forks (Kangaraj R, 
et al., 2006; Machwe A, et al., 2006; Machwe A, et al., 2007). Mutations in this protein lead 
to Werner syndrome, mostly known for the accelerated aging in affected individuals. We thus 
reckoned that WRN could be a potentially interesting candidate to assess fork slowing and 
reversal in vivo. We performed initial fibers experiments, but - despite effective WRN 
downregulation -  we failed to observe defective replication fork slowing upon mild CPT 
treatment (Figure 2.19), which is usually a predictive phenotype for defective fork reversal. 
Figure 2.18 Ubc13 KO cells show no, or marginal reversed fork formation upon genotoxic treatment. The 
HCT116 WT or Ubc13 KO cells were treated with either CPT (50nM) or MMC (200nM) for one hour. 
Afterwards, cells were crosslinked in order to preserve replication intermediates, the DNA was extracted, spread 
on carbon-coated copper grids, and analyzed by transmission electron microscope (TEM). Experiment was done 
once. 
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The next section includes the results of additional experiments performed on WRN, as part of 
a collaborative effort with the lab of A. Vindigni in St. Louis, USA (see 2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
2.8.2 HARP (SMARCAL1). 
As explained in detail in the introduction, HARP was the first annealing helicase to be 
described (Yusufzai and Kadonaga, 2009). It also has both fork regression (oligonucleotide 
and plasmid based assays) and fork restoration activity (only oligonucleotide based). RPA 
addition to these biochemical reactions, which contributes to having these biochemical assays 
in more physiological conditions, has a strong influence on HARP enzymatic activity and 
substrate specificity (Betous R, et al., 2013). For these reasons, we tested its requirement for 
replication fork slowing and reversal in vivo.  
 
GAPDH (35 kDa) 
WRN (162 kDa) 
siLuc siWRN 
   siWRN siLuc 
  NT          CPT    NT          CPT 
Figure 2.19 Downregulation of WRN showed no influence on replication fork progression upon mild CPT 
treatment. Cells were either mock transfected or depleted of WRN protein using siRNA. Afterwards, cells were 
provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min later, cells were washed and 
supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or without low dose (50nM) 
camptothecin (CPT) for 30 min. The length of the tracks synthesized during the second label (green tracks) was 
measured to assess the ability of cells to continue replication in the presence or absence of the genotoxic agent. 
At least one hundred tracts were scored per sample. Whiskers: 10-90th percentile (****, P < 0.0001; ***, P < 
0.001; ns, non-significant, Mann – Whitney test. The experiment was done twice. 
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2.8.2.1 Depletion of Harp impairs reduction of replication fork speed upon mild CPT 
treatments. 
As in the case of WRN, we started by testing whether HARP depletion by siRNA could 
affect in any way replication fork progression in the conditions of mild replication stress 
induced by mild CPT treatment. We observed that HARP depletion leads to a complete 
defect in reducing  replication fork speed upon CPT treatment.  
 
 
 
 
 
 
 
 
 
 
 
We also perform simultaneous knock down of Harp and ZRANB3 together. In light of the 
results obtained with individual downregulations (Figs. 2.1 and 2.20), it was not surprising to 
observe a complete defect in CPT-induced fork slowing also simultaneous downregulation of 
both cellular factors in U2OS cells (Fig. 2.21). 
 
 
 
 
GAPDH (35 kDa) 
Harp (100 kDa) 
           NT             CPT           NT            CPT 
                 siLUC                           siHarp 
siHarp siLuc 
Figure 2.20 Harp depletion leads to complete replication fork speed rescue. Cells were either 
mock transfected or depleted of HARP protein using siRNA. Afterwards, cells were provided with 
first nucleotide analogue, chlorodeoxyuridine (CldU). 30 min later, cells were washed and 
supplemented with second nucleotide analogue, iododeoxyuridine (IdU) with or without low dose 
(50nM) camptothecin (CPT) for 30 min. The length of the tracks synthesized during the second label 
(green tracks) was measured to assess the ability of cells to continue replication in the presence or 
absence of the genotoxic agent. At least one hundred tracts were scored per sample. Whiskers: 10-
90th percentile (***, P < 0.001; ns, non-significant, Mann – Whitney test). The experiment was done 
at least twice. On the right is Western Blot showing downregulation efficiency. 
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2.8.2.2 Harp depletion leads to partial decrease in reversed fork frequency upon 
genotoxic treatment. 
 
Following the logic that replication fork slowdown is usually coupled to reversed fork 
accumulation, we were expecting that defective replication fork slowdown would be 
accompanied by a drastic reduction in the frequency of reversed forks. 
However, despite the complete defect in fork slowing observed upon HARP downregulation, 
when we assessed by EM fork reversal in U2OS upon downregulation of Harp following 1h 
low dose CPT treatment, we only found a 2-fold reduction in reversed fork frequency (from 
around 36% in mock transfected to around 18% in downregulated cells; Fig. 2.22). As 
already observed for other defects in drug-induced reversal (e.g. ZRANB3 or UBC13 
inactivation) the basal levels of reversed forks were found to be slightly increased, likely 
resulting from accumulated replication stress, leading to HARP-independent fork reversal. 
     NT             CPT              NT              CPT 
              siLUC                              siZ+H 
Figure 2.21 Double Harp and ZRANB3 depletion leads to complete replication fork speed 
rescue. Cells were either mock transfected, depleted of both HARP and ZRANB3 proteins using 
siRNA. Afterwards, cells were provided with first nucleotide analogue, chlorodeoxyuridine (CldU). 
30 min later, cells were washed and supplemented with second nucleotide analogue, 
iododeoxyuridine (IdU) with or without low dose (50nM) camptothecin (CPT) for 30 min. The length 
of the tracks synthesized during the second label (green tracks) was measured to assess the ability of 
cells to continue replication in the presence or absence of the genotoxic agent. At least one hundred 
tracts were scored per sample. Whiskers: 10-90th percentile (***, P < 0.001; ns, non-significant, 
Mann – Whitney test). The experiment was done once. On the right is Western Blot showing 
downregulation efficiency. 
B tubulin (55 kDa) 
Harp (100 kDa) 
ZRANB3 (123 kDa) 
siLuc 
siZRANB3 
+ 
siHarp 
NT     CPT NT     CPT 
G
re
en
 tr
ac
t l
en
gt
h 
(µ
m
) 
2. Results. 
 
 
 
 
 
 
 
In light of the less striking results obtained with HARP, we decided to focus our investigation 
on PRR and ZRANB3, and we plan to continue our investigations on HARP once a first 
research manuscript will be submitted on PRR/ZRANB3, containing most of the data 
described above. 
 
2.9 Following polyubiquitination of PCNA with Western Blot and Chromatin 
enrichment. 
In parallel to our efforts to elucidate the contribution of mono- and poly-ubiquitination (via 
K63 ubiquitin chains) of PCNA to the process of fork reversal by means of DNA fibers and 
EM technique, we invested considerable effort in the attempt to directly observe endogenous 
PCNA polyubiqutination and thereby to identify its genetic dependencies upon conditions of 
mild replication stress.  
We initially tried to use whole cell extracts in classical Western Blotting to detect mono- and 
poly- ubiquitination of PCNA, after very harsh treatment of the cells (30-40 J/m2 of UV 
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Figure 2.22 Cells with Harp downregulation show no, or marginal reversed fork formation upon 
genotoxic treatment. U2OS cells were depleted of Harp protein by means of siRNA interference, as in 
fibers experiments. Then the cells were cells were treated with CPT (50nM) for one hour. Afterwards, 
cells were crosslinked in order to preserve replication intermediates, the DNA was extracted, spread on 
carbon-coated copper grids, and analyzed by transmission electron microscope (TEM). Experiment was 
done once. 
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irradiation with 4h recovery, or 30 µM MMC treatment for 24 hours), using a total PCNA 
antibody. Although in certain conditions the antibody did recognize monoubiquitinated 
PCNA, we failed to reproducibly observe additional retarded bands, expected to represent 
polyubiquitinated PCNA (data not shown). 
We next decided to use chromatin extracts, designed to eliminate all cytoplasmic and 
nucleoplasmid proteins and enrich for those stably bound to chromatin, where PCNA is 
expected to reside while performing its function. Furthermore, upon western blotting, we 
used a specific antibody raised against PCNA ubiquitinated at the K164 residue, reckoning 
that this antibody may also specifically detect polyubiqitinated forms of PCNA.  
Somehow promisingly, following 40 J/m2 of UV irradiation with 4h or 12h recovery, by this 
approach we could clearly detect bands appearing above monoubiquitinated PCNA, which 
were not detected in the same samples by the total anti-PCNA antibody (Figure 2.23). 
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Ub PCNA K164 antibody 
normal PC10  
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Figure 2.23. Mono and potential polyubiquitination of PCNA following 40 J/m2 of UV irradiation 
with 4 or 12h recovery. Cells were irradiated, then the chromatin was enriched and run on Western 
Blot gel. For blotting we used specific antibody recognizing monoubiquitination of PCNA at specific 
residue – K164 and also standard PCNA antibody on the side to compare results.  
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Inspired by the detection of these upper bands, we assessed whether they showed the 
expected genetic dependencies for PCNA polyubiquitination, upon downregulation of factors 
that should either abrogate them – namely Rad18 and Ubc13 - or enhance them, as for 
downregulation of PCNA deubiquitinating enzyme USP1. Therefore, we performed 
experiments where we had combinations of these proteins depleted by siRNA and collected 
protein samples 12h after optional 40 J/m2 UV irradiation following. Unfortunately, we 
could not confirm any of the expected genetic dependencies, by intensification or 
disappearance of the bands detected above monoubiquitinated PCNA (Fig. 2.24). We only 
confirmed the expected effect of RAD18 depletion on PCNA mono-ubiquitination, which 
confirmed sufficient downregulation of this protein (Figure 2.23-2.24). These results suggest 
that the retarded bands observed above mono-ubiquitinated PCNA are unlikely to represent 
poly-ubiquitinated PCNA. 
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Figure 2.23. Suspected diUb PCNA band does not seem to show genetic dependencies.  Cells were 
downregulated, and then treated with 40 J/m2 of UV irradiation with 12h recovery. Then the chromatin 
fraction was isolated, and the chromatin bound proteins were ran on Western Blot. 
2. Results. 
 
 
 
 
 
 
 
 
 
 
Since we could not confidently follow endogenous polyubiquitination of PCNA (mostly 
diUbPCNA), we decided to try to express either wild type or K63 mutant FLAG tagged 
ubiquitin in HEK293T cells, treat them with high doses of UV as in previous experiments, 
and perform chromatin enrichment, followed with immunoprecipitation using anti-FLAG 
beads. We reasoned that this way we could enrich for ubiqitinated species, among them 
mono, di, tri etc. Ub PCNA molecules. So we transfected the cells with either empty vector, 
FLAG tagged WT ubiquitin, or FLAG tagged K63 mutant ubiquitin. Then we treated them 
with 40 J/m2 of UV irradiation following 12h recovery and then performed above mentioned 
procedure. Even in the cells expressing K63 mutant we could still see the and above 
monoubiquitinated PCNA band (Figure 2.25), further suggesting that this band does not 
entail K63-dependent PCNA polyubiqutination and may instead represent a different type of 
post-translational modification of PCNA. 
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Figure 2.24. Western Blot showing downregulation efficiency of particular proteins. 
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To consolidate these results, we also decided to use the ubiquitin replacement system, already 
described in chapter 2.5.4. This tetracycline inducible system allows for shut down of 
expression of endogenous ubiquitin, and expression of HA tagged WT or HA tagged K63 
mutant. In the absence of Tet, endogenous ubiquitin is expressed, while in its presence either 
the WT or the K63R-ubiquitin mutant replace endogenous ubiquitin. We optionally treated 
the cells with high doses of MMC (15 µM; 24h), to possibly boost PCNA ubiquitination), 
and performed chromatin enrichment prior to protein analysis by Western Blot with the Ub-
PCNA antibody (Fig. 2.26) 
 
 
 
 
Figure 2.25. Western Blot showing monoubiquitinated PCNA that was immunoprecipitated from 
the cells expressing either wild type or K63 mutant version of ubiquitin. Cells were transfected, 
then left untreated or treaded with UV, chromatin enrichment was performed and then 
immunoprecipitation.  
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2. Results. 
 
 
 
 
 
 
 
Also in this case, we detected retarded bands above mono-ubiquitinated PCNA, but we failed 
to observe any difference in the intensity of those bands when endogenous ubiquitin is 
replaced by the K63R mutant.  Thus, these bands seem unrelated from K63-linked 
polyubiquitin chains and we need to conclude that we have not yet identified controlled 
experimental conditions to reveal endogenous levels of polyubiquitinated PCNA. Additional 
experiments, based on different methods of enrichment, are currently ongoing in the lab and 
may possibly lead to successful detection of polyubiquitinated PCNA.  
  
  
Anti MonoUb  
PCNA (42 kDa) 
TFIIH (100 kDa) 
Figure 2.26. Western Blot showing monoubiquitinated PCNA isolated from cells that were 
expressing either WT or K63 mutant ubiquitin. After treatment with 15 µM of MMC for 24h, 
chromatin was enriched and then ran on Western Blot. 
2. Results. 
 
 
2.10 Contribution to collaborative projects with the lab of Prof. Alessandro Vindigni 
(Department of Biochemistry and Molecular Biology, Edward A. Doisy Research 
Center, Saint Louis University School of Medicine, St. Louis, USA). 
2.10.1 RecQ1 involvement in reversed replication fork restart. 
 
A previous study from our lab had showed that inhibition of PARP1 activity led to dramatic 
drop of reversed replication fork frequency upon low doses of camptothecin (Ray Chaudhuri 
A, et al., 2012). I participated in 2012 into a first collaborative project with the Vindigni lab, 
investigating the role of RecQ1 helicase in the process of reversed replication forksrestart. 
The work was published in 2013 in Nature Structural and Molecular Biology, and the 
manuscript is here included in the next few pages. In this study it was shown that RecQ1 
interacts with PARylated PARP1, and that this interaction is strongly inhibiting RecQ1 fork 
restoration activity (biochemical data). To investigate replication fork progression in TopI 
inhibited cells after treatment with PARP1 inhibitor Olaparib, we performed DNA fibers 
assay. The experiment confirmed that PARP1 inhibition rescues replication fork speed upon 
TopI inhibition, but showed that this is suppressed by depleted of RecQ1. My contribution to 
the project was to extend this set of experiments and to investigate the potential role of two 
other members of the RecQ helicase family, i.e. Bloom protein (BLM) and Werner syndrome 
protein (WRN), in the process of replication fork restart.  
Unlike RecQ1 downregulation, downregulation of BLM and WRN did not affect the rescue 
of replication fork speed induced by PARP1 inhibition upon TopI poisoning (Figure 3e and 
d), proving the specific role of RECQ1 in this context. 
2. Results. 
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TOP1 inhibitors are an important class of anticancer drugs that 
exert their function by perturbing DNA replication1,2. The mecha-
nisms of tumor response to TOP1 inhibitors and combinations of 
TOP1 inhibitors with other drugs for more effective tumor treat-
ment are areas of active investigation3,4. One widely accepted mecha-
nism for the cytotoxicity of TOP1 inhibitors has been their ability to 
create single-strand breaks (SSBs), which are converted to toxic 
DNA double-strand breaks (DSBs) upon colliding with the replica-
tion fork during replication5. This notion was recently challenged by 
the discovery that TOP1 inhibitors also impair TOP1 relaxation 
activity, inducing an accumulation of positive supercoils ahead 
of the replication fork that may hamper fork progression and the 
conversion of SSBs to DSBs1,6. Recent studies extended this obser-
vation by showing that replication forks rapidly slow and undergo 
fork reversal upon treatment with clinically relevant doses of camp-
tothecin (CPT), the prototype TOP1 inhibitor7,8. This prevents DSB 
formation and requires the activity of PARP1, a well-known chro-
matin-associated enzyme that modifies various nuclear proteins 
by poly(ADP-ribosyl)ation (PARylation), to accumulate regressed 
forks7. However, the exact role of PARP1 in promoting fork reversal 
remains unexplained. In addition, other factors are likely to be 
involved in this process, and the protein(s) required to restore and 
restart reversed replication forks after the lesion is repaired have not 
been identified.
RecQ helicases have long been proposed to assist replication forks 
in dealing with replication stress and have attracted considerable 
interest in recent years owing to their connection to heritable human 
diseases associated with cancer predisposition9,10. RecQ helicase 
enzymatic activities (such as DNA unwinding, branch migration 
and strand annealing) may have multiple roles during replication by 
virtue of their ability to interconvert numerous replication and recom-
bination intermediates11–13. Moreover, previous studies have pointed 
to a potential role of RecQ helicases in fork reversal and restart by 
showing that two of the five human RecQ helicases, BLM and WRN, 
promote both regression and re-establishment of model replication 
forks in vitro14–16. However, distinct roles or molecular functions for 
the five human RecQ helicases in replication stress and cancer remain 
to be defined10,17.
For the present study, we combined biochemical, single-molecule 
DNA fiber and EM approaches to investigate the function of the 
human RECQ1 helicase (also known as RECQL or RECQL1) during 
the replication stress response. Of the five human RecQ proteins, 
RECQ1 was the first to be discovered, owing to its potent ATPase 
activity, and it is the most abundant in cells18,19. However, little 
is known about its cellular functions to date. Here, we show that 
RECQ1 has an essential role—one not shared by other human RecQ 
 helicases—in restoring active replication forks that have regressed as 
a result of TOP1 inhibition. Moreover, we provide a rationale for the 
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University of Zurich, Zurich, Switzerland. 3Structural Biology Laboratory, Sincrotrone Trieste, Trieste, Italy. 4International Centre for Genetic Engineering and 
Biotechnology, Trieste, Italy. 5Institute for Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland. 6Competence Center 
for Systems Physiology and Metabolic Diseases, ETH Zurich, Zurich, Switzerland. 7Faculty of Science, University of Zurich, Zurich, Switzerland. 8Department of 
Pathology, University of Washington, Seattle, Washington, USA. 9Department of Genome Sciences, University of Washington, Seattle, Washington, USA.  
10Present address: Proteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland. 11These authors contributed equally to this work.  
Correspondence should be addressed to A.V. (avindign@slu.edu) or M.L. (lopes@imcr.uzh.ch).
Received 18 June 2012; accepted 26 December 2012; published online 10 February 2013; doi:10.1038/nsmb.2501
Human RECQ1 promotes restart of replication forks 
reversed by DNA topoisomerase I inhibition
Matteo Berti1,11, Arnab Ray Chaudhuri2,11, Saravanabhavan Thangavel1, Shivasankari Gomathinayagam1,  
Sasa Kenig3, Marko Vujanovic2, Federico Odreman4, Timo Glatter5,10, Simona Graziano1,  
Ramiro Mendoza-Maldonado4, Francesca Marino3, Bojana Lucic4, Valentina Biasin4, Matthias Gstaiger5,6,  
Ruedi Aebersold5–7, Julia M Sidorova8, Raymond J Monnat Jr8,9, Massimo Lopes2 & Alessandro Vindigni1
Topoisomerase I (TOP1) inhibitors are an important class of anticancer drugs. The cytotoxicity of TOP1 inhibitors can be 
modulated by replication fork reversal through a process that requires poly(ADP-ribose) polymerase (PARP) activity. Whether 
regressed forks can efficiently restart and what factors are required to restart fork progression after fork reversal are still 
unknown. We have combined biochemical and EM approaches with single-molecule DNA fiber analysis to identify a key role  
for human RECQ1 helicase in replication fork restart after TOP1 inhibition that is not shared by other human RecQ proteins.  
We show that the poly(ADP-ribosyl)ation activity of PARP1 stabilizes forks in the regressed state by limiting their restart by 
RECQ1. These studies provide new mechanistic insights into the roles of RECQ1 and PARP in DNA replication and offer  
molecular perspectives to potentiate chemotherapeutic regimens based on TOP1 inhibition.
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requirement of the PARylation activity of PARP1 in replication fork 
reversal. Our observations give new insight into a pivotal mechanism 
responsible for replication stress response and replication fork restart 
after chemotherapeutic drug damage. These findings have important 
clinical implications, as RECQ1 inactivation might affect the efficacy 
of combinatorial therapies that employ PARP inhibitors and DNA-
damaging agents and are already in promising clinical trials.
RESULTS
RECQ1 interacts with PARP1 and PAR
To better define the role of human RECQ1 helicase in DNA replica-
tion and repair, we first identified proteins associated with RECQ1 
using a new, integrated proteomic approach20. We used human 
embryonic kidney (HEK293) cells to generate a stable, inducible cell 
line expressing a doubly tagged version of RECQ1 (consisting of a 
streptavidin-binding peptide and a hemagglutinin epitope tag), then 
isolated protein complexes containing RECQ1 by affinity purifica-
tion (Supplementary Fig. 1a–d); we characterized the resulting com-
plexes by MS20. Among the most abundant co-purified proteins were 
PARP1, Ku70 and Ku80 (key components of the DNA nonhomolo-
gous end–joining pathway) and several nucleosomal components 
(Supplementary Fig. 1e). Given recent reports indicating a role for 
PARP1 in replication stress response7,21, we decided to focus our work 
on defining the role of RECQ1 interactions with PARP1.
We confirmed the RECQ1-PARP1 interaction by co- 
immunoprecipitation (co-IP) using nuclear extracts from human oste-
osarcoma (U-2 OS) cells and an antibody to RECQ1 (anti-RECQ1) that 
recognizes the C terminus of RECQ1 (residues 633–648). We obtained 
similar results using an anti-RECQ1 antibody that recognizes the 
N terminus of the protein (data not shown). We also performed recipro-
cal co-IPs using an anti-PARP1 antibody (Fig. 1a and Supplementary 
Fig. 1f). All co-IPs were performed in the presence of ethidium bro-
mide or Benzonase to ensure that DNA did not mediate the interac-
tions. We obtained similar results with other cell lines (Supplementary 
Fig. 1f and data not shown), indicating that the association between 
RECQ1 and PARP1 is not cell-type specific. These observations are 
in agreement with a previous report showing that RECQ1 and PARP1 
interact at viral replication origins and with a recent study reporting an 
interaction between RECQ1 and PARP1 in human cells22,23.
The RECQ1–PARP1 interaction is regulated by PARP1 PARylation 
activity: we observed increased association of the two proteins upon 
DNA damage and sharply reduced association upon inhibition 
of PARP1 activity with the PARP inhibitor NU1025 (Fig. 1a and 
Supplementary Fig. 1g). Using recombinant, purified PARP1 and 
RECQ1, we found that these two proteins interact directly, and the 
interaction was considerably stronger when we used a PARylated form 
of PARP1, indicating that the PAR modification of PARP1 is important 
for the interaction with RECQ1 (Supplementary Fig. 2a,b). Indeed, 
we observed that RECQ1 interacted with PAR, and binding to PAR 
was resistant to extensive washing with 1 M salt, although we could 
not identify any canonical PAR binding motifs in RECQ1 (ref. 24) 
(Supplementary Fig. 2c). We verified that NU1025 did not affect 
the interaction between recombinant RECQ1 and PARP1 in vitro, 
indicating that the reduced RECQ1-PARP1 interaction we observed 
by co-IP in the presence of this inhibitor is due to the inhibition of 
PARP1 PARylation activity rather than to a potential effect of NU1025 
on PARP conformation (Supplementary Fig. 2b).
We next mapped the domains of RECQ1 that interact with PARP1 and 
PAR using a series of glutathione S-transferase (GST)-tagged RECQ1 
fragments (Fig. 1b–d). Both PARP1 and PAR interacted with the 
C-terminal region of RECQ1 (residues 391–649; fragment names below 
indicate residue numbers), which contains the zinc-binding (Zn) and 
winged helix (WH) domains that form the ‘RecQ–C-terminal’ (RQC) 
domain, but not with fragment 391–473, which contains the Zn domain 
alone (Fig. 1c). The WH domain alone (fragment 474–649) also bound 
PARP1, although more weakly than fragment 391–649. These results 
suggest that the region containing residues 391–473 might be important 
for the stability and/or conformation of the WH domain. Our data also 
suggest that the region containing residues 391–649 is PARylated by 
PARP1 in vitro (Supplementary Fig. 2d and Supplementary Note); 
however, RECQ1 does not seem to be PARylated in vivo22.
To determine which region(s) of PARP1 are involved in RECQ1 
interaction, we overexpressed truncated versions of PARP1 fused to 
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Figure 1 Analysis of the RECQ1-PARP1 interaction. (a) Immunoprecipitation 
from U-2 OS cells using the anti-RECQ1 antibody with (+) or without (−) 
NU1025 (50 MM) and with CPT (100 nM for 2 h) or without DNA damage 
(mock). Rabbit IgG IP served as a negative control. Immunoblots were 
developed with anti-RECQ1 and anti-PARP1 antibodies. (b) Schematic 
representation of the domain structure of RECQ1 and the GST-tagged 
RECQ1 fragments. D1 and D2, RecA-like domains. (c) Pulldown assays 
with GST-tagged RECQ1 fragments. Top, Coomassie-stained gel of GST-
RECQ1 fragments. Bottom, autoradiography of in vitro GST pulldown 
assay using 35S-labeled PARP1. MW, molecular weight (kDa). (d) Analysis 
of PAR binding to GST-RECQ1 fragments (2 pmol) dot-blotted onto a 
nitrocellulose membrane. The arrows indicate the two RECQ1 fragments 
that interact with 32P-labeled PAR. (e) Schematic representation of the 
domain structure of PARP1 and the GST-tagged PARP1 fragments: A, DNA 
binding domain; B, nuclear localization signal; D, BRCT automodification 
domain; E, contains a WGR motif; F, catalytic domain; FI and FII, zinc-
finger motifs; NLS, nuclear localization sequence. A third zinc-finger 
motif has been recently identified in domain C36,37 in addition to FI and 
FII. (f) Pulldown assays with GST-tagged PARP1 (GST-PARP) fragments. 
Bound proteins were detected by autoradiography (bottom). Purified GST 
or GST-PARP1 proteins were detected with an anti-GST antibody (top). 
Input, 20% of the amount used in binding reactions.
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GST in HeLa cells (Fig. 1e,f). Only fragments 1–371 and 384–524 
could efficiently pull down RECQ1 in immunoprecipitation experi-
ments, and fragment 174–366 did not pull down RECQ1. These 
results indicate that the interaction with RECQ1 involves the first 173 
N-terminal residues of PARP1 (containing the DNA binding domain) 
and residues 384–524 (containing the BRCT domain, which is also 
the automodification domain). These two PARP1 domains are also 
involved in homodimerization and the binding of several partners, 
including WRN helicase25,26.
RECQ1 catalyzes restoration of synthetic replication forks
On the basis of the recent discovery that PARP1 has an important role 
in reversal of replication forks after CPT treatment7, we investigated 
whether RECQ1 is required for the cellular response to TOP1 inhibi-
tion. First, we confirmed previous observations that RECQ1 depletion 
leads to increased CPT sensitivity27. Flow-cytometric analysis showed 
that RECQ1-depleted cells are only mildly sensitive to most replication 
inhibitors and DNA-damaging agents, apart from CPT and etoposide 
(Supplementary Fig. 3a and Supplementary Note). These two drugs 
inhibit DNA replication by suppressing the relaxation activity of the 
type IB and type IIA topoisomerases, respectively2. Next, to confirm 
that RECQ1 binds to replication forks in vivo and that the interac-
tion increases upon CPT treatment, we labeled newly replicated DNA 
with 5-chlorodeoxyuridine (CldU), and confirmed RECQ1 co-IP with 
CldU in the presence and absence of CPT (Supplementary Fig. 3b 
and Supplementary Note).
We then tested whether RECQ1 mediates replication fork regres-
sion and/or restoration on synthetic DNA substrates and whether 
PARP1 affects RECQ1 activity. To measure these RECQ1 activities 
in vitro, we used a set of four oligonucleotides that can anneal into two 
alternative substrates that mimic model replication fork and ‘chicken-
foot’ structures14,28 (Supplementary Fig. 3c and Supplementary 
Table 1). We found that RECQ1 promotes model replication fork 
restoration very efficiently and in a concentration-dependent fashion: 
50 nM RECQ1 converted >75% of the chicken-foot structure into the 
model replication fork after 20 min (Fig. 2a,b). In contrast, RECQ1 
failed to catalyze the opposite reaction (fork regression): we detected 
<2% of chicken-foot structure, even at the highest RECQ1 concentra-
tion. We obtained identical results using a variant of the same sub-
strate lacking the 6-nucleotide (nt) single-stranded DNA (ssDNA) gap 
on the leading-strand template, thus ruling out the possibility that the 
presence of the ssDNA gap prevented RECQ1-mediated fork regres-
sion (Supplementary Figs. 3d and 4a). Next, we confirmed that the 
ATPase activity of RECQ1 is essential to promote branch migration 
of the chicken-foot structure and restoration of the active replication 
fork. We observed that the poorly hydrolyzable ATP analog ATPGS 
and the nonhydrolyzable analog AMP-PNP strongly inhibited the 
reaction, and two previously characterized ATPase-deficient RECQ1 
mutants, K119R and E220Q, lacked fork restoration (Supplementary 
Fig. 4b). Additional experiments using Holliday junction substrates 
with heterology regions of 1 and 4 bases confirmed that RECQ1 
has a strong branch migration activity and that its helicase activity 
may be important to bypass regions of heterology. However, we 
observed a 50% reduction in the formation of the branch migration 
product when the heterology region was increased from 1 to 4 bases 
(Supplementary Fig. 5a,b).
On the basis of our results showing that RECQ1 interacts with 
PARylated PARP1 and previous observations that the PARylation 
activity of PARP has a key role in mediating the accumulation of 
regressed forks after DNA damage7, we examined the effect of 
PARylated PARP1 on RECQ1 fork restoration activity. We found 
that PARylated PARP1 strongly inhibited the fork restoration rates of 
RECQ1: 40 nM RECQ1 converted approximately 80% of the chicken-
foot structure into a replication fork structure within 20 min. Addition 
of an equimolar concentration of PARylated PARP1 reduced the frac-
tion of restored fork structures to <30% (Fig. 2c,d). Experiments per-
formed at increasing concentrations of PARylated PARP1 showed that 
a two-fold excess of PARylated PARP1 did not inhibit the reaction 
further, indicating that equimolar concentrations are sufficient for 
maximal inhibition (Supplementary Fig. 4c). We observed a similar 
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Figure 2 Inhibition of in vitro  
fork restoration activity of RECQ1  
by PARylated PARP1 and PAR.  
(a) Fork restoration assays  
(lanes 1–7) and fork regression assays  
(lanes 8–14) performed using increasing RECQ1 concentrations (0, 15, 25, 35, 50, 100 and 200 nM) and a fixed concentration of chicken-foot 
substrate (2 nM, for restoration assay) or replication fork structure (2 nM, for regression assay). Right, schematic of the reaction products. (b) Left, 
schematic of restoration and regression reactions. Lined regions indicate heterologous sequences included in the vertical arms to prevent complete 
strand separation. In addition, we inserted two mismatches and a single isocytosine modification to prevent spontaneous fork regression and restoration 
(Supplementary Fig. 3). Stars indicate [G-32P]ATP-labeled 5 ends. Right, percentage of fork restoration and regression products plotted as a function 
of protein concentration. (c) Kinetic experiments using RECQ1 (40 nM) and the chicken-foot substrate (2 nM), visualized by gel electrophoresis. Lanes 
1–7, RECQ1 alone; lanes 8–14, RECQ1 in the presence of PARylated PARP1 (40 nM); lanes 15–21, RECQ1 in the presence of PAR (100 nM). (d) Left, 
schematic of restoration reaction. Right, percentage of fork restoration for RECQ1 alone and RECQ1 in the presence of PARylated PARP1 or PAR. Data 
in a–d represent the mean of three independent experiments. Error bars, s.e.m.
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inhibition of RECQ1 activity in the presence of PARylated PARP1 
using the Holliday junction (Supplementary Fig. 5c,d). To confirm 
that PARylated PARP1 is also able to inhibit the DNA unwinding 
activity of RECQ1, we used a fork duplex substrate with a duplex 
region of 20 bp (Supplementary Fig. 5e,f). In agreement with previ-
ous findings29, electrophoretic mobility shift assays using increasing 
concentrations of PARylated PARP1 confirmed that PARylated PARP1 
binds DNA with low affinity, indicating that the inhibitory effect of 
PARylated PARP1 on RECQ1 activity is not due to a competition for 
DNA binding (Supplementary Fig. 6). Additional fork restoration 
assays performed with PAR instead of PARylated PARP1 supported 
this conclusion, confirming that the interaction of RECQ1 with PAR 
is responsible for the inhibition of the fork restoration activity (Fig. 2). 
Collectively, our biochemical data show that RECQ1 has strong fork 
restoration activity that could be responsible for restarting reversed 
forks associated with CPT treatment. PARylated PARP1 inhibits this 
RECQ1 activity through a process that does not involve competition 
for DNA binding.
To investigate whether other human RecQ helicases share this 
activity, we performed additional experiments with an exonucle-
ase-deficient WRN mutant (WRN-E84A) that allows the branch 
migration reaction to be monitored without possible complications 
arising from substrate digestion. WRN-E84A promoted fork restora-
tion and regression with similar efficiency, with a slight bias toward 
fork restoration (Supplementary Fig. 7). Furthermore, the presence 
of PARylated PARP1 did not inhibit the fork restoration activity of 
WRN-E84A, in agreement with previous studies in which a differ-
ent set of substrates was used26. These results, along with previous 
observations for BLM14, show that although other helicases are able 
to promote fork restoration and regression, RECQ1 has a marked 
preference to promote fork restoration over fork regression, and its 
activity is uniquely regulated by PARylated PARP1.
RECQ1 and PARP control CPT-induced replication fork slowing
Next, we used genome-wide single-molecule DNA replication assays 
to test whether RECQ1 depletion affects the rate of replication fork 
progression upon TOP1 inhibition in a cellular context. We pulse-
labeled U-2 OS cells with the thymidine analog CIdU for 30 min then 
treated cells with 50 nM CPT, concomitantly labeling them with a 
second thymidine analog (IdU) for an additional 30 min (Fig. 3). We 
then analyzed the IdU tract-length distributions after CPT treatment 
with or without PARP inhibition. Using this approach, we initially 
confirmed previous findings that replication forks rapidly slow upon 
treatment with low CPT doses (50 nM), and that this effect requires 
the action of PARP1 (refs. 7,8). This is consistent with the notion 
that PARP inactivation does not perturb normal fork progression but 
prevents fork slowing after TOP1 inhibition. We then measured rates 
of fork progression in RECQ1-depleted cells treated with CPT and 
the PARP inhibitor olaparib. Our results showed that PARP inhibi-
tion does not rescue CPT-induced fork slowing in RECQ1-deficient 
cells. These results identify an essential role for RECQ1 in the control 
of fork progression upon TOP1 inhibition. RECQ1 downregulation 
using a lentiviral system and a different RNA interference (RNAi) tar-
geting sequence showed similar results, supporting the notion that the 
observed effect was specifically associated with RECQ1 loss (Fig. 4  
and data not shown). Additional DNA fiber experiments showed 
that—in contrast to the results obtained with RECQ1-depleted 
cells—PARP inhibition was still able to rescue CPT-induced fork 
slowing in BLM- and WRN-depleted cells. These results strongly 
support the notion that the identified role of RECQ1 in the control 
of fork progression upon TOP1 inhibition reflects a specific function 
and not a more general role of the RecQ helicase family (Fig. 3e). 
Genetic knockdown–rescue experiments confirmed that comple-
mentation in RECQ1-depleted U-2 OS cells with short hairpin RNA 
(shRNA)-resistant wild-type RECQ1 abrogated the effect of RECQ1 
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Figure 3 Replication fork progression after TOP1 and PARP inhibition is  
impaired in RECQ1-depleted U-2 OS cells. (a) Top, schematic of single  
DNA fiber replication track analysis. U-2 OS cells were transfected with  
siRNA against Luc or RECQ1 before CldU or IdU labeling, as indicated.  
Red, CldU-containing tract; green, IdU-containing tract. CPT (50 nM) was  
added concomitantly with the second label. Bottom, representative DNA  
fiber tracts from microfluidic-assisted replication tract analysis of RECQ1- 
depleted cells upon TOP1 and/or PARP inhibition. Scale bar, 12.5 Mm.  
(b) Statistical analysis of IdU tract-length measurements from Luc- or  
RECQ1-depleted cells. Relative length of IdU tracts synthesized after  
mock (NT) or CPT treatment (50 nM). n q175 tracts were scored for  
each data set. Olaparib (OLA, 10 MM) was optionally added 2 h before CldU  
labeling and maintained during labeling. Whiskers indicate the 10th and  
90th percentiles. NS, not significant; **P < 0.006, ****P < 0.0001 (Mann- 
Whitney test). (c) Smoothed histogram of IdU tract-length distribution after  
TOP1 and/or PARP inhibition in RECQ1-depleted (RECQ1 siRNA) cells. (d) RECQ1, BLM and WRN expression after siRNA knockdown, detected 
by western blotting. Tubulin and transcription factor II H (TFIIH) were detected as loading controls. (e) Statistical analysis of IdU tract-length 
measurements from Luc-, WRN- and BLM-depleted cells, as in b. ***P < 0.0001. 
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depletion on replication fork progression upon TOP1 inhibition 
(Fig. 4). Moreover, expression of the ATPase-deficient RECQ1 mutant 
K119R in RECQ1-depleted cells confirmed that the ATPase activity 
of RECQ1 is essential for its role in replication fork progression upon 
TOP1 inhibition (Fig. 4). Notably, we observed a minor but statisti-
cally significant (P < 0.006) difference between the mean length of 
the replication tracts measured in RECQ1-depleted cells relative to 
luciferase-depleted cells in the absence of CPT treatment (Fig. 3b). 
This is in line with our previous studies, in which we observed that the 
replication tracts were slightly shorter in RECQ1-depleted cells than 
in luciferase-depleted control cells in the absence of DNA damage19. 
These data might reflect an additional role for RECQ1 in replication 
fork progression in unperturbed cells.
Previous work has showed that CPT-induced fork slowing is uncou-
pled from DSB formation in human cells7. To determine whether 
RECQ1 depletion also influenced DSB accumulation after CPT treat-
ment, we used a recently optimized pulsed-field gel electrophoresis 
(PFGE) protocol7,30. Our PFGE analysis confirmed that PARP inhibi-
tion in U-2 OS cells leads to the induction of high levels of DSBs after 
CPT treatment (100 nM) (Fig. 5a,b). These results are consistent with 
the notion that PARP-inhibited or PARP-depleted cells do not slow 
or accumulate reversed forks after CPT treatment, leading to DSB 
formation even at low CPT doses7. RECQ1 depletion, however, had 
the opposite effect: PARP1 inhibition did not prevent fork slowing 
after CPT or lead to increased DSB formation in RECQ1-depleted 
cells (Fig. 5a,b). As an alternative method of monitoring DSB for-
mation, we looked at phosphorylated histone H2AX (GH2AX) and 
p53-binding protein 1 (53BP1) foci colocalization under the same 
conditions used for the PFGE experiments. In agreement with pre-
vious findings, we found that only a minor fraction of GH2AX foci 
colocalized with 53BP1 upon 100 nM CPT treatment and that PARP 
inhibition led to a considerably higher degree of GH2AX and 53BP1 
colocalization7 (Fig. 5c,d). However, RECQ1 depletion reduced the 
fraction of colocalizing foci in the presence of olaparib, supporting 
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the notion that RECQ1 depletion prevents DSB formation after PARP 
inhibition. Collectively, these data indicate that RECQ1 regulates the 
rate of replication fork progression and that RECQ1 depletion makes 
PARP activity dispensable in the prevention of DSB accumulation 
after TOP1 inhibition.
RECQ1 is essential for fork restart upon TOP1 inhibition
The observation that RECQ1 loss makes PARP activity dispensable 
in the prevention of fork slowing and DSB formation in CPT-treated 
cells suggests that regressed forks accumulate in RECQ1-depleted 
cells. This is in agreement with our biochemical results pointing to 
a role for RECQ1 in replication fork restart. To provide more direct 
evidence for this idea, we used EM to visualize the fine architec-
ture of in vivo replication intermediates31,32. A previous EM analysis 
of replication intermediates showed that replication forks undergo 
rapid fork reversal upon TOP1 inhibition7. Furthermore, effective 
fork reversal required PARP1 activity, possibly by promoting the 
accumulation or stabilization of regressed replication forks and thus 
preventing fork collision with a CPT-induced lesion to generate a 
DSB7. To test the hypothesis that the accumulation of reversed forks is 
increased in RECQ1-depleted, CPT-treated cells, we used EM to com-
pare RECQ1-depleted, CPT-treated U-2 OS cells in which PARP was 
inhibited to those in which it was not inhibited (Fig. 6). Consistent 
with previous findings, we observed a high frequency of fork reversal 
(approximately 30% of molecules analyzed) in control U-2 OS cells 
transfected with a small interfering RNA (siRNA) against Luc (encod-
ing luciferase) and treated with 25 nM CPT. The same experiments 
performed in the presence of olaparib confirmed that PARP inhibition 
RECQ1-depleted cells did not result in marked reduction in the frac-
tion of regressed forks, suggesting that regressed forks do not restart 
upon RECQ1 inactivation, even in the absence of PARP activity. To 
test this hypothesis directly, we performed recovery experiments 
in which we measured reversed fork frequency after CPT removal. 
Whereas control cells showed a marked decrease in the frequency of 
fork reversal (from 30% to 10%) after drug removal, RECQ1-depleted 
cells maintained a high frequency of reversed forks (~33%) 3 h after 
CPT withdrawal. These data strongly suggest that RECQ1 is essen-
tial in restarting reversed forks and indicate that the requirement of 
PARP for CPT-induced fork reversal reflects a unique role for PARP 
in limiting RECQ1-mediated fork reactivation.
DISCUSSION
Replication fork regression is rapidly emerging as a pivotal response 
mechanism to the induction of replication stress. This notion is sup-
ported by the recent discovery that TOP1 inhibition by CPT induces 
replication fork slowing and reversal, preventing DSB formation 
at clinically relevant doses of CPT7,8. PARP1 is a crucial cellular 
mediator required for the accumulation or stabilization of regressed 
forks upon TOP1 poisoning. PARP1 itself is a target for anticancer 
therapies, particularly breast and ovarian cancers involving muta-
tion of the genes BRCA1 and BRCA2. PARP inactivation prevents 
the accumulation of regressed forks without affecting the checkpoint 
response7. However, the mechanism by which PARP activity pro-
motes fork reversal is still unknown, and the requirements for the 
restart of reversed forks have not been defined. Our work provides 
new insight into these mechanisms by showing that regressed forks 
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a b Figure 6 Reversed forks accumulate and are 
unable to restart in RECQ1-depleted cells after 
CPT treatment. (a) Representative electron 
micrograph of a reversed fork observed on genomic 
DNA from U-2 OS cells transfected with RECQ1 
siRNA and treated with CPT (25 nM) and olaparib 
(10 MM). D, daughter strand; P, parental strand;  
R, reversed arm. (b) Frequency of fork reversal in 
U-2 OS cells transfected with Luc siRNA or RECQ1 
siRNA and treated with CPT and/or olaparib. 
Restart experiments measuring the frequency 
of fork reversal were performed 3 h after CPT 
removal. Numbers above bars indicate proportion 
of reversed forks as a percentage of total number 
of molecules (bottom, parentheses). Right, RECQ1 
expression after siRNA knockdown detected by 
western blotting. TFIIH, loading control. 
Figure 7 Schematic model of the combined roles of PARP1 and RECQ1 in 
response to TOP1 inhibition. (a,b) PARP PARylation activity is not required to 
form reversed forks, but it promotes the accumulation of regressed forks  
by inhibiting RECQ1 fork restoration activity, thus preventing premature 
restart of regressed forks. (c) Inhibition of PARP1 activity leads to replication 
runoff and increased DSB formation upon TOP1 inhibition, as RECQ1 can 
cause untimely restart of reversed forks. (d) PARP activity is not required in 
RECQ1-depleted cells because the cells lack the enzyme (RECQ1) necessary 
to promote fork restart. Homologous recombination (HR) might be required to 
promote fork restart in the absence of RECQ1 and PARP activity. 
in control cells markedly decreased the 
 fraction of reversed forks, from 30% to <10%. 
RECQ1 depletion by siRNA upon CPT treat-
ment resulted in a higher frequency of fork 
reversal events (~44%) than that observed in 
control cells. Notably, PARP inactivation in 
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can restart in vivo and identifying a key role for human RECQ1 in 
promoting, through ATPase and branch migration activities, efficient 
replication fork restart after TOP1 inhibition (Fig. 7). Our results also 
show that this function of RECQ1 is not shared by other helicases, 
such as BLM and WRN. Furthermore, our results provide new insight 
into the molecular role of PARP in fork reversal by showing that the 
PARylation activity of PARP is important in regulating RECQ1 activ-
ity on replication forks after CPT treatment. A notable aspect of these 
data is that PARP activity is dispensable in the formation of reversed 
forks (Fig. 7a) but required to ‘accumulate’ them—that is, to maintain 
or protect them from counteracting activity (by RECQ1) that would 
otherwise cause an untimely restart of reversed forks, leading to DSB 
formation (Fig. 7b,c). Indeed, we show that in RECQ1-depleted cells, 
PARP activity is dispensable in the accumulation of reversed forks or 
the avoidance of CPT-induced DSBs (Fig. 7d). We propose that PARP 
‘signals’ the presence of lesions on the template and inhibits RECQ1 
locally, thereby restraining the restart of reversed forks until repair 
of the TOP1 cleavage complex is complete (Fig. 7b). An important 
next step will be to identify factors that modulate RECQ1-catalyzed 
fork restart by PARP activity.
These data provide a new mechanistic insight that could help to 
predict the efficiency of anticancer therapies that include both PARP 
and TOP1 inhibitors. These combinations are now in clinical trials. 
Our results also suggest that RECQ1 might represent a new therapeutic 
target to be used in conjunction with TOP1 inhibitors. In principle, 
induction of fork reversal (by TOP1 poisons) and inhibition of reversed 
fork reactivation (by RECQ1 depletion) should synergize, which would 
explain the observed CPT sensitivity of RECQ1-depleted cells.
RecQ helicases are DNA unwinding enzymes essential for the 
maintenance of genome stability in many organisms. Why human 
cells should express five RecQ homologs, and microorganisms such 
as Escherichia coli, Saccharomyces cerevisiae and Schizosaccharomyces 
pombe only one or two, remains unexplained. Our previous studies 
provided new insight by identifying important and distinct roles for 
RECQ1 and RECQ4 during DNA replication19. These data, com-
bined with previous observations that RECQ1 depletion leads to 
increased DNA damage and affects cellular proliferation27,33,34, sug-
gest that RECQ1 might have a distinct role in the stabilization and 
repair of replication forks. Our discovery that RECQ1 is required 
for replication fork restoration after TOP1 poisoning provides what 
is, to our knowledge, the first indication of a specific cellular func-
tion for this RecQ helicase. U-2 OS cells lacking BLM or WRN do 
not show similar defects in replication fork restoration upon TOP1 
poisoning, suggesting that RECQ1 is the RecQ helicase specifi-
cally responsible for promoting replication fork restart upon CPT-
induced fork reversal. Moreover, RECQ1 shows a striking preference 
for fork restoration over regression, and its activity, unlike that of 
WRN, is specifically regulated by PARylation of PARP1 (ref. 26) 
(Supplementary Fig. 7). However, we cannot yet rule out the pos-
sibility that other human RecQ helicases are involved in different 
steps of the same process.
It will be important for future studies to determine whether reversed 
forks are detected in response to genotoxic stress other than TOP1 
inhibition and whether RECQ1 or other helicases are implicated in 
replication fork reversal or restart, depending on the type of DNA 
damage. WRN- and BLM-deficient cells show increased sensitiv-
ity to select genotoxic agents35, whereas RECQ1-deficient cells are 
markedly sensitive to CPT and etoposide, supporting the notion that 
these three RecQ helicases have distinct roles in replication stress 
response. The fact that RECQ1-depleted cells show increased sen-
sitivity to etoposide opens the possibility that a similar mechanism 
of fork reversal and restart might take place upon treatment with 
topoisomerase II poisons. EM analysis of replication intermediates 
after treatment with different classes of chemotherapeutic drugs will 
provide early clues about combinations of drugs and RecQ helicases 
to pursue in future studies.
The discovery that RECQ1 is essential for fork restart upon TOP1 
poisoning suggests that RECQ1 may itself be a new therapeutic target 
and that it could modulate the efficacy of combinatorial cancer thera-
pies using PARP and TOP1 inhibitors that are already in clinical trials. 
A key experimental goal will be to determine the fate of regressed 
replication forks that accumulate in the absence of RECQ1. One pos-
sibility is that active replication forks are restored by the homologous- 
recombination machinery in the absence of the fork restart activity 
of RECQ1 (Fig. 7d). Thus, RECQ1 depletion or inhibition might 
result in synthetic lethality in a background deficient for homologous 
recombination, providing a new way to target and increase the effi-
cacy of cancer therapies when homologous-recombination repair is 
inefficient or inhibited.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Materials. The antibodies used were rabbit polyclonal antibody to PARP1 
(anti-PARP1) Enzo, ALX-210-302-R100) (1:2,000), mouse monoclonal anti-
PARP1 (Santa Cruz, sc-8007) (1:1,000), mouse monoclonal anti-PAR (Enzo, 
ALX-804-220-R100, clone 10H) (1:2,000), rabbit polyclonal anti-PAR (Trevigen, 
4336-BPC-100) (1:2,000), mouse monoclonal anti-Ku70 and anti-Ku86 (Santa 
Cruz, sc-5309 and sc-5280) (1:2,000), mouse monoclonal anti-tubulin (Sigma, 
T5168) (1:5,000), mouse monoclonal anti-WRN (BD laboratories, 611169) 
(1:1,000), rabbit polyclonal anti-BLM (Abcam, ab476) (1:1,000), rabbit poly-
clonal anti-TFIIH (Santa Cruz, sc293) (1:2,000), rabbit polyclonal anti-RECQ1 
raised against residues 1–110 (Santa Cruz, sc-25547) (1:2,000) and a custom-
made rabbit anti-RECQ1 polyclonal antibody to a synthetic peptide of a unique 
sequence in the last 16 residues at the C terminus of RECQ1 (Sigma) (1:2,000)33. 
Camptothecin and etoposide were from Sigma. The PARP1 inhibitors olaparib 
and NU1025 were from Selleck Chemicals and Sigma, respectively.
Protein complex purification. To isolate protein complexes containing a RECQ1 
bait protein, we prepared a HEK293 cell line expressing a double-tagged version 
of the human RECQ1 helicase by Flp recombinase-mediated integration. This 
system allows the generation of stable mammalian cell lines exhibiting tetracy-
cline-inducible expression of a gene of interest from a single genomic location20. 
The protein complexes containing RECQ1 were isolated and analyzed by MS as 
previously described20 (Supplementary Fig. 1).
Immunoprecipitation. HEK293T or human osteosarcoma U-2 OS cells were 
treated as indicated, washed two times with ice-cold PBS and resuspended 
in cytoplasmic extraction buffer (10 mM Tris-HCl (pH 7.9), 0.34 M sucrose, 
3 mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, 1 mM DTT, 20 mM 
NaF, 10 mM B-glycerophosphate, 0.2 mM Na3VO4, 0.5% Nonidet P-40 and 
protease inhibitors (Roche)) for 10 min at 4 °C. Intact nuclei were pelleted 
by low-speed centrifugation, washed with cytoplasmic lysis buffer (without 
Nonidet P-40) and lysed in nuclear lysis buffer (20 mM HEPES (pH 7.9), 150 mM 
KCl, 1.5 mM MgCl2, 20 mM NaF, 10 mM B-glycerophosphate, 0.2 mM Na3VO4 
10% glycerol, 0.5% Nonidet P-40 and protease inhibitors) by homogenization, 
and DNA and RNA in the suspension were digested with 50 U per microliter 
Benzonase (Sigma) at 4 °C for 1 h. The nuclear-soluble extract was clarified 
from insoluble material by centrifugation at 20,000 × g for 20 min, pre-cleared 
with a 50-Ml slurry of protein A beads (Santa Cruz) at 4 °C for 1 h and incu-
bated overnight with anti-RECQ1 (Sigma), anti-PARP1 (Enzo) or a control IgG 
rabbit polyclonal antibody at 4 °C. Immunocomplexes were captured by add-
ing 50 Ml of a protein A bead slurry for 2 h at 4 °C. After extensive washing, 
proteins were eluted from beads with 2× Laemmli sample buffer at 95 °C for 
5 min, separated by SDS-PAGE and detected by immunoblotting with the 
appropriate antibodies.
GST pulldown experiments with in vitro–translated PARP1. Pulldown assays 
with GST-RECQ1 fragments were performed as previously described38. Briefly, 
[35S]Met-labeled, in vitro–translated PARP1 was incubated with GST-fused 
RECQ1 fragments bound to 10 Ml of glutathione-Sepharose beads (Amersham) 
in binding buffer TNEN (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.0 mM 
EDTA (pH 8.0), 0.5% NP-40, 1 mM DTT and 1 mM PMSF) supplemented with 
0.1 mg/ml ethidium bromide for 2 hr at 4 °C. The beads were subsequently 
washed two times in ethidium bromide–supplemented TNEN buffer and three 
times with TNEN buffer. Bound proteins were eluted with SDS sample buffer, 
resolved by gel electrophoresis and visualized by autoradiography. For the pull-
downs with the GST-PARP1 fragments, [35S]Met-labeled, in vitro-translated 
RECQ1 was incubated with immobilized GST or GST–PARP1 domains. The 
GST-PARP fragments were expressed in HeLa cells as previously described25,26. 
Cells were lysed 48 h later in 50 mM Tris-HCl (pH 8), 250 mM NaCl, 0.5% NP-40, 
0.5 mM PMSF and protease inhibitors. Lysates were cleared by centrifugation and 
incubated for 2 h with glutathione-Sepharose beads. Beads were washed three 
times with lysis buffer and two times with lysis buffer supplemented with 1 M 
NaCl and resuspended in GST binding buffer for pulldown experiments with the 
purified GST-PARP1 fragments.
PAR binding assay. The PAR binding assays were performed using 1 M NaCl for 
the washing step as previously described39.
Purification of recombinant proteins and in vitro PARylation of PARP1. 
Recombinant RECQ1 and PARP1 were purified from insect cells as previously 
described40,41. For in vitro poly(ADP-ribosyl)ation of PARP1, recombinant 
PARP-1 was incubated in 20 Ml of activity buffer (50 mM Tris (pH 7.5), 4 mM 
MgCl2, 50 mM NaCl, 200 MM DTT, 0.1 Mg/Ml BSA, 4 ng/Ml DNaseI-activated calf 
thymus DNA and 400 MM NAD+) for 10 min at 37 °C.
In vitro fork regression and restart assays. The oligonucleotide sequences and 
the procedure used for the preparation of [G-32P]ATP-labeled substrate are shown 
in Supplementary Table 1 and Supplementary Figure 3, respectively. Reactions 
were performed using the indicated protein concentrations and 2 nM DNA sub-
strate in branch migration buffer (35 mM Tris-HCl (pH 7.5), 20 mM KCl, 5 mM 
MgCl2, 0.1 mg/ml BSA, 2 mM DTT, 15 mM phosphocreatine, 30 U/ml creatine 
phosphokinase and 5% glycerol) at 37 °C. The reaction was started by the addi-
tion of 2 mM ATP. Concentration-dependence experiments were stopped after 
20 min. For the poly(ADP-ribosyl)ation experiments, the indicated concentra-
tions of PARP1 and 200 MM NAD or 100 nM purified PAR were added to the 
reaction mixture without ATP and pre-incubated together with RECQ1 and the 
substrate at 37 °C for 10 min. DNA substrates were deproteinized by adding 3× 
stop reaction (1.2% SDS, 30% glycerol supplemented with proteinase K (3mg/ml)) 
at room temperature for 10 min before being resolved on a native 8% polyacryl-
amide gel run in Tris-borate-EDTA (TBE) buffer at 4 °C.
Genetic knockdown–rescue assays. siRNA-mediated transient depletion of 
RECQ1 was achieved using an siRNA SMART pool against human RECQ1 
(NM_032941, Dharmacon) in U-2 OS cells and a previously described protocol 
in which we established the specificity of the siRNA pool19,33. siRNA-mediated 
depletion of WRN and BLM was achieved using the following siRNAs from 
Microsynth: WRN siRNA (5`-UAGAGGGAAACUUGGCAAAdTdT-3`) and 
BLM siRNA (5`-CCGAAUCUCAAUGUACAUAGA dTdT-3`). shRNA-mediated 
downregulation was achieved by cloning the sequence targeting RECQ1  
(5`-GAGCTTATGTTACCAGTTA-3`) into the pLKO.1 lentiviral shRNA expres-
sion vector. Virus was generated by transient cotransfection of pLKO.1 and the 
packaging plasmids psPAX2 and pM2D.G into 293T cells. Viral supernatants 
were filtered through a 0.45 MM filter and transduced on U-2 OS cells for 
24 h, followed by selection with puromycin (8 Mg/ml) for 3 d. Control transduc-
tions were performed using the pLKO.1 vector expressing a shRNA targeting 
the gene encoding Luciferase (5`-ACGCTGAGTACTTCGAAATGT-3`). The 
level of depletion was verified by western blotting. For the complementation 
assays, we cloned a RECQ1 RNAi–resistant open reading frame into a pIRES 
vector under the control of the CMV promoter. Specifically, the nucleotides tar-
geted by the RNAi (5`-GAGCTTATGTTACCAGTTA-3`) were partially substituted 
without changing the amino acid sequence (5`-GTCACTATGCTATCAATTA-3`) 
by site-directed mutagenesis. Lentiviral depletion of endogenous RECQ1 was 
achieved using the protocol described above, and the resulting RECQ1-depleted 
cells were then nucleofected with a shRNA-resistant RECQ1 expression vec-
tor. Expression of the RNAi-resistant, Flag-tagged RECQ1 and K119R mutant 
was verified in control and RECQ1-depleted cells by western analysis 48 h 
after transfection.
Microfluidic-assisted DNA fiber stretching and replication fork progres-
sion analysis. Asynchronous U-2 OS cells were transiently transfected for 72 h 
with siRNA SMART pools (or specific shRNA) against RECQ1 or Luciferase as 
reported earlier19,33. RECQ1- or Luciferase-depleted U-2 OS cells were labeled 
for 30 min each with 50 MM CldU followed by 50 MM IdU. Cells were collected 
by trypsinization, and high–molecular weight DNA from cells embedded in aga-
rose plugs was isolated and stretched using a microfluidic platform as described 
earlier42. For immunostaining, stretched DNA fibers were denatured with 2.5 N 
HCl for 45 min, neutralized in 0.1 M sodium borate (pH 8.0) and PBS, and 
blocked with PBS, 5% BSA and 0.5% Tween-20 for 30 min. Rat anti-CldU/BrdU 
(Abcam, ab6326) (1:6), goat anti-rat Alexa 594 (Invitrogen, A11007) (1:1,000), 
mouse anti-IdU/BrdU (BD Biosciences, 347580) (1:6) and goat anti-mouse Alexa 
488 (Invitrogen, A11001) (1:1,000) antibodies were used to reveal CldU- and 
IdU-labeled tracts, respectively. A Leica SP5X confocal microscope was used to 
visualize the labeled tracts, and tract lengths were measured using ImageJ (http://
rsbweb.nih.gov/ij/). Statistical analysis of the tract length was performed using 
GraphPad Prism (http://www.graphpad.com/scientific-software/prism/).
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Double-strand break detection by pulsed-field gel electrophoresis.  
DSB detection by PFGE was performed as previously described with minor 
modifications7,30.
Immunofluorescence analyses. U-2 OS cells were grown on coverslips, fixed in 
3.7% PFA, permeabilized in 0.5% Triton X-100 and blocked in 3% BSA. Coverslips 
were then stained with rabbit polyclonal anti-53BP1 (Novus Biologicals, 
NB100-304) (1:500) and mouse monoclonal anti-GH2AX (Millipore, 05-636) 
(1:300), and detected by appropriate Alexa 488– and Alexa 594–conjugated 
secondary antibodies (1:700). Toto3 iodide (Life Technologies, T3604) was 
used as a nuclear counter-stain. Cells were imaged using a Zeiss LSM 510 Meta 
confocal microscope. Images were acquired using the LSM 5 software. Foci were 
counted with ImageJ ‘Analyze particles’ function and ‘JACoP’ plugin was used 
to calculate colocalization. The average number of foci was obtained from three 
independent experiments analyzing at least 35 cells per sample.
Electron microscopy analysis of genomic DNA in mammalian cells.  
EM analysis of replication intermediates has been described in detail31,32, includ-
ing a description of the important parameters to consider specifically for the 
identification and the scoring of reversed forks32.
38. Lucic, B. et al. A prominent B-hairpin structure in the winged-helix domain of 
RECQ1 is required for DNA unwinding and oligomer formation. Nucleic Acids Res. 
39, 1703–1717 (2011).
39. Ahel, D. et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin 
remodeling enzyme ALC1. Science 325, 1240–1243 (2009).
40. Cui, S. et al. Analysis of the unwinding activity of the dimeric RECQ1 helicase in 
the presence of human replication protein A. Nucleic Acids Res. 32, 2158–2170 
(2004).
41. Muzzolini, L. et al. Different quaternary structures of human RECQ1 are associated 
with its dual enzymatic activity. PLoS Biol. 5, e20 (2007).
42. Sidorova, J.M., Li, N., Schwartz, D.C., Folch, A. & Monnat, R.J. Jr. Microfluidic-
assisted analysis of replicating DNA molecules. Nat. Protoc. 4, 849–861 (2009).
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2.10.2 DNA2 /WRN contribution to reversed replication fork restart, by regressed arm 
processing. 
 
A second collaborative effort was done with the same group of Dr. Vindigni in 2014, 
resulting in the publication in 2015 of an article in the Journal of Cell Biology, included here 
in the next few pages. In this study it was revealed that the nuclease activity of the DNA2 
protein, and the ATP-ase dependent helicase activity of WRN, play a role in a second 
pathway of replication fork restart upon prolonged nucleotide depletion, which is uncovered 
in the absence of RECQ1. The conserted action of DNA and WRN in these specific 
experimental conditions leads to controlled reversed forks restart by resection of the 
regressed arm. I significantly contributed to perform several electron microscopy experiments 
and to analyze the resulting data, finally leading to the results published in Figure 6.  
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Introduction
The accurate replication of our genome is an essential require-
ment for the high-!delity transmission of genetic information 
to daughter cells. DNA replication forks are constantly chal-
lenged and arrested by DNA lesions, induced by endogenous 
and exogenous agents, and by a diverse range of intrinsic repli-
cation fork obstacles, such as transcribing RNA polymerases, 
unusual DNA structures or tightly bound protein–DNA com-
plexes (Carr and Lambert, 2013). An emerging model of how 
stalled or damaged forks are processed is that replication forks 
can reverse to aid repair of the damage (Atkinson and McGlynn, 
2009; Ray Chaudhuri et al., 2012; Berti et al., 2013). This model 
implies signi!cant remodeling of replication fork structures into 
four-way junctions and the molecular determinants required for 
reversed fork processing and restart are just beginning to be 
elucidated. The !rst evidence that supports the physiological re-
levance of this DNA transaction during replication stress in 
human cells arose from studies with DNA topoisomerase I 
(TOP1) inhibitors (Ray Chaudhuri et al., 2012). Additional 
studies established that the human RECQ1 helicase promotes 
the restart of replication forks that have reversed upon TOP1 
inhibition by virtue of its ATPase and branch migration activi-
ties (Berti et al., 2013). These observations were recently ex-
tended to show that the RECQ1 mechanism of reversed fork 
restart is a more general response to a wide variety of replica-
tion challenges (Zellweger et al., 2015). Nonetheless, new lines 
of evidence point to alternative mechanisms and factors that 
might mediate either formation or processing of reversed repli-
cation forks (Bétous et al., 2012; Gari et al., 2008). These puta-
tive mechanisms likely include nucleases that are capable of 
processing stalled replication intermediates upon genotoxic 
stress (Cotta-Ramusino et al., 2005; Schlacher et al., 2011; 
Hu et al., 2012; Ying et al., 2012).
Here, we investigate the contribution of the human DNA2 
nuclease/helicase in reversed fork processing. DNA2 is a highly 
conserved nuclease/helicase initially identi!ed in Saccharomyces 
cerevisiae screening for mutants de!cient in DNA replication 
(Kuo et al., 1983; Budd and Campbell, 1995). Yeast Dna2 plays 
Accurate processing of stalled or damaged DNA replication forks is paramount to genomic integ-rity and recent work points to replication fork 
reversal and restart as a central mechanism to ensuring 
high-fidelity DNA replication. Here, we identify a novel 
DNA2- and WRN-dependent mechanism of reversed rep-
lication fork processing and restart after prolonged geno-
toxic stress. The human DNA2 nuclease and WRN ATPase 
activities functionally interact to degrade reversed replica-
tion forks with a 5-to-3 polarity and promote replication 
restart, thus preventing aberrant processing of unresolved 
replication intermediates. Unexpectedly, EXO1, MRE11, 
and CtIP are not involved in the same mechanism of 
reversed fork processing, whereas human RECQ1 limits 
DNA2 activity by preventing extensive nascent strand 
degradation. RAD51 depletion antagonizes this mecha-
nism, presumably by preventing reversed fork formation. 
These studies define a new mechanism for maintaining 
genome integrity tightly controlled by specific nucleolytic 
activities and central homologous recombination factors.
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single-molecule DNA !ber replication assays. We pulse- 
labeled human osteosarcoma (U-2 OS) cells with the thymidine 
analogue CldU for 20 min, followed by a 60-min exposure to a 
selected genotoxic agent during the CldU labeling period, and 
by labeling with the second thymidine analogue, IdU, for an ad-
ditional 40 min after removal of the genotoxic drug. We found 
that DNA2 plays an important role in restarting replication 
forks after treatment with the ribonucleotide reductase inhibitor 
hydroxyurea (HU), the topoisomerase I inhibitor camptothecin 
(CPT), and the interstrand cross-linking agent mitomycin C 
(MMC) (Fig. 1 A). In addition, DNA2 depletion increased the 
percentage of origin !ring, but not of fork termination events 
(Fig. S1 A). Genetic knockdown–rescue experiments con!rmed 
that complementation in DNA2-depleted U-2 OS cells with 
siRNA-resistant WT DNA2 abrogated the effect of DNA2 de-
pletion on replication fork restart upon HU treatment. More-
over, expression of the nuclease-de!cient DNA2 mutant D294A 
in DNA2-depleted cells revealed that the nuclease activity 
of DNA2 was essential for its role in replication fork restart 
(Fig. 1 B and Fig. S1 B).
We next measured whether DNA2 uses its nuclease activ-
ity to process stalled replication intermediates by monitoring 
the integrity of the newly synthesized DNA after HU treatment. 
To this purpose, we changed the DNA labeling scheme. We !rst 
pulsed U-2 OS cells with IdU for 45 min, and then varied the 
exposure time to HU from 0 to 8 h. The mean length of the IdU 
tracts progressively decreased during HU treatment from 18.2 µm 
(0 h) to 12.0 µm (8 h; Fig. 1 C). However, shRNA-mediated 
DNA2 depletion largely prevented IdU tract shortening, con-
!rming that DNA2 is responsible for the observed nascent 
strand degradation (Fig. 1 D). Double-labeling experiments 
con!rmed that the observed nascent tract shortening is indeed 
caused by the DNA2-dependent processing of ongoing replica-
tion forks and that this degradation is important to mediate ef-
!cient replication fork restart upon prolonged HU treatment 
(Fig. 1 E). Clonogenic analysis of U-2 OS cells treated with the 
same HU concentration used for the DNA !ber experiments 
showed a signi!cantly reduced cell survival upon DNA2 deple-
tion, indicating that the DNA2-dependent processing of stalled 
replication intermediates is critical for recovery from replica-
tion fork blockage (Fig. 2 A). The results obtained with the 
shRNA DNA2-depleted U-2 OS cells were validated using a 
new conditional knockout human colorectal carcinoma cell line 
(HCT116) where addition of tamoxifen to the culture medium 
led to DNA2-null cells. Analysis of the mean tract lengths con-
!rmed that DNA2 knockout in HCT116 cells abrogates the 
prominent degradation observed upon HU treatment (Fig. 2 B). 
Collectively, these results indicate that human DNA2 degrades 
nascent strands at stalled replication forks to facilitate fork re-
start and promote viability after genotoxic stress induction.
RECQ1 regulates the fork processing 
activity of DNA2
On the basis of the recent discovery that RECQ1 is required to 
restart replication forks that have reversed upon genotoxic stress 
induction (Berti et al., 2013), we investigated whether RECQ1 
regulates the fork processing activity of DNA2. Nascent IdU 
an essential role in Okazaki fragment maturation during lagging 
strand DNA replication (Budd and Campbell, 1997; Bae et al., 
2001; Ayyagari et al., 2003). However, increasing evidence sug-
gests that DNA2 has important—albeit yet unde!ned—roles in 
DNA replication stress response and DNA repair, which go be-
yond its postulated role in Okazaki fragment processing (Duxin 
et al., 2012; Karanja et al., 2012; Peng et al., 2012). The notion 
that DNA2 is important for DNA replication is strengthened by 
the observation that DNA2 forms a complex with various repli-
cation core components, including the replisome protein And-1 
(Wawrousek et al., 2010; Duxin et al., 2012). Moreover, human 
DNA2 seems to play a partially redundant role with human exo-
nuclease I (EXO1) in replication-coupled repair (Karanja et al., 
2012), whereas a recent study in S. pombe suggested that the 
nuclease activity of DNA2 is required to prevent stalled forks 
from reversing upon HU treatment (Hu et al., 2012).
DNA2 also has an independent function in dsDNA break re-
pair. Two distinct pathways act redundantly to mediate processive 
DSB resection downstream from the MRE11-RAD50-NBS1 
(MRN) and CtIP factors in eukaryotic cells: one requires DNA2 
and the other EXO1 (Gravel et al., 2008; Mimitou and Symington, 
2008; Zhu et al., 2008; Nicolette et al., 2010). Speci!cally, DNA2 
and EXO1 resect the 5 ends of double-strand DNA breaks (DSBs) 
to generate 3 single-stranded overhangs, which are essential to 
initiate homologous recombination. In yeast, DNA2-dependent 
dsDNA-end resection reaction requires the Sgs1 helicase to un-
wind the DNA from the break (Zhu et al., 2008; Cejka et al., 2010; 
Niu et al., 2010). This mechanism appears to be largely conserved 
in mammalian cells where DNA2 cooperates with the human BLM 
helicase to resect dsDNA ends in vitro (Nimonkar et al., 2011). 
However, mammalian cells possess !ve human RecQ homologues 
(RECQ1, RECQ4, RECQ5, BLM, and WRN) and WRN can also 
assist DNA2-dependent end resection, suggesting that BLM might 
not be the sole RecQ homologue required for this process (Liao 
et al., 2008; Sturzenegger et al., 2014). The ability of DNA2 and 
EXO1 to process dsDNA ends might also be relevant in the con-
text of DNA replication to prevent the accumulation of replica-
tion-associated DSBs by promoting homologous recombination 
(HR) repair (Peng et al., 2012). Alternatively, these nucleases 
might be involved in the recovery of replication fork blockage 
by processing speci!c stalled replication fork structures.
This work uncovers a new DNA2- and WRN-dependent 
mechanism that mammalian cells use to process replication 
forks that have reversed as a result of replication inhibition. Im-
portantly, it also shows that this mechanism is tightly regulated 
by human RECQ1 and the HR factor RAD51. Our observations 
shed light on a novel pathway for the suppression of chromo-
somal instability in mammalian cells and provide important 
new insight into the mechanisms of replication stress response 
associated with chemotherapeutic drug damage.
Results
DNA2 is required for stalled fork 
processing and restart
To begin elucidating the role of human DNA2 during replication 
stress, we monitored replication perturbation by genome-wide 
2. Results. 
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Figure 1. DNA2 is required for replication fork restart and stalled fork processing upon genotoxic stress. (A) Schematic of DNA fiber tract analysis. 
U-2 OS cells were transfected with control siRNA or DNA2 siRNA before CldU or IdU labeling. Red tracts, CldU; curved red tracts, CldU with genotoxic agents 
(HU or CPT or MMC); green tracts, IdU. (bottom) Representative DNA fiber image. (right) quantification of red-green contiguous tracts (restarting forks). 
Mean shown, n = 3. Error bars, standard error. ns, not significant; *, P < 0.05; **, P < 0.01 (paired t test). (B) Quantification of restarting forks in DNA2-
depleted cells expressing DNA-WT or DNA2-D294A. ns, not significant; *, P < 0.05 (paired Student’s t test). (C, top) Representative DNA fiber image. 
(bottom) Representative IdU tract length distributions in Luc-depleted cells during different exposure time to HU (out of 3 repeats; n ≥ 300 tracts scored 
for each dataset). Mean tract lengths are indicated in parentheses. (D) Top, DNA2 expression after shRNA knockdown. Bottom, representative IdU tracts 
in DNA2-depleted U-2 OS cells in the presence or absence of HU (out of 2 repeats; n ≥ 700 scored for each dataset). (E, left) Representative DNA fiber 
images. (middle) Quantification of red-green contiguous tracts (restarting forks) after 8 h of HU. Mean shown, n = 3. Error bars, standard error. **, P < 
0.01 (paired Student’s t test). (right) Statistical analysis of CldU tracts detected within contiguous red-green tracts. Whiskers the 10th and 90th percentiles. 
****, P < 0.0001 (Mann-Whitney test).
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Genetic knockdown–rescue experiments con!rmed that 
complementation in RECQ1-depleted U-2 OS cells with shRNA-
resistant WT RECQ1 abrogates the effect of RECQ1 depletion 
on replication fork processing upon HU treatment (Fig. 3 F). 
Interestingly, expression of the ATPase-de!cient RECQ1 mutant 
K119R in RECQ1-depleted cells also abrogated the effect of 
RECQ1 depletion indicating that the ATPase activity of RECQ1 
was not required for its role in protecting stalled forks from 
DNA2-dependent degradation (Fig. 3 F). These results point to 
an additional role of RECQ1 in protecting replication forks 
from extensive DNA2-dependent degradation, which is inde-
pendent of RECQ1 ATPase activity.
tracts were substantially shorter in RECQ1-depleted cells com-
pared with control when replication forks were stalled with HU 
(after 8 h of HU treatment, the mean tract lengths were 7.9 and 
12.0 µm, respectively; P < 0.0001; Fig. 3, A and B). In agree-
ment with results from luciferase-depleted cells, DNA2 was 
also responsible for the nascent strand degradation phenotype 
observed in RECQ1-de!cient U-2 OS cells (Fig. 3 C). Analo-
gous results were obtained using the conditional DNA2 knock-
out HCT116 cell line (Fig. 2 C). In addition, we con!rmed that 
the DNA2-dependent nascent strand degradation observed in 
the absence of RECQ1 is not limited to a speci!c replication in-
hibitor by replacing HU with CPT or MMC (Fig. 3, D and E).
Figure 2. DNA2 processes stalled replication forks. (A, top) DNA2 expression after siRNA knockdown. (bottom) Colony-forming assays in control and 
DNA2-depleted U-2 OS cells treated with 4 mM HU for the indicated time. (B) Representative IdU tracts in DNA2 conditional knockout HCT116 cells (out 
of two repeats). Tamoxifen was added to generate conditional knockout cells (see Materials and methods). (C, left) Expression of DNA2 and RECQ1 in 
tamoxifen-treated HCT116 cells. Right, representative IdU tracts in DNA2 conditional knockout HCT116 cells depleted for Luc or RECQ1 (out of three 
repeats). n ≥ 300 tracts scored for each dataset shown in B and C.
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part of the WRN:DNA2 complex. Collectively, these results 
suggest that DNA2 cooperates with WRN to promote nascent 
strand processing and fork restart after HU treatment.
The nuclease activity of DNA2  
and the ATPase activity of WRN are 
essential to process stalled replication forks
DNA2 is characterized by an N-terminal nuclease domain and 
by a C-terminal helicase domain, but the function of its helicase 
activity is still debated (Masuda-Sasa et al., 2006). To assess the 
roles of these two activities in stalled fork processing, we per-
formed genetic knockdown-rescue experiments where we de-
pleted DNA2 and then attempted to rescue fork processing by 
expressing a Flag-tagged siRNA resistant WT DNA2 control, 
nuclease-de!cient DNA2-D294A, or ATPase-de!cient DNA2-
K671E. All the experiments were performed in RECQ1-depleted 
cells, where the effect of DNA2 is more apparent. DNA !ber 
analysis showed that complementation with nuclease-de!cient 
DNA2 prevents fork processing, whereas complementation 
with WT or ATPase-de!cient DNA2 leads to the same fork pro-
cessing phenotype observed in DNA2-pro!cient cells (Fig. 5 D 
and Fig. S2 C). Therefore, the nuclease, but not the ATPase ac-
tivity of DNA2, is necessary for fork processing.
Next, we used a Werner Syndrome (WS) !broblast cell 
line (AG11395) expressing missense mutant forms of WRN, 
which inactivate either the exonuclease (WRN-E84A) or the 
ATPase (K577M) activity of WRN (Pirzio et al., 2008). The 
ATPase, but not the nuclease activity of WRN, was important 
for fork processing (Fig. 5 E and Fig. S2 D). These !ndings 
were validated by genetic knockdown-rescue experiments where 
we complemented WRN-depleted U-2 OS cells either with 
an shRNA resistant WT WRN control or the ATPase-de!cient 
WRN-K577M mutant and found that complementation with 
the ATPase-de!cient mutant prevented fork processing (Fig. S2, 
E and F). Collectively, these results show that human DNA2 
needs the support of the ATPase activity of WRN to promote 
degradation of the nascent DNA strands.
DNA2 processes reversed replication forks
To gain insight into the actual replication structures processed 
by DNA2, we inspected the !ne architecture of the replication 
intermediates using a combination of in vivo psoralen cross-
linking and EM (Neelsen et al., 2014). Our analysis showed 
a substantial fraction of reversed replication forks (Y24% of 
molecules analyzed) in control U-2 OS cells treated with 4 mM 
HU. RECQ1-depletion, and to an even greater extent DNA2-
depletion, resulted in a higher frequency of fork reversal events 
(Y30 and 40%, respectively) compared with HU-treated cells. 
Co-depletion of RECQ1 and DNA2 further increased the fre-
quency of reversed forks (Y50%), suggesting that RECQ1 and 
DNA2 are involved into two distinct mechanisms of reversed 
fork processing. Interestingly, RECQ1 and/or DNA2 depletion 
also led to a signi!cant amount of fork reversal events in unper-
turbed U-2 OS cells (Fig. 6, A and B). WRN-depletion pheno-
copied DNA2-depletion in terms of reversed fork accumulation, 
both the presence and in the absence of HU. Moreover, DNA2/
DNA2 function in stalled fork processing  
is distinct from EXO1, Mre11, and CtIP
Next, we tested whether other nucleases share a function similar 
to DNA2 in stalled fork processing. To address this point, we 
depleted Mre11, EXO1, and CtIP in U-2 OS cells with siRNA-
mediated technologies. We found that none of these nucleases 
share the same phenotype of DNA2 in RECQ1-pro!cient cells 
(Fig. 4 A). Furthermore, depletion of these nucleases had only a 
marginal effect on the rescue of the prominent nascent strand 
degradation phenotype observed in the absence of RECQ1, indi-
cating that DNA2 has a unique function in reversed fork pro-
cessing that is not shared by these human nucleases (Fig. 4, B–D). 
MUS81 is another structure-speci!c nuclease that plays a critical 
role in replication fork rescue by converting stalled replication 
forks into DNA DSBs that can be processed by Homology Di-
rected Repair (HDR) (Hanada et al., 2007; Franchitto et al., 
2008). This raised the possibility that the DNA2-dependent 
degradation originated from the processing of MUS81-dependent 
DSBs. However, MUS81 depletion did not prevent nascent 
strand degradation, indicating that DNA2 is not processing 
stalled replication intermediates that are cleaved by MUS81 
(Fig. 4 E).
DNA2 and WRN act together to process 
stalled replication forks
DNA2-dependent dsDNA-end resection needs the support of 
a RecQ helicase to unwind the DNA from the break (Cejka 
et al., 2010; Niu et al., 2010; Nimonkar et al., 2011). To deter-
mine the identity of the helicase that acts in conjunction with 
DNA2 in stalled fork processing, we measured the extent of na-
scent strand degradation in BLM-, WRN-, and RECQ4-depleted 
U-2 OS cells. Our DNA !ber analysis showed that WRN deple-
tion mimicked the effect of DNA2-depletion, completely abro-
gating the prominent nascent strand degradation phenotype 
observed in RECQ1-depleted U-2 OS cells (Fig. 5 A). The same 
results were con!rmed using WRN and DNA2 codepleted cells, 
suggesting that DNA2 and WRN are epistatic in nucleolytic 
processing of stalled forks (Fig. S1 C). The partial nascent 
strand degradation observed in RECQ1-pro!cient U-2 OS cells 
was also abrogated by WRN depletion (Fig. S1 D). Conversely, 
BLM depletion had only a marginal effect on the nascent strand 
degradation phenotype observed in RECQ1-depleted cells, 
whereas RECQ4 depletion had no effect (Fig. S2, A and B). Thus, 
the WRN helicase plays a prominent role in assisting DNA2-
dependent degradation of stalled replication forks.
We next compared the percentage of restarting replication 
forks in DNA2-depleted, WRN-depleted, and DNA2/WRN-
codepleted cells. WRN depletion leads to a decrease in restart-
ing forks (69 to 50%; P = 0.0068). These results are almost 
identical to those obtained with the DNA2-depleted or DNA2/
WRN-codepleted cells, implying that WRN and DNA2 are 
epistatic also in the restart process (Fig. 5 B). The notion that 
DNA2 and WRN functionally interact to process stalled repli-
cation intermediates is further supported by our observation that 
the two proteins form a complex both in the presence and ab-
sence of replication stress (Fig. 5 C). Of note, RECQ1 is not 
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Figure 4. EXO1, MRE11, CtIP, and MUS81 depletion does not affect stalled fork processing. (A) Statistical analysis of IdU tracts from U-2 OS cells depleted 
for the indicated proteins in the presence of 4 mM HU. (B) Representative IdU tracts in control, RECQ1-, MRE11-, or RECQ1/MRE11-codepleted U-2 
OS cells (out of 2 repeats). (top) Expression of RECQ1 and MRE11 after siRNA knockdown. (C) Representative IdU tracts in control, RECQ1-, EXO1-, or 
RECQ1/EXO1-codepleted U-2 OS cells (out of 2 repeats). (top) Expression of RECQ1 and EXO1 after siRNA knockdown. (D) Representative IdU tracts in 
control, RECQ1-, CtIP-, or RECQ1/CtIP-codepleted U-2 OS cells (out of 2 repeats). (top) Expression of RECQ1 and CtIP after siRNA knockdown. 
(E) Representative IdU tracts in Luc-, RECQ1-, MUS81-, or RECQ1/MUS81-codepleted U-2 OS cells in the presence of HU (out of 2 repeats). (left) Expres-
sion of RECQ1 and MUS81 after shRNA knockdown. n ≥ 300 tracts scored for each dataset shown in A–E.
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Figure 5. DNA2 and WRN are epistatic in stalled fork processing and replication restart. (A) Representative IdU tracts in RECQ1-, WRN-, or RECQ1/
WRN-codepleted U-2 OS cells (out of 2 repeats; n ≥ 300 tracts scored for each dataset). (top) RECQ1 and WRN expression after shRNA knockdown. 
(B) Quantification of restarting forks in DNA2-, WRN-, or DNA2/WRN-codepleted cells. Mean shown, n = 3. Error bars, standard error. *, P < 0.05; 
**, P < 0.01 (paired t test). (top) Expression of WRN and DNA2 after shRNA knockdown. (C) Co-IP experiments in HEK293T cells transfected with empty vec-
tors, Flag-DNA2, or Strep-HA-WRN. Cells were treated with 4 mM HU (3 h) where indicated. Whole-cell extracts were analyzed before (input) and after IP. 
(D) Statistical analysis of IdU tracts from RECQ1/DNA2-codepleted U-2 OS cells complemented with WT, ATPase-deficient (K671E), or nuclease-deficient 
(D294A) DNA2, when indicated. (E) Statistical analysis of IdU tracts from RECQ1-depleted WS cells complemented with WT, ATPase-deficient (K577M), 
or nuclease-deficient (E84A) WRN. Whiskers in D and E indicate the 10th and 90th percentiles. ns, not significant; ****, P < 0.0001 (Mann-Whitney 
test). n ≥ 300 tracts scored for each dataset shown in D and E.
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Figure 6. DNA2 resects reversed replication 
forks. (A) Electron micrograph of a partially 
single-stranded (left) and entirely double-
stranded (right) reversed fork observed on 
genomic DNA upon HU-treatment. The black 
arrow points to the ssDNA region on the re-
versed arm. Inset, magnified four-way junction 
at the reversed replication fork. D, Daughter 
strand; P, Parental strand; R, Reversed arm. 
(B) Frequency of fork reversal and ssDNA 
composition of the reversed arms in RECQ1- 
or DNA2-depleted U-2 OS cells treated with 
HU (left) or in unperturbed conditions (right). 
The percentage values are indicated on the 
top of the bar. “# RI” indicates the number of 
analyzed replication intermediates. Data in B 
are reproduced with very similar results in at 
least one independent experiment.
WRN-codepletion did not cause a further increase in reversed 
fork frequency, thus supporting our conclusion that DNA2 and 
WRN work together in reversed fork processing (Fig. S3 A).
Next, we evaluated the single-strand composition of the 
regressed arms. To measure ssDNA, we carefully inspected 
the frequency and length of ssDNA regions on the regressed 
arms by detecting local difference in filament thickness. 
DNA2 depletion led to a higher frequency of reversed forks 
with a dsDNA arm—and a corresponding decrease of partially 
or entirely single-stranded reversed forks—in both RECQ1-
pro!cient and de!cient cells (Fig. 6). Thus, DNA2-mediated 
resection is directed to completely or partially digest one 
strand of the reversed arm leading to reversed forks that are 
either entirely single stranded or have a protruding ssDNA 
tail. However, prolonged stalling by HU was associated with 
accumulation of postreplicative ssDNA gaps on replicated 
duplexes, which was maximal in RECQ1-depleted cells and 
suppressed by DNA2 depletion (Fig. S3, B and C). Conse-
quently, ssDNA gaps may re"ect additional activity of the 
same nucleolytic apparatus along the postreplicated duplexes 
or restart of partially resected reversed forks.
As an alternative readout for DNA2-dependent resection, 
we examined the phosphorylation status of RPA and the check-
point kinase Chk1 (Zeman and Cimprich, 2014). DNA2 deple-
tion caused a reduction in RPA and Chk1 phosphorylation in both 
RECQ1-pro!cient and RECQ1-de!cient U-2 OS cells, suggest-
ing that the DNA2-dependent resection of nascent strands might 
also contribute to checkpoint activation (Fig. S3 D).
RAD51 promotes DNA2-dependent 
degradation of reversed replication forks
The central recombinase factor RAD51 is directly implicated in 
reversed fork formation upon genotoxic stress (Zellweger et al., 
2015). Thus, we investigated whether RAD51 depletion may 
affect the reversed fork processing activity of DNA2. We found 
that RAD51 knockdown largely prevents DNA2 nucleolytic 
processing both in RECQ1 pro!cient and RECQ1-de!cient 
cells (Fig. 7 A). Genetic knockdown–rescue experiments 
con!rmed that expression of exogenous RAD51 in RAD51- 
depleted U-2 OS cells restored the fork processing phenotype 
(Fig. 7 B). These results indicate that DNA2-dependent nucleolytic 
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Figure 7. RAD51 promotes DNA2-depedent 
degradation of reversed replication forks.  
(A) Representative IdU tracts in RECQ1-, RAD51-, 
or RECQ1/RAD51-codepleted U-2 OS cells 
(out of 2 repeats). Above, RECQ1 and RAD51 
expression after siRNA knockdown RAD51-
WT are U-2 OS cells stably expressing siRNA 
resistant exogenous RAD51. (B) Representa-
tive IdU tracts in U-2 OS cells expressing exog-
enous RAD51 (out of 2 repeats). n ≥ 300 tracts 
scored for each dataset shown in A and B.
processing is speci!cally targeted to reversed fork structures 
because it is not detected in a genetic background that prevents 
reversed fork formation—i.e., RAD51 knockdown.
DNA2 preferentially degrades reversed 
fork structures with a 5-to-3 polarity
The notion that DNA2 end resection has a preferential polarity 
in vivo is consistent with biochemical studies showing that even 
though DNA2 has the intrinsic capacity to degrade both 5- and 
3-terminated ssDNA, RPA enforces a primarily 5-to-3 end-
resection bias (Cejka et al., 2010; Niu et al., 2010; Nimonkar et al., 
2011). Thus, we set up new biochemical assays to test whether 
human DNA2 prefers four-way junction substrates—i.e., re-
versed replication forks—versus linear DNA duplexes and 
whether it degrades these substrates with a 5-to-3 polarity in 
the presence of RPA (Fig. 8, A and B). The sequences of the 
four arms of the four-way junction substrates are mutually 
heterologous to prevent four-way junction branch migration. 
DNA2-degraded four-way junction substrates more ef!ciently 
than linear dsDNA duplexes, with 20 nM DNA2 required to de-
grade Y60% of the four-way junction substrates versus only 
Y30% of the linear duplex (Fig. 8 C). Importantly, supplement-
ing the reaction with RPA greatly stimulated the degradation 
activity of human DNA2 (Fig. 8 D and Fig. S4 A). Additional 
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Figure 8. Human DNA2 preferentially degrades branched 
DNA in a 5-3 direction in reactions stimulated by WRN. 
(A) Degradation of a four-way junction by human DNA2 
(hDNA2) in the presence of hRPA (native 6% polyacryl-
amide gel) (B) Experiment as in A, but with dsDNA. 
(C) Quantitation of data from A and B. Averages shown ± 
SEM; n = 2. (D) DNA degradation is stimulated by 
hRPA. The data points from +hRPA condition are the 
same as in C. Averages shown ± SEM; n = 2. (E) Quan-
titation of degradation of a 3 or 5 ssDNA-tailed three-
way junction by hDNA2. The reactions were performed in 
3 mM magnesium acetate and 22.3 nM hRPA. Averages 
shown ± SEM; n = 2. (F) Kinetics of degradation of a four-
way junction by hDNA2 (9 nM) in the presence of hRPA 
(denaturing 20% polyacrylamide gel). The substrate was 
labeled at the 5 end (*). D294A, nuclease-dead variant 
of hDNA2. (G) Experiment as in F, but using a four-way 
junction labeled at the 3 end. (H) Quantitation of DNA 
cleavage near (less than 15 nt) a 5 or 3 DNA end from 
experiments of F and G. Averages shown ± SEM; n = 2. 
(I) WRN and hDNA2 degrade four-way junction DNA in a 
synergistic manner. Reactions with indicated hDNA2 
and/or WRN concentrations and 65 nM hRPA were ana-
lyzed on a 6% native polyacrylamide gel. Heat, partially 
heated DNA substrate indicating the positions of DNA 
unwinding intermediates. (J) Quantitation of four-way junc-
tion and dsDNA degradation by human EXO1 (hEXO1). 
Averages shown ± SEM; n = 2.
experiments using either 5-end or 3-end 32P-labeled four-way 
junctions con!rmed that human DNA2 had a strong 5-to-3 
bias in end resection in the presence of RPA (Fig. 8, E–H; and 
Fig. S4, B and C). Catalytically dead DNA2 D294A had no 
capacity to degrade DNA, showing that the nuclease activity 
is inherent to WT DNA2 (Fig. 8 F). The same results were 
recapitulated using puri!ed yeast DNA2 (Fig. S5, A–F). Inter-
estingly, addition of the ATPase-de!cient RECQ1 mutant 
(RECQ1-K119R) to the reaction mix signi!cantly inhibited 
the four-way junction degradation activity of human DNA2 
(Fig. S4, D and E). These results suggest that the binding of 
RECQ1 to stalled replication forks limits the fork processing 
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DNA2 function during DNA replication is vital for main-
tenance of genome stability (this study; Duxin et al., 2012; 
Karanja et al., 2012). These !ndings indicate that the controlled 
DNA2-dependent degradation of reversed replication forks is a 
physiologically relevant mechanism to provide resistance to 
prolonged genotoxic treatments. This mechanism is distinct 
from the pathological MRE11-dependent degradation of stalled 
replication intermediates detected in the absence of crucial 
Fanconi Anemia (FA)/HR factors (Schlacher et al., 2011, 2012; 
Hashimoto et al., 2012; Ying et al., 2012).
We !nd that depletion of the central recombinase factor 
RAD51 prevents nascent strand degradation. This !nding, coupled 
with the recent observation that RAD51 is directly implicated in 
reversed fork formation (Zellweger et al., 2015), reinforce our con-
clusion that the DNA2-dependent pathway starts from the reversed 
arm of stalled replication forks and acts downstream of the 
RAD51-mediated replication fork reversal. Given that RAD51 is 
required for reversed fork formation (Zellweger et al., 2015), we 
speculate that the MRE11-dependent pathway is only uncovered in 
the absence of fork reversal—i.e., via a perturbation in RAD51 
function—and likely attacks unprotected and nonreversed forks 
upon prolonged stalling. A crucial challenge for future studies will 
be to investigate why we do not observe a contribution of the 
MRE11 pathway in nascent strand degradation upon RAD51 
depletion. It is tempting to speculate that RAD51 depletion might 
interfere with MRE11-dependent fork processing, in addition to 
preventing fork reversal. Conversely, perturbation of RAD51 
function—e.g., via BRCA2 depletion (Schlacher et al., 2011)—
might be suf!cient to prevent fork reversal—hence DNA2- 
dependent degradation—but still allow residual RAD51 loading 
to promote MRE11-dependent degradation.
Our DNA !ber analysis suggests that DNA2 degrades 
stalled replication intermediates beyond the maximum length 
of the reversed arms measured by EM (up to several kilobases). 
A possible interpretation of these results is that after the initial 
DNA2/WRN-mediated regressed arm degradation is complete, 
other nucleolytic activities or DNA2 itself may codegrade both 
sides of the replication fork, thus leading to extensive degra-
dation events detectable by DNA !bers. In this scenario, our 
EM images likely represent snapshots of the “slow steps” of 
this reaction—i.e., the DNA2/WRN-mediated degradation of 
the regressed arms—resulting in the drastic increase in reversed 
fork frequency observed in the absence of DNA2. Once the 
regressed arm has been resolved, the nucleolytic degradation 
might quickly proceed to degrade nascent strands behind the 
junction—as suggested by the DNA2-dependent increase in 
ssDNA gaps behind the observed forks—!nally leading to re-
annealing of the parental strands and backtracking of the fork 
(Fig. S3 E). A new reversal event may occur when this extensive 
degradation leads to asymmetric ssDNA accumulation at the fork 
(Zellweger et al., 2015), resetting the backtracked fork to the slow 
step of the process. However, fork backtracking is only one possi-
ble model to explain the extensive degradation detected by DNA 
!bers and further work would be required to uncover additional 
nucleolytic activities that might be involved in this process.
Biochemical studies suggested that Schizosaccharomyces 
pombe Dna2 cleaves the leading and lagging reversed strands of 
activity of DNA2, as inferred by our cellular studies. However, 
we cannot rule out the possibility that the inhibitory effect ob-
served in the biochemical assays is simply associated with com-
petition for substrate recognition between the two proteins. In 
agreement with our in vivo data, we show that WRN promoted 
the degradative capacity of DNA2 on nicked, gapped, or four-
way junction substrates (Fig. 8 I and Fig. S4, F and G); similar 
behavior was observed when yeast Dna2 was coupled with the 
Sgs1 helicase (Fig. S5, G and H). DNA was degraded by WRN 
and DNA2 in a remarkably synergistic manner: 5 nM concen-
tration of either WRN or DNA2 alone led only to a minor DNA 
unwinding/degradation (Fig. 8 I, lanes 2 and 8). When com-
bined, both enzymes completely degraded the four-way junc-
tion DNA (Fig. 8 I, lane 5). In contrast, no such synergy was 
observed when human DNA2 was combined with the noncog-
nate yeast meiotic Mer3 helicase (Fig. S4 H), suggesting that 
the species-speci!c interaction between DNA2 and WRN re-
sults in a vigorous DNA degradation. Similarly, WT RECQ1 
did not promote DNA degradation by DNA2 (Fig. S4 I).
On the basis of our results that DNA2 does not share the 
same function of EXO1 in reversed fork processing, we decided to 
compare the end-resection activities of human DNA2 and human 
EXO1 using the four-way junction substrates. EXO1—unlike 
DNA2—degraded both four-way junction substrates and linear 
duplexes with equal ef!ciency (Fig. 8 J and Fig. S4, J and K). The 
use of yeast variants of Dna2 and Exo1 yielded analogous results 
(Fig. S5, I–K). Collectively, these studies further implicate DNA2, 
and its nuclease activity, in reversed replication fork degradation—
that is speci!cally stimulated by WRN—and point to an important 
difference in substrate preference between DNA2 and EXO1. 
Moreover, the polarity of reversed fork degradation by DNA2 
measured in the presence of RPA displays the same bias antici-
pated from the EM analysis of the replication intermediates.
Discussion
The present work uncovers a new mechanism for reversed fork 
processing and restart that requires the coordinated activities of 
the human DNA2 nuclease and WRN helicase (Fig. 9). The 
DNA2-dependent end resection leads to partially single-stranded 
reversed forks and is required for ef!cient replication fork re-
start under conditions of persistent replication blockage. WRN 
interacts with DNA2 and its ATPase activity is needed for 
DNA2-dependent degradation, presumably to transiently open 
the dsDNA arm of the reversed replication forks.
To date, we have identi!ed two mechanisms of reversed 
replication fork resolution, one dependent on RECQ1 ATPase 
and branch migration activity (Berti et al., 2013) and the other on 
DNA2 nuclease and WRN ATPase activity. Moreover, the DNA2/
WRN mechanism is tightly regulated by an ATPase-independent 
function of RECQ1 that might limit DNA2 activity by binding to 
reversed forks. Of note, our EM experiments show that reversed 
replication forks accumulate in RECQ1- and DNA2-depleted 
cells also in unperturbed conditions suggesting that fork reversal 
is remarkably frequent when DNA replication faces intrinsic rep-
lication fork obstacles, and that RECQ1 and DNA2 have a con-
served role in restarting reversed forks in unperturbed S-phase.
2. Results. 
 
 
557DNA2 drives reversed replication fork restart • Thangavel et al.
depletion is consistent with observations that the deregulation 
of checkpoint activity leads to a large increase in the number of 
newly initiated origins (Couch et al., 2013). However, the extent 
of ATR activation does not necessarily re!ect the amount of 
ssDNA detected at replication forks, whether at the junction, at 
ssDNA gaps, or at regressed arms (Zellweger et al., 2015). In 
light of these "ndings, we rather suggest that DNA2-dependent 
ATR activation may re!ect DNA2 recruitment to the stalled 
forks per se, or subtle changes of fork architecture that are asso-
ciated with its recruitment but possibly escape our EM analysis. 
This interpretation is supported by the recent discovery that 
yeast Dna2 has a direct role in Mec1 activation (the ortholog of 
human ATR), independent from its nuclease or helicase activity 
(Kumar and Burgers, 2013). Of note, the increased origin "ring 
frequency observed upon DNA2 depletion is not associated to a 
parallel increase in the frequency of termination events (Fig. S1 A) 
possibly because the defects in replication fork restart associated 
a model replication fork with similar ef"ciency in the absence of 
replication protein A (Hu et al., 2012). However, it is likely that 
only the 5-to-3 directionality is important in vivo, because RPA 
is known to stimulate the 5-to-3 and inhibit the 3-to-5 nuclease 
activity of yeast DNA2 (Cejka et al., 2010; Niu et al., 2010). In 
agreement with this conclusion, our biochemical data show that 
DNA2-dependent end resection proceeds with a 5 to 3 polarity 
in the presence of RPA. Moreover, our EM experiments clearly 
show that DNA2 depletion affects the frequency of reversed forks 
that are either entirely or partially single-stranded supporting the 
notion that DNA2-dependent degradation of reversed forks oc-
curs with a preferential polarity in vivo.
The resection activity of human DNA2 was postulated to 
activate the ATR/Chk1 checkpoint under conditions of replica-
tion stress (Karanja et al., 2012). Indeed, we "nd that DNA2 de-
pletion prevents ATR checkpoint activation after HU treatment. 
Moreover, the increased origin "ring observed upon DNA2 
Figure 9. Schematic model for the combined 
roles of DNA2 and WRN in reversed fork pro-
cessing. DNA2 and WRN functionally interact 
to process reversed forks. DNA2 degrades 
reversed forks with a 5-to-3 polarity. WRN 
ATPase activity assists DNA2 degradation pos-
sibly by promoting the opening of the reversed 
arm of the fork. RECQ1 limits DNA2 activity 
by an ATPase-independent function. Branch 
migration factors specifically recognize the 
partially resected reversed forks to promote 
fork restart. Alternatively, the newly formed 3  
overhang of the reversed fork invades the 
duplex ahead of the fork, resulting in Holliday 
junction structures that can be resolved by spe-
cific resolvases or dissolvases to promote fork 
restart. Gray box, RECQ1 can independently 
restart reversed forks by virtue of its ATPase 
and branch migration activity.
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speci!c genetic backgrounds. For example, MRE11 degrades 
stalled replication intermediates only in a BRCA2-de!cent back-
ground, as already discussed (Schlacher et al., 2011). Moreover, 
the cleavage of unresolved replicative intermediates by the 
structure-speci!c MUS81 endonuclease is a late response to 
replicative stress, which becomes activated only when other 
attempts to overcome stalled replication have been exhausted 
(Hanada et al., 2007; Franchitto et al., 2008). Thus, MUS81 
might still resolve reversed replication forks as a back-up sys-
tem to unlink sister chromatids and facilitate mitotic segregation 
in the absence of DNA2 or WRN.
Collectively, these studies highlight a new important 
mechanism for the recovery from replication blockage. This 
mechanism relies on the DNA2-dependent processing of re-
versed forks—leading to ssDNA stretches on the regressed 
arms—which appear to promote ef!cient fork restart. A possi-
ble explanation for the need of partially single-stranded DNA 
structures to promote fork restart is that they represent a key in-
termediate to activate an HDR-like mechanism of reversed fork 
restart, as recently proposed in S. pombe (Carr and Lambert, 
2013). In particular, the newly formed 3 overhang of the re-
versed fork might invade the duplex ahead of the fork resulting 
in Holliday junction structures that can be resolved by speci!c 
resolvases or dissolved by the combined action of the BLM 
helicase (Sgs1 in yeast) and the type I topoisomerase TOP3 
(Fig. 9). Alternatively, resumption of DNA replication might be 
obtained by reverse branch migration, where the partially re-
sected reversed fork structures might be speci!cally recognized 
by a motor protein—e.g., SMARCAL1 (Béous et al., 2013) or a 
human RecQ helicase—to promote the branch migration-assisted 
reestablishment of a functional replication fork.
Materials and methods
Cell lines, culture conditions, and reagents
U-2 OS, HEK 293, and Werner Syndrome fibroblast (AG11395) cells were 
grown in DMEM supplemented with 10% FBS at 37°C in 5% CO2. HCT116 
cells were grown in McCoy’s 5A medium supplemented with 10% FBS. 
CldU, IdU, BrdU, hydroxyurea, mitomycin C, camptothecin, tamoxifen, pu-
romycin, and hygromycin were obtained from Sigma-Aldrich.
DNA2 conditional knockout HCT116 cells
To examine the response of cells to the complete absence of DNA2, we used 
a DNA2 conditional knockout cell line where exon 2 of the DNA2 gene is 
deleted (Karanja et al., 2014). The colorectal carcinoma HCT116 cell line 
carries 3 copies of DNA2 due to a duplication on chromosome 10. Two 
chromosomal copies were disrupted using rAAV-mediated gene targeting 
technology and exon 2 of the third allele was replaced with a conditional 
exon where the exon was flanked by loxP sites (DNA2flox//). To create 
a conditional cell line these cells were stably transduced with a tamoxifen 
(4-OHT)-inducible Cre recombinase. Thus, the cell line is viable and can be 
propagated. The addition of tamoxifen to the culture media leads to excision 
of the endogenous DNA2 and the generation of a true DNA2-null cell. Com-
plete loss of DNA2 occurs after 72 h of tamoxifen treatment. However, the 
DNA fiber experiments were performed after 40 h of tamoxifen treatment to 
have enough S-phase cells for DNA labeling.
Antibodies
Anti-DNA2 rabbit polyclonal (ab96488; 1:1,000), anti-MUS81 mouse 
monoclonal (ab14387; 1:1,000), and anti-CldU/BrdU rat monoclonal 
(ab6326; 1:6) antibodies (all from Abcam); anti-CtIP rabbit polyclonal 
(A300-488A; 1:1,000), anti-EXO1 rabbit polyclonal (A302-639A; 
1:1,000), anti-pRPA32 (S4/S8) rabbit polyclonal (A300-245A; 1:1,000), 
and anti-pRPA32 (S33) rabbit polyclonal (300-246A; 1:2,000; all from 
with DNA2 depletion limit the number of termination events 
even under conditions of increased origin !ring.
WRN plays an important—albeit mechanistically ill- 
de!ned—role in the recovery from replication blockage, and 
mutations in the WRN gene are linked to the cancer predisposi-
tion disorder Werner Syndrome (Sidorova et al., 2008; Murfuni 
et al., 2012). Our studies infer that the high genomic instability 
of WRN-de!cient cells may result from aberrant processing of 
reversed replication intermediates. In particular, given the con-
solidated role of WRN at dif!cult-to-replicate regions—e.g., 
telomeres and fragile sites (Crabbe et al., 2004; Murfuni et al., 
2012)—we speculate that WRN, in conjunction with DNA2, is 
required to process reversed forks arising spontaneously at 
these genomic loci. Biochemical studies pointed to a putative 
role of WRN in fork reversal and/or restart by showing that 
WRN ef!ciently promotes both the formation and restoration 
of oligonucleotide-based reversed fork substrates (Machwe 
et al., 2011). We show that WRN ATPase activity is needed for 
the DNA2-dependent degradation of reversed replication forks. 
Our interpretation for the role of WRN ATPase activity is that 
it facilitates DNA2-dependent degradation of the reversed forks 
by transiently opening the dsDNA arm of the reversed fork. 
This mechanism is reminiscent to the DNA2-dependent mecha-
nism of DSB resection where the yeast Sgs1 helicase is required 
to transiently open the DNA duplex to generate a 5 ssDNA tail 
that is in turn degraded by DNA2 (Zhu et al., 2008; Cejka et al., 
2010; Niu et al., 2010). We suggest that WRN is the functional 
homologue of Sgs1 in mammalian cells, at least in the context 
of DNA2-dependent reversed replication fork processing. How-
ever, BLM was also shown to interact and cooperate with DNA2 
to resect dsDNA ends in vitro opening the possibility that other 
human RecQ helicases might substitute for WRN, depending 
on the nature of the DNA lesion being processed or the particu-
lar cellular context (Nimonkar et al., 2011; Sturzenegger et al., 
2014). This mechanism seems to be well-conserved throughout 
evolution because it is highly reminiscent of the stalled fork 
processing pathway described in E. coli where the RecJ nucle-
ase cooperates with bacterial RecQ to process blocked replication 
intermediates (Courcelle et al., 2003). In addition, the prokary-
otic RecBCD helicase-nuclease plays an important role in re-
secting replication forks after reversal (Seigneur et al., 1998) 
and DNA2 is of the same family of nucleases as RecB. Whether 
the DNA2/WRN-mediated resection activity can degrade addi-
tional stalled replication intermediates other than reversed forks 
is worth future investigation.
EXO1, MRE11, and CtIP play central roles in DNA repair 
and are also implicated in the recovery from replication fork 
blockage (Cotta-Ramusino et al., 2005; Schlacher et al., 2011; 
Yeo et al., 2014). None of these nucleases, however, partici-
pates in the DNA2-dependent processing of reversed replica-
tion forks pointing to a speci!c role of DNA2 that, unlike 
its function in DSB resection, is not shared by other nucleases. 
A possible interpretation of these results is that the reversed 
forks are characterized by a particular structure of the terminal 
end that does not require the trimming activity of other nucle-
ases to promote DNA2-dependent resection. However, some of 
these nucleases might still be able to access stalled forks under 
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were kind gifts from Dr. Pietro Pichierri (Insituto Superiore di Sanità, Rome, 
Italy). All transfections were done with Lipofectamine 2000 (Life technolo-
gies Catalog no: 11668027). An shRNA targeting luciferase (5-ACGCT-
GAGTACTTCGAAATGT-3) was used for control shRNA experiments. The 
silencer select negative control (Life technologies, Catalog no. 4390843) or 
an siRNA targeting luciferase (5-CGUACGCGGAAUACUUCGA-3) were 
used for control siRNA experiments, as indicated. Lentiviral mediated shRNA 
depletions were achieved using the following sequences cloned into the 
pLKO.1 lentiviral shRNA expression vector: BLM (5-CGAAGGAAGTTGTAT-
GCACTA-3), WRN (5-GCTGGCAATTACCAGAACAAT-3), and MUS81 
(5-CACGCGCTTCGTATTTCAGAA-3). The procedure for lentiviral genera-
tion and transduction has been described (Berti et al., 2013). Transduced U-2 
OS cells were selected with 6 µg/ml puromycin. siRNA-mediated depletions 
were achieved using the following siRNAs from Invitrogen: DNA2 (5-AUA-
GCCAGUAGUAUUCGAU-3), CtIP (5-CGAAUCUUAGAUGCACAAA-3), 
EXO1 (Invitrogen-HSS113557), and RAD51 (Invitrogen-1299001). In brief, 
siRNAs were transfected using Lipofectamine RNAiMAX (Life Technologies) 
following the manufacturer’s protocol. MRE11 (5-GAAAGGCUCUAUC-
GAAUGU-3) and RECQ4 (SMART pool) siRNAs were from Dharmacon 
and were transfected as previously described (Thangavel et al., 2010).
Microfluidic-assisted DNA fiber stretching
For DNA replication fork restart analysis, asynchronous cells were pulse-
labeled with 50 µM CldU for 20–30 min. 2 mM HU, 300 nM MMC, or 
150 nM CPT was added to the CldU containing media and incubated for the 
indicated times. Cells were washed three times with medium and released 
with 50 µM IdU for 40 min. For nascent strand degradation analysis, asyn-
chronous cells were pulse-labeled with 50 µM IdU for 45 min, washed 
three times with medium, incubated with 4 mM HU, 100 nM CPT, 200 nM 
MMC, or medium for times indicated. The pulse-labeled cells were trypsin 
collected and lysed in agarose plugs to prevent any mechanical breakage 
of replication tracts. Microfluidic platform for stretching the high-molecular 
weight DNA, coverslips, immunostaining and image acquisition of replica-
tion tracts were performed as described (Sidorova et al., 2009; Berti et al., 
2013). In brief, polydimethylsiloxane (PDMS) stamps with microchannels 
were Oxygen plasma treated and reversibly sealed to the silanized cover-
slips. High-molecular weight DNA was loaded and stretched by capillary 
force into the microchannels. PDMS stamps were peeled-off and coverslips 
were left drying overnight. For immunostaining, DNA-stretched coverslips 
were denatured (2.5N HCL for 45 min), neutralized (0.1 M sodium borate 
and 3 washes with PBS), blocked (5% BSA and 0.5% Tween 20 in PBS for 
30 min), incubated with primary antibodies (Anti-IdU/BrdU or both anti-
IdU/BrdU and anti-CldU/BrdU for 30 min), washed (1% BSA and 0.1% 
Tween 20 in PBS, 3 times 5 min each) and incubated with secondary anti-
bodies (anti–mouse Alexa Fluor 488-conjugated, or both anti–mouse Alexa 
Fluor 488–conjugated and anti–rat Alexa Fluor 594–conjugated for 1 h). 
Washed slides were mounted in prolong gold anti-fade reagent (Life Tech-
nologies) and images were sequentially acquired (for double-label) with 
LAS AF software using TCS SP5 confocal microscope (Leica). A 63×/1.4 
oil immersion objective was used. Images were captured at room tempera-
ture. n ≥ 300 fiber tracts scored for each dataset. The DNA tract lengths 
were measured using ImageJ and the pixel length values were converted 
into micrometers using the scale bars created by the microscope. Statistical 
analysis was done using GraphPad Prism.
Clonogenic survival assay
Colony-forming assays were performed as previously described (Franken 
et al., 2006). In brief, 1,000 cells were plated per well and treated on the 
next day with 4 mM HU for 3, 6, and 8 h or 100 nM CPT for 6 h. Colonies 
were fixed, stained, and quantified 10 d after release from genotoxic stress. 
The plating efficiency and survival fraction were calculated as previously 
described (Franken et al., 2006). In brief, colonies were counted using an 
inverted stereomicroscope and the plating efficiency was calculated using 
the following formula: Plating Efficiency (PE) = (no. of colonies formed/no. of 
cells seeded) × 100%. From the plating efficiency, the surviving fraction (SF) 
was calculated as: SF = (no. of colonies formed after treatment/no. of cells 
seeded) × PE. The experiments were performed in triplicate and the statistical 
analysis was performed using GraphPad Prism.
Western blotting
Cells were washed with PBS and lysed either in standard RIPA buffer (PBS, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 µg/ml aprotinin, 
10 µg/ml PMSF, 1 mM Na3VO4, and 1 mM NaF) or MCL buffer (50 mM 
Tris, pH 8.0, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl, 2 mM DTT, and 
freshly added protease and phosphatase inhibitors from Roche (1 tablet/10 ml 
of buffer). Cell lysates were resolved by SDS-PAGE and transferred to 
Bethyl); anti-WRN rabbit polyclonal (NB100-471; 1:1,000); and anti-
MRE11 rabbit polyclonal (NB100-142; 1:2,000; Novus); anti-RAD51 (H-92) 
rabbit polyclonal (sc-8349; 1:1,000) and anti-RECQ1 rabbit polyclonal 
(sc-25547; 1:2,000) from Santa Cruz; anti-rat Alexa (594-A11007; 
1:1,000); and anti–mouse Alexa Flour (488-A11001; 1:1,000; Invitro-
gen); anti-rabbit (31460; 1:10,000; Thermo Fisher Scientific); anti-tubulin 
mouse monoclonal (T5168; 1:5,000; Sigma-Aldrich); anti-IdU/BrdU 
mouse monoclonal (347580; 1:6) from BD; anti-Chk1 mouse monoclonal 
(sc-8408; 1:1,000; Santa Cruz Biotechnology, Inc.); anti-p-Chk1 (S345) 
rabbit monoclonal (2348; 1:1,000; Cell Signaling Technology); anti-RPA32 
mouse monoclonal (NA19L; 1:1,000) from EMD Millipore; anti-RECQ1 
rabbit polyclonal, raised against residues 634–649 of human RECQ1, is 
custom made (Mendoza-Maldonado et al., 2011); anti-BLM rabbit poly-
clonal, raised against residues 1–449 of human BLM (Wu and Hickson, 
2003), was a gift from I. Hickson (University of Copenhagen, Copenha-
gen, Denmark); and anti-RECQ4 rabbit polyclonal, raised against residues 
60–111 of human RECQ4 (Yin et al., 2004), was a gift from W. Wang 
(National Institute on Aging, Baltimore, MD).
Recombinant proteins
Yeast Dna2 was expressed in yeast WDH668 strain from pGAL:DNA2 
vector (Budd et al., 2000) and purified as previously described (Levikova 
et al., 2013). In brief, the cells were lysed and Dna2 was purified by 
affinity chromatography on Ni-NTA agarose (QIAGEN) and anti-Flag M2 
affinity gel (Sigma-Aldrich). Yeast RPA was expressed in yeast BJ5464 
strain containing three plasmids coding for Rfa1, Rfa2, and Rfa3 and 
purified as previously described (Kantake et al., 2003). In brief, the cells 
were lysed and yeast RPA was purified by affinity on ssDNA cellulose 
column (USB corporation) and by ion exchange chromatography using 
HiTrap Q column (GE Healthcare). Human DNA2 was expressed in Sf9 
cells from a pFastBac:hDNA2 vector (polyhedrin promoter) provided by 
J. Campbell (Masuda-Sasa et al., 2006). The soluble extracts were obtained 
by salt extraction as previously described for Sgs1 (Cejka and Kowalc-
zykowski, 2010). The subsequent purification of hDNA2 was performed 
as previously described for yeast Dna2 (Levikova et al., 2013) by affinity 
chromatography using Ni-NTA agarose (QIAGEN) and Anti-Flag M2 
affinity gel (Sigma-Aldrich). Human RPA was expressed from p11d-tRPA 
vector (Henricksen et al., 1994) in BL21 E. coli cells and purified as 
described (Henricksen et al., 1994). In brief, hRPA was first bound to 
HiTrap Blue column (GE healthcare) and then to HiTrap Q column. The 
sequence coding for yeast Mer3 helicase was amplified from yeast genomic 
DNA (SK1 strain) using primers Mer3FO (5-GCGCGCGGGCCCATGAAAA-
CAAAGTTTGATCGCCTCGGTACAGGAAAAAGAAGTAGACCCTCTC-
CAAATAATATTGACTTTAACGACCAG-3) and Mer3RE (5-CGCGCGCTC-
GAGTTCAAACTCTATATCGGAAC-3). The PCR product was digested 
with ApaI and XhoI restriction endonucleases (both from New England 
Biolabs) and cloned into corresponding sites in pFB-MBP-Sgs1-his after the 
polyhedrin promoter, creating pFB-MBP-Mer3-his vector. Mer3 was then 
expressed in Sf9 cells and purified using affinity chromatography as 
previously described for Sgs1 (Cejka and Kowalczykowski, 2010). In 
brief, MBP-tagged Mer3 was first bound to amylose resin (New England 
Biolabs), eluted and digested with PreScission protease to cleave the MBP 
tag. Mer3 was further purified by affinity on Ni-NTA agarose (QIAGEN) 
exploiting the 10x His-tag at its C-terminus. Sequence information is available 
on request.
Genetic knock-down-rescue experiments
RECQ1, DNA2, and RAD51 genetic knockdown-rescue experiments were 
performed using the procedure described (Berti et al., 2013; Yata et al., 
2012). In brief, RECQ1 is depleted using the pLKO.1-puro-shRECQ1 (5-GAG-
CTTATGTTACCAGTTA-3) construct and rescue experiments are performed 
using the shRNA resistant pIRES-RECQ1-WT or K119R (ATPase dead) con-
structs as described (Berti et al., 2013). DNA2 is depleted using an siRNA 
targeting the 3UTR of DNA2 (5-CAGUAUCUCCUCUAGCUAG-3). At 
least one isoform of DNA2 is not targeted by this sequence. DNA2 rescue 
experiments are performed using the pBabe-hygro-3xFLAG-DNA2 WT, 
D294A (Nuclease dead), or K671E (helicase dead) constructs. RAD51 
is depleted using siRNAs targeting the 3UTR (5-GACUGCCAGGAU-
AAAGCUU-3 and 5-GUGCUGCAGCCUAAUGAGA-3) in U-2 OS stable 
cell lines expressing WT RAD51 as described (Yata et al., 2012). WRN 
depletions were achieved using pRS-puro-shWRN (5-AGGCAGGTGTAG-
GAATTGAAGGAGATCAG-3; sequence ID: TI333414) and exogenous 
expression is done with the shRNA resistant Flag-pCMVTag2B-WRN WT 
or K577M (helicase dead) constructs. Constructs for WRN depletion and 
overexpression of WT WRN and ATPase-deficient WRN (WRN-K577M) 
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pyruvate kinase, 1 nM DNA substrate (molecules), and recombinant pro-
teins, as indicated. The reactions were assembled on ice and incubated 
for 30 min at 30°C for yeast proteins and at 37°C for human proteins. Un-
less indicated otherwise, RPA was present in the reactions at saturating 
concentrations corresponding to a threefold excess over DNA, assuming 
all DNA was single-stranded and a DNA-binding site size of 25 nt for 
hRPA and of 20 nt for yRPA. The reactions were terminated by adding 5 µl 
Stop buffer (150 mM EDTA, 2% SDS, 30% glycerol, and 0.01% bromo-
phenol blue), incubated for 30 min at room temperature and separated on 
polyacrylamide gels in TBE buffer under native conditions. Alternatively, 
for denaturing conditions, the reaction were terminated by adding 15 µl 
Formamide stop buffer (95% (vol/vol) formamide, 20 mM EDTA, 0.01% 
bromophenol blue), denatured by heating at 95°C for 5 min and sepa-
rated on 20% denaturing polyacrylamide gels in TBE buffer. Gels were 
fixed, dried, exposed to a storage phosphor screen, and analyzed on 
Typhoon phosphor imager (GE Healthcare).
Online supplemental material
Fig. S1 shows quantification of stalled forks, new origins, and termination 
events in DNA2-depleted cells upon genotoxic stress induction, as well as 
the statistical analysis of IdU tracts from RECQ1-, DNA2-, WRN-, RECQ1/
DNA2-, RECQ1/WRN-, WRN/DNA2-, and RECQ1/WRN/DNA2-depleted 
U-2 OS cells. Fig. S2 shows the IdU tract length distribution in BLM- and 
RECQ4-depleted cells, respectively, as well as statistical analysis of IdU 
tracts from RECQ1/WRN-codepleted cells complemented with WT WRN 
or with ATPase-deficient WRN. Fig. S3 shows additional EM analysis, as 
well as the Western blot analysis of ATR-checkpoint activation in RECQ1- 
and/or DNA2-depleted U-2 OS cells. Fig. S4 shows additional biochemi-
cal analysis of substrate specificity of human DNA2 and human EXO1. 
TFig. S5 shows biochemical assays of substrate specificity of yeast Dna2 
and yeast Exo1. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201406100/DC1.
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PVDF membrane (GE Healthcare). Incubation with antibodies was per-
formed overnight at 4°C. Proteins were visualized using ECL (Thermo 
Fisher Scientific) according to the manufacturer’s instructions.
Co-immunoprecipitation experiments
HEK293T cells were transfected with empty vectors, FLAG-DNA2, and Strep-
HA-WRN by calcium phosphate. 48 h after transfection, cells were treated 
with 4 mM HU for 3 h, lysed in benzonase lysis buffer (50 mM Tris-HCl, 
pH 7.5, 75 mM KCl, 2 mM MgCl2, 20 mM NaF, 10 mM B-glycerophosphate, 
0.2 mM Na3VO4, and 0.2% Triton X-100) supplemented with protease in-
hibitors (EDTA-free tablet; Sigma-Aldrich) by passing 10 times through a 
26-G syringe needle and incubated 1 h at 4°C with 2 U/µl Benzonase 
(Sigma-Aldrich) to digest genomic DNA. KCl and EDTA concentrations were 
adjusted to 120 and 3 mM, respectively, and lysates were centrifuged at 
14,000 rpm for 30 min. Immunoprecipitations of clarified lysates were per-
formed with FLAG M2 or HA affinity agarose resin (Sigma-Aldrich) overnight 
at 4°C. Beads were washed 5 times with wash buffer (50 mM Tris-HCl, 
pH 7.5, 150 mM KCl, 3 mM EDTA, 2 mM MgCl2, 20 mM NaF, 10 mM 
B-glycerophosphate, 0.2 mM Na3VO4, and 0.2% Triton X-100) and bound 
proteins were eluted by boiling in SDS-PAGE sample buffer.
EM analysis of genomic DNA in mammalian cells
EM analysis of replication intermediates has been described in detail (Ray 
Chaudhuri et al., 2012; Neelsen et al., 2014), including a description of the 
important parameters to consider specifically for the identification and the 
scoring of reversed forks (Neelsen et al., 2014). In brief, 5–10 × 106 U-2 
OS cells were harvested and genomic DNA was cross-linked by two rounds 
of incubation in 10 µg/ml 4,5,8-trimethylpsoralen (Sigma-Aldrich) and 
3 min of irradiation with 366 nm UV light on a precooled metal block. Cells 
were lysed and genomic DNA was isolated from the nuclei by proteinase K 
(Roche) digestion and phenol-chloroform extraction. DNA was purified by 
isopropanol precipitation, digested with PvuII HF in the proper buffer for 3–5 h 
at 37°C, and replication intermediates were enriched on a benzoylated 
naphthoylated DEAE–cellulose (Sigma-Aldrich) column. EM samples were 
prepared by spreading the DNA on carbon-coated grids in the presence of 
benzyl-dimethyl-alkylammonium chloride and visualized by platinum rotary 
shadowing. Images were acquired on a transmission electron microscope 
(JOEL 1200 EX) with side-mounted camera (AMTXR41 supported by AMT 
software v601) and analyzed with ImageJ (National Institutes of Health).
Preparation of oligonucleotide-based DNA substrates
DNA oligonucleotides were purchased from Microsynth and 32P-labeled 
either at the 5 terminus with [G-32P] ATP and T4 polynucleotide kinase (New 
England Biolabs), or at the 3 end with [A-32P] cordycepin-5-triphosphate 
and terminal transferase (New England Biolabs) according to manufacturer’s 
instructions. Unincorporated nucleotides were removed using MicroSpin 
G25 columns (GE Healthcare). The substrates were prepared by heating the 
respective oligonucleotides at 95°C and gradually cooling to room temperature. 
The following oligonucleotides were used for the preparation of the four- 
way junction (X12-3 TOP L, HJ 1, HJ 2, and HJ 3), three-way junction with 
3 tail (X12-3 TOP L, HJ 1, HJ 2Sb, and HJ 3), three-way junction with 5 ssDNA 
tail (X12-3 TOP L, HJ 1S, HJ 2, and HJ 3), nicked four-way junction (X12-3 
TOP L, HJ 1, HJ 2Sa, HJ 2Sb, and HJ 3), replication fork (X12-3 TOP L, HJ 
1S, HJ 2Sb, and HJ 3), and dsDNA (X12-3 TOP L and Bottom LC), respec-
tively. The sequences of the oligonucleotides were: X12-3 TOP L (93 nt), 
5-GACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATC-
GCGACTTACGTTCCATCGCTAGGTTATTTTTTTTTTTTTTTTTTT-3 X12-3 HJ 1 
(93 nt), 5-AAAAAAAAAAAAAAAAAAATAACCTAGCGATGGAACGTA-
AGTCGCGATGGGCTTAACTAGGATGCTACTGGCCCCGAATCAACCGT-
ACTTGGG-3 X12-3 HJ 1S (48 nt), 5-AAAAAAAAAAAAAAAAAAAT-
AACCTAGCGATGGAACGTAAGTCGCGAT-3 X12-3 HJ 2 (93 nt), 
5-CCCAAGTACGGTTGATTCGGGGCCAGTAGCATCCTAGTT AAGCCCA-
TTACGATTCGTTACCCATTCACTGTCAGAAGGCACCAGATAGATCTC-3 
X12-3 HJ 2Sa (45 nt), 5-CCCAAGTACGGTTGATTCGGGGCCAGTAGCA-
TCCTAGTTAAGCCC-3 X12-3 HJ 2Sb (48 nt), 5-ATTACGATTCGTTACCC-
ATTCACTGTCAGAAGGCACCAGATAGATCTC-3 X12-3 HJ 3 (93 nt), 
5-GAGATCTATCTGGTGCCTTCTGACAGTGAATGGGTAACGAATCGT-
AATAGTCTCTAGACAGCATGTCCTAGCAATGTAATCGTCTATGACGTC-3 
X12-3 BOTTOM LC, 5-AAAAAAAAAAAAAAAAAAATAACCTAGCGAT-
GGAACGTAAGTCGCGATAGTCTCTAGACAGCATGTCCTAGCAATGTA-
ATCGTCTATGACGTC-3.
Nuclease assays
The experiments were performed in a 15-µl volume in 25 mM Tris-acetate 
(pH 7.5), 2 mM magnesium acetate, 1 mM ATP, 1 mM dithiothreitol, 
0.1 mg/ml BSA (New England Biolabs), 1 mM phosphoenolpyruvate, 80 U/ml 
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Replication fork reversal was first proposed long time ago as a mechanism for DNA damage 
bypass in mammalian cells (Higgins N.P., et al., 1976). The concept, initially largely ignored, 
found some support from genetic and biochemical data in bacteria in the 80s-90s (Atkinson 
and McGlynn, NAR 2009). More recently, studies in yeast (S. cerevisiae and S. pombe) 
proved that indeed these structures can be formed, but they only accumulate in checkpoint-
deficient yeast cells and under specific DNA damaging conditions (Sogo et al., 2002; 
Bermejo et al., Cell 2011; Hu et al., Cell 2012). These yeast findings challenged the 
importance and physiological significance of these structures in eukaryotic cells. However, it 
was recently shown that in different eukaryotic systems – yeast (S. cerevisiae), Xenopus 
laevis egg extracts, mouse embryonic fibroblasts and human osteosarcoma cell line – 
reversed forks readily accumulate, even in checkpoint proficient cells, in response to 
treatments with Topoisomerase I inhibitors (Ray Chaudhuri A, et al., 2012). Later on it was 
shown that replication fork reversal is more general response to cancer relevant conditions of 
replication stress (Neelsen et al., 2013a and b), to repetitive DNA sequence prone to form 
secondary structures (Follonier et al., 2013) and to a wide variety of genotoxic agents 
(Zellweger R, et al., 2015), bringing further support to its proposed function in the protection 
of replication forks challenged by genotoxic stress (Neelsen and Lopes, 2015).  
In this project, we wanted to investigate in vivo the potential role of the newly discovered 
class of proteins named annealing helicases (focusing on two of them: ZRANB3 and HARP), 
that are able to re-anneal RPA coated ssDNA strands into dsDNA and can drive replication 
fork reversal in vitro (Yusufzai and Kadonaga, 2008; Yusufzai and Kadonaga, 2010; Ciccia 
A, et al., 2012; Weston R, et al., 2012; Yuan J, et al., 2012; Betous R, et al., 2011; Betous R, 
et al., 2012; Betous R, et al., 2013; Carrol C, et al., 2014). 
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In parallel, we wanted to test if proteins involved in error-free branch of post replicative 
repair (PRR), play a direct role in replication fork reversal upon DNA damage. Published 
data suggest that error-free PRR repair entails template switching strategy for DNA damage 
tolerance, either using fork reversal to bypass the lesion, or - after replication restart by re-
priming - promoting recombinational bypass of the damage behind the fork. A crucial 
replication factor playing a role in these processes is the polymerase clamp PCNA, via its 
posttranslational modifications by mono- and poly-ubiquitination at lysine K164. For the 
template switching events, yeast studies proposed a key role for PCNA polyubiquitination at 
K164, via K63-linked ubiquitin chains (Ghosal and Chen, 2013). 
To investigate if these factors could be involved in replication fork regression in vivo, we 
decided to focus on two major techniques: 1) DNA fiber spreading, described in detail in 
other chapters, to assess replication fork speed, which is expected to decrease upon DNA 
damage, by active promotion of fork remodelling; 2) electron microscopic analysis of 
replication intermediates (also described previously), to assess reversed replication fork 
frequency upon different genotoxic treatments. 
Using these techniques, we could conclude that ZRANB3 plays a crucial role in mediating 
replication fork slow down upon at least two different genotoxic treatments - camptothecin 
(CPT) and mitomycin C (MMC). We could also show that ZRANB3-defective cells failed to 
accumulate reversed forks upon both of these treatments (over the slightly increased basal 
level observed in untreated cells), implicating this protein in effective fork slowing and 
reversal upon treatment with genotoxic agents. We initially tested the role of ZRANB3 in 
fork slow down and reversal, coupling siRNA-mediated protein depletion with DNA fiber 
assays or EM visualization. To possibly strengthen our observations, and to exclude the 
possibility of off-target effects or insufficient downregulation of the protein, we performed 
the same assays on ZRANB3 knock out cells. The key results were remarkably similar by 
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both strategies of gene inactivation. Importantly, although ZRANB3 defective cells fail to 
significantly induce fork reversal upon exogenous damage, we repeatedly observed elevated 
basal levels of reversed replication forks upon ZRANB3 inactivation. We attribute this to 
mild replication stress accumulating in these cells, luckily as a consequence of impaired fork 
reversal in face of endogenous lesions, possibly stimulating ZRANB3-independent 
mechanisms of fork remodelling. Overall, we can confidently conclude that, in agreement 
with previous in vitro data on plasmid substrates (Ciccia A, et al., 2012), ZRANB3 annealing 
helicase has a crucial role in inducing reversed replication fork formation, and that its 
function is required to minimize replication stress during unperturbed S phase. 
As described previously in the text, ZRANB3 has several domains, mediating its biochemical 
activities and its interaction with other factors. After producing mutant cell lines and 
performing the experiments described above, we could determine that fork reversal in vivo 
strictly depends on ZRANB3 helicase activity and on its interaction with PCNA (PIP and 
APIM domains), at least upon the two tested genotoxic treatments (CPT and MMC). 
Mutations in these domains phenocopied complete absence of the protein upon these 
treatments, as they impaired active fork slowdown and reversed fork accumulation above 
basal levels. We could also show that cells harbouring mutations in ZRANB3 nuclease 
domain behave identically to wild type cells in our assays, i.e. they display replication fork 
slow down and high frequency of reversed replication forks upon CPT or MMC treatment. 
This implies that ZRANB3 nuclease domain does not have a direct role in replication fork 
reversal upon genotoxic treatment, and may well play a role in some other, yet unrecognized, 
function of ZRANB3, related or not to replication fork metabolism. The results obtained so 
far on the NZF domain – which still require experimental confirmation -  suggest a role for 
this domain in delaying replication fork progression, but not in inducing efficient replication 
fork reversal. Indeed, mutations in the NZF domain lead to unrestrained replication fork 
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progression upon genotoxic treatments, but do not seem to impair accumulation of reversed 
replication forks in the same experimental conditions. If confirmed, this apparent discrepancy 
may be explained by the different sensitivity and the different read-out of the two assays. 
While the fibers assay is a “dynamic” approach that measures the rate of replication fork 
progression over a period of time in different genetic backgrounds and upon different 
treatments, our electron microscopy approach is providing a “static” snapshot of the 
replication intermediates present in the cells at a given time point. it is thus possible that – 
upon certain genetic manipulations (e.g. mutations in ZRANB3 NZF domain) -  replication 
forks can progress at accelerated rates upon genotoxic treatments, while still retaining their 
propensity to transit through a regressed state in a similar proportion of the forks, by possibly 
restarting reversed forks at a higher rate than in wild type cells. A study (Ciccia A, et al., 
2012) has shown that PIP&APIM domains are necessary for recruitment to damage site via 
interaction with PCNA, and NZF domain is important for retention at the damage site via 
interaction with polyubiqitinated PCNA. It could well be that initial recruitment via 
interaction with PCNA is necessary for prompt and efficient replication fork reversal, while 
retention at the damage sites may play role in abovementioned unrecognized functions of 
ZRANB3 (where nuclease domain could be crucial). What shall also be considered is that 
mutations in the particular domain (NZF) in the full length protein could give rise to different 
phenotypes than mutation in individual domains tested individually.  Further investigations 
will be required to possibly confirm this discrepancy and to clarify its molecular 
determinants. 
 
Importantly, a second genetic perturbation completely impairing fork slowing, but having 
only partial effects on fork reversal, is HARP downregulation (see below), further suggesting 
that the penetrance of a fork progression phenotype may not necessarily be mirrored by 
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equivalent defects in the efficiency of fork reversal. Conversely, differently from genetic 
ablation of UBC13, which has complete DNA fiber and EM phenotypes, its partial siRNA-
mediated downregulation of UBC13 leads to partial effects on fork progression upon damage, 
but drastic impairment of replication fork reversal upon CPT and MMC treatments. 
Elucidating the mechanisms leading to detectable effects by each of these approach will 
likely require detailed investigation of several other genetic perturbations.   
 
Ubc13 is an E2 conjugating enzyme, involved in many processes in the cell, and thus its 
function on fork slowing and reversal may result from inactivation of various ubiquitin-
regulated pathways. However, several additional lines of evidence in this thesis strongly 
suggest that its function on fork progression and remodelling stems from its role in 
polyubiquitination of PCNA via K63 linked ubiquitin chains.  
Using a previously described system, where the endogenous ubiquitin can be replaced by WT 
ubiquitin or its K63 mutant, we could show that cells expressing the K63 ubiquitin mutant 
display defective fork slowing (data not shown) and only marginal induction of fork reversal 
upon genotoxic treatments. A very similar phenotype was observed when we applied the 
same techniques to mouse embryonic fibroblasts bearing a point mutation on the PCNA 
residue (K164) which is the acceptor of both mono- or poly- ubiquitination. Altogether these 
results strongly suggest that PCNA polyubiquitination is strictly required to enable 
replication fork remodelling and effective fork slowing upon mild treatments with genotoxic 
stress. 
 Our preliminary investigations on a second annealing helicase (HARP/SMARCAL1) 
showed promising effects on the regulation of fork progression (DNA fibers), but only partial 
effects on the efficiency of replication fork reversal (EM analysis). However, it should be 
noted that this analysis was uniquely performed upon CPT treatment. In light of the 
  
 
abundance of replication fork reversal in response to different sources of genotoxic stress 
(Zellweger et al., 2015; Neelsen and Lopes, 2015), it is conceivable that different cellular 
factors may promote fork remodelling in response to different drugs, possibly because of the 
accumulation of different molecular precursors (e.g. amount and/or distribution of ssDNA 
regions at stalled forks) or different chromatin marks around forks challenged by different 
sources of stress. It will thus be important to extend our analysis on annealing helicases – as 
well as other candidate cellular factors in fork remodelling – to different genotoxic 
treatments, including for example HU and UV treatments, that challenge the replication 
process by rather different mechanisms, in respect to CPT or MMC. 
Other important areas that will require further investigation and protocol optimization 
include: 1) methods to directly detect endogenous levels of polyubiquitinated PCNA; being 
able to follow directly the putative effects on this specific post-translational modification 
would possibly provide additional confidence in the interpretation of a subset of data in this 
thesis; 2) optimized iPOND protocol to directly detect binding to forks of relatively large 
(>100kDa) proteins, such as the annealing helicases HARP and ZRANB3. We have been as 
of yet unsuccessful in detecting ZRANB3 by the standard iPOND approach coupled to 
western blotting. However, testing protocols optimized for the detection of large proteins by 
iPOND would possibly enable assessing whether different effects on fork slowing and 
reversal closely mirror defects in having these proteins recruited to the fork, via defective 
binding to PCNA and/or to its polyubiquitinated form. 
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 4.1 Cell culture and cell lines. 
 
Human U2OS osteosarcoma cells were cultivated at 37°C (10% CO2) in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% Fetal Bovine Serum 
(FBS, Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were treated with 
different cancer chemotherapeutics and DNA damaging agents at indicated time points, 
trypsinized and collected for Western blot analysis, PFGE and EM extraction.  
Human U2OS wild type or ZRANB3 knock out cells were cultivated at 37°C (10% CO2) in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) supplemented with 7.5%Fetal 
Bovine Serum (FBS, Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin. 
Human HEK293T cells were cultivated at 37°C (10% CO2) in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 100 
U/ml penicillin and 100 µg/ml streptomycin.  
Human HCT116 cell line were cultivated at 37°C (10% CO2) in McCoy’s (5A) Modified 
Medium (26600-023, Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 100 
U/ml penicillin and 100 µg/ml streptomycin. 
Human U20S cells with inducible ubiquitin mutant expression were kept in media without 
tetracycline until the expression was needed. Then  
 
4.2 Transfections. 
For knockdown experiments, cells were transfected 48-60 h with the indicated siRNA using 
RNAiMax transfection reagent (Invitrogen), according to the manufacturer’s instructions: 
siLuc (40nM; 5′-CGUACGCGGAAUACUUCGAdTdT-3’), siHARP (40nM; 5’-
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GCUUUGACCUUCUUAGCAAdTdT-3’), siUbc13 (40nM; 
5’AAUGGCAGCCCCUAAAGUAdTdT-3’), siRad18 (40nM; 
5’AUGGUUGUUGCCCGAGGUUAAdTdT-3’), siHLTF (40nM; 5’-
GGUGCUUUGGCCUAUAUCAdTdT-3’), siUSP1 (40nM; 5’-
UCGGCAAUACUUGCUAUCUUAdTdT-3’), all purchased from Microsynth. The two 
ZRANB3 oligos were siGENOME siRNA D-010025-03-005 (84083) and siGENOME 
siRNA J-010025-10 purchased from Dharmacon (60nM final concentration for transfection).  
 4.3. Drugs and reagents. 
Camptothecin (C9911, Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) to yield 
freshly made 20 mM stock (7 mg/ml). Mitomycin C (M0503, Sigma-Aldrich) was prepared 
in ddH2O to obtain freshly made 3 mM stock (1 mg/ml). UV 254 nm was measured with 
digital radiometer (UVP. Inc. Upland. CA), 20 mW/cm2, cells were irradiated with Camag 
UV lamp dual wavelength, 254/366 (V 220; A 0.2). Cells were UV-irradiated and utilized for 
analysis after 12 or 4 h recovery.  
EDTA-free protease inhibitor cocktail (Roche) and N-ethylmaleimide (Sigma-Aldrich) were 
freshly added to immunoprecipitation buffers. 
  
4.3 Western blotting. 
 
Intracellular protein level and protein expression after knockdown experiments were 
determined by Western blot analysis of cell extracts. Mammalian cells were collected and 
lysed using 2xLaemmli buffer (4% SDS, 20% glycerol, 120 mM Tris-HCl pH 6.8). Protein 
amounts were normalized using known BSA (Bovine Serum Albumin) concentrations and 
protein absorbance was measured using Agilent Technologies Cary60 UV-Vis 
115pectrophotometer technology. Proteins (20-60 µg) were resolved on 6-12% casted SDS-
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gels, or gradient 4-15% SDS-gels. SDS-gels were run at 12 mA-18 mA (voltage/gel). 
Proteins were then wet-blotted on nitrocellulose blotting membranes (GE Healthcare) in 
buffer containing 20% methanol and 80% 1x transfer buffer (transfer buffer 10x: 25 mM 
Tris, 192 mM glycine, 10% methanol), either for 2 h (100 V, 4°C) or overnight (30 V, 4°C). 
Membranes were blocked for at least 30 min in 2% ECL (GE Healthcare) in 0.1% TBST (1x 
Tris-Buffered Saline supplemented with 0.1% Tween-20), 5% milk or 5% BSA dissolved in 
0.1% TBST (different proteins demanded different blocking solutions). Afterwards, 
membranes were incubated with primary antibodies, either overnight at 4°C or for 3-4h at 
RT. Secondary antibodies were added in blocking solution for 1h at RT. Membranes were 
washed 3 times with 0.1% TBST (10 min each) after incubation with primary and secondary 
antibodies. Membranes were detected with ECL detection reagents (GE Healthcare) using 
Fusion SOLO chemiluminescence imaging system (Vilber Lourmat). 
 
 4.4 Detection of chromatin-bound PCNA. 
 
To prepare nuclear extracts cells were washed once with ice-cold 1× PBS and incubated 5 
min on ice with pre-extraction buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 
3 mM MgCl2, 300 mM sucrose and 0.2% Triton X-100). Pre-extraction buffer was removed 
and cells were harvested by scraping with 2× Laemmli buffer. Nuclear fractions were 
incubated 5 min at RT and sonicated 2 times for 15sec each (30%). Absorbance of 
chromatin-bound proteins was measured using Agilent Technologies Cary60 UV-Vis 
spectophotometer technology and proteins (20-60 µg) were separated by 8% SDS-gels and 
incubated with antibodies.  Membranes were blocked for at least 30 min in 5% milk in 0.1% 
TBST (1× TBS supplemented with 0.1% Tween-20) and washed 5 times with 0.1% TBST 
(10 min each) after incubation with primary and secondary antibodies. Membranes were 
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immunoblotted with anti-PCNA (PC10) or anti-Ubiquitin antibodies and visualized with 
SuperSignal West-Femto (Thermo Scientific) or ECL detection reagents (GE Healthcare). 
Images were acquired using Fusion SOLO chemiluminescence imaging system (Vilber 
Lourmat). 
 
4.5 Immunoprecipitation. 
 
To prepare nuclear extracts cells were trypsinized and resuspended in pre-extraction buffer 
(25 mM HEPES pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% 
Triton X-100, EDTA-free protease-inhibitor cocktail, 20 mM N-ethylmaleimide). Cells were 
kept on ice for 15 min and centrifugated at 400 rpm for 15 min (4°C). Protein pellet was 
resuspended in lysis buffer (1% SDS, 50 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 
EDTA-free protease inhibitor cocktail, 20 mM N-ethylmaleimide), sonicated once for 20sec 
(30%) and centrifugated at maximal speed for 10 min (4°C). Protein absorbance was 
measured by Nanodrop technology and 200-500 µg of total protein was utilized for 
immunoprecipitation. Protein lysate volume was adjusted with IP buffer (1.2 mM EDTA, 
1.1% Triton X-100, 16.7 mM Tris-HCl pH 8.0, 300 mM NaCl, EDTA-free protease inhibitor 
cocktail, 20 mM N-ethylmaleimide) and incubated with 1 µg of anti-PCNA monoclonal 
antibody (PC10) for 3-4 h at 4°C. Subsequently, the lysates were incubated with protein G 
Sepharose beads (GE Healthcare) for 2-4 h at 4°C. Beads were centrifugated for 1 min at 
2000 rpm (4°C) and washed 3-5 times with washing buffer (0.1% SDS, 1% Triton X-100, 2 
mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, EDTA-free protease inhibitor cocktail, 
20 mM N-ethylmaleimide). Proteins were eluted by boiling at 95°C in 2× Laemmli buffer for 
5-10 min. Proteins absorbance was measured by Nanodrop technology and anti-PCNA 
immunoprecipitates were separated by 8% SDS-gels, transferred onto nitrocellulose blotting 
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membranes (GE Healthcare) and detected with anti-PCNA (PC10) or anti-Ubiquitin 
monoclonal antibodies. 
 
4.6 Antibodies. 
 
The following primary antibodies were used for Western blotting: ZRANB3 (A303-033A, 
Bethyl laboratories; 23111-1-AP, Proteintech), Beta tubulin (sc-9104, Santa Cruz 
Biotechnology, Inc.), GAPDH (MAB374, Millipore), Ub K164 PCNA (13439S, Cell 
Signalling), Harp (SMARCAL1) (ab69900, Abcam), Ubc13 (#4919; Cell Signaling 
Technology), Rad18 (provided by J. Jiricny, IMCR, Zurich), USP1 (provided by S.Ferrari, 
IMCR, Zurich), PCNA (sc-56; Santa Cruz Biotechnology, Inc.), TFIIH (sc-293; Santa Cruz 
Biotechnology, Inc.), GAPDH (provided by A. Sartori, IMCR, Zurich). Secondary antibodies 
used for Western blotting were anti-rabbit and anti-mouse ECL (GE Healthcare). Primary 
antibodies used for DNA fibers spreading were mouse anti-BrdU/IdU (347580; Becton 
Dickinson) and rat anti-BrdU/CldU (ab6326; Abcam). Secondary antibodies used for DNA 
fibers spreading were anti-mouse Alexa Fluor 488 (Molecular Probes) and anti-rat Cy3 
(Jackson Immuno Research). 
 
4.7 Pulse-field gel electrophoresis. 
 
Asynchronous subconfluent (40-70% confluency) mammalian U2OS cells were treated with 
defined concentration of specific DNA damaging agent for 4 h. Cells were harvested by 
trypsinization and embedded in 0.8% agarose plugs (3x105 cells/plug). Plugs were digested 
for 36-72 h at 37°C in lysis buffer (100 mM EDTA pH 8.0, 1% [wt/vol] sodium lauryl 
sarcosyne, 0.2% [wt/vol] sodium deoxycholate, and 1 mg/ml proteinase K) and washed 3-4 
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times (30 min each) in 20 mM Tris-HCl pH 8.0 and 50 mM EDTA. Electrophoresis was 
performed at 14°C in 0.9% [wt/vol] Pulsed Field Certified Agarose (Bio-Rad) containing 
0.5× TBE buffer (Tris/Borate/EDTA) in CHEF DR III apparatus (Block I: 9 h, 120°, 5.5 
V/cm, 30-18 s switch time; Block II: 6 h, 117°, 4.5 V/cm, 18-19 s switch time; Block III: 6 h, 
112°, 4 V/cm, 9-5 s switch time). The gel was stained with ethidium bromide and imaged on 
an Alpha Innotech Imager. 
 
4.8 DNA fiber spreading. 
 
Asynchronously growing U2OS cells (40-60% confluency) were pulse-labelled for 30 min 
with 30 µM CldU, washed 3 times with warm 1x PBS and labelled 30 min with 250 µM IdU. 
DNA damaging agents or chemotherapeutics were optionally added with the second labelling 
(30 min). Cells were trypsinized and resuspended in ice-cold 1xPBS to 2.5*105 cells/mL. 
Labelled cells were mixed 1:5 with unlabelled cells and cell suspension was mixed by stirring 
with lysis buffer (200 mM Tris-HCl pH 7.4, 50 mM EDTA, 0.5% SDS) on glass slides. After 
9 min at RT the slides were tilted manually (30°-45°) to allow the DNA to spread down the 
slide. Slides were air-dried and fixed with methanol/acetic acid 3:1 overnight at 4°C. DNA 
fibers were denaturated with 2.5 M HCl, washed 5 times (3 min each) with 1xPBS and 
blocked for 40 min with 2% BSA (Bovine Serum Albumin) in 0.1% PBST (1xPhosphate-
Buffered Saline supplemented with 0.1% Tween-20). Slides were incubated in dark for 2.5h 
at RT with anti-BrdU antibodies recognizing CldU (ab6326; Abcam, rat) and IdU (347580; 
BD, mouse). Slides were washed 5 times (3 min each) in 0.2% PBST (0.2% Tween-20) and 
incubated in dark for 1h at RT with appropriate secondary antibodies; anti-mouse Alexa 488 
(Molecular Probes) and anti-rat Cy3 (Jackson Immuno Research). After washing 5 times (3 
min each) in 0.2% PBST, the slides were air-dried, coverslip mounted with 20 µL/slide 
4. Materials and Methods. 
 
 
Antifade Gold (Invitrogen) and sealed with transparent nail polish. Slides were stored at 4°C.  
Images were acquired with either Olympus IX81 fluorescence microscope equipped with 
CCD camera (Orca AG, Hamamatsu) or Leica DMRB equipped with a camera (model 
DFC360 FX, Leica). Images were processed with CellR software (Olympus) or Leica 
Application Suite 3.3.0. CldU and IdU tract lengths were measured using ImageJ (National 
Institutes of Health). Mann-Whitney test was utilized to assess if differences in tract length 
were significant using Prism (GraphPad Software). 
 
4.9 Electron microscopic analysis of genomic DNA. 
 
In vivo psoralen cross-linking, isolation of total genomic DNA, enrichment of replication 
intermediated and EM visualization were performed as described in (Neelsen et al., 2014). 
Asynchronous sub confluent U2OS cells were treated with defined concentration of specific 
DNA damaging agent for 1 h. Cells were harvested by trypsinization and washed with ice-
cold 1xPBS. Genomic DNA was cross-linked by two rounds of incubation (5 min each) with 
10 µM 4,5’, 8- trimethylpsoralen (TMP) followed by irradiation pulses of 3 min with 366 nm 
UV light (Stratagene UV Stratlinker 1800). Cell suspension was washed 2 times with ice-
cold 1xPBS and and cells were lysed with lysis buffer (1.28 M sucrose, 40 mM Tris-HCl pH 
7.5, 20 mM MgCl2, 4% Triton X-100) and incubated on ice for 10 min. After a brief 
centrifugation step, the lysed cells were resuspended in ice-cold 1xPBS. DNA was isolated 
from nuclei by incubation at 50°C with digestion buffer (800 mM guanidine-HCl, 30 mM 
Tris-HCl pH 8.0, 30 mM EDTA pH 8.0, 5% Tween-20, 0.5% Triton X-100) and proteinase K 
(stock 20 mg/mL in ddH2O) until the solution became clear (1-2 h).  Samples were cooled 
down to room temperature and mixed with chlorophorm/isoamylalcohol.  Samples were 
centrifugated for 20 min at 8000 rpm, the upper phase was removed and isopropanol was 
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added to precipitate DNA. DNA was washed with 70% ethanol, air-dried and resuspended in 
1xTE buffer (Tris/EDTA). Purified mammalian DNA was digested for 4-5 h with PvuII HF 
restriction enzyme. Replication intermediates were enriched on BND cellulose 
chromatography columns (Bio-Rad, BND cellulose granules 0.1 g/mL dissolved in 10 mM 
Tris-HCl pH 8.0, 300 mM NaCl). Columns were washed 6 times with 10 mM Tris-HCl pH 
8.0, 1 M NaCl and subsequently washed 6 times with 10 mM Tris-HCl pH 8.0, 300 mM 
NaCl to equilibrate cellulose. Samples were loaded on the columns and incubated for 30 min 
at RT. The columns were washed 2 times with 10 mM Tris-HCl pH 8.0, 1 M NaCl and 
incubated for 10 min with 10 mM Tris-HCl pH 8.0, 1 M NaCl, 1.8% caffeine. The flow-
troughs, enriched in replication intermediates, were collected in microcentrifuge tubes and 
DNA was purified and enriched using Amicon size-exclusion filters (EMD Millipore). EM 
samples were prepared by spreading the DNA on carbon-coated grids and visualized by 
platinum rotary shadowing. Images were acquired on a transmission electron microscope 
(CM100, Philips) and analysed with ImageJ (National Institutes of Health). 
 
4.10 Chromatin enrichment. 
 
Cells were scraped in buffer A (100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM 
Pipes (pH 6.8), 1 mM EGTA, 0.2% Triton X-100, 100 µM NaVO4, 50 mM NaF, and 
protease inhibitors (Roche Applied Science) + DUB inhibitors, then incubated for 5 min on 
ice with gentle inverting. The supernatants were recovered as the soluble fraction after 
centrifugation (e.g. 5 min 5000 rpm 4C). This was followed by washing with the same 
volume of buffer A, the pellet was resuspended in buffer B (50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 100 µM NaVO4, 50 mM NaF, and 
protease inhibitors+ DUB inhibitors) for immunoblotting.  Next was a 10-min incubation on 
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ice, then the samples were sonicated (bioruptor with cycles 30s sonication, 30s pause for 10 
min) and then incubated for another 10 min on ice before centrifugation (full speed 
(approximately 10min, 4°C) to isolate the chromatin-bound fraction (supernatant). Protein 
concentrations were measured (using Lowry or Bradford methods). Lastly, Laemmli buffer 
supplemented with DTT (1M for 2X Laemmli) was added.  
 
4.11 Creation of stable cell lines. 
 
Phoenix retrovirus producer cells were transfected (grown in DMEM media with 10% FBS 
and 1% Glutamine) with plasmids that were carrying the corresponding retroviruses (the 
mutants that were produced had mutations in following domains: mutants in annealing 
helicase domain (HD, aspartic acid at position 157 and glutamic acid at position 158 changed 
to alanine), in endonuclease domain (ND, histidine at position 1045 changed to leucine in the 
domain responsible for interaction with polyubiquitinated PCNA (NZF, threonine at position 
631 changed to leucine, and tyrosine at position 632 changed to valine), and domains 
responsible for interaction with PCNA (PIP, where glutamine at position 519 was changed to 
alanine, and isoleucine at position 522 was changed to alanine; APIM, where phenylalanines 
at position 525 and 526 were changed to alanines, and a stop codon was introduced instead of 
threonine at position 1073)). 1h before transfection we added Chloroquine (final 
concentration of 20 µm), and then added the transfection mixture (H2O, 10 µg plasmid DNA 
and 2 M CaCl2). 8h post transfection fresh media was added. 48h post transfection 
supernatant from Phoenix cells containing viruses was collected. Polybrene (8mg/ml) was 
added to the supernatant, and it was used as a media for target cells (in this case ZRANB3 
knock out cells), that were supposed to be infected. 3h later the infection procedure was 
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repeated. After second infection procedure, the media was changed to usual growth media 
(DMEM, 7.5% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin). 
48h post infection cells were kept in selection media containing puromycin (3 µg/ml) for few 
days until cells from control group without resistance died out. If the integration took place in 
the infected cells, they were supposed to survive, while the cells with no integration should 
die, as control uninfected cells. Two different strategies for collecting surviving cells 
expressing the protein were used.  The first strategy was included collection of all the 
surviving cells from particular mutant. The second strategy included growing different 
dilutions of particular mutant cell line in an attempt to obtain individual colonies, which were 
then further propagated. After obtaining stable cell lines, protein levels were assessed using 
Western Blot  
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